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Introduction and thesis outline
THE HisTORical cOnTExT
A long time ago, on the African continent Homo Erectus distinguished itself from all 
other species as it started to use fire in a controlled setting (1). Ironically, this milestone 
approximately 300 - 400.000 years ago might have been the event that triggered the 
evolutionary emergence of one of the most lethal infectious diseases known to man (2). 
Social gathering around fire in combination with smoke-induced airway damage has 
been hypothesized to provide the ideal environment for the emergence of Mycobacte-
rium tuberculosis as a specialized human-specific pathogen causing TB (3).
M. tuberculosis co-evolved with mankind at every step of human evolution. The great 
migration of Homo sapiens out of Africa 100.000 years ago and its subsequent spread 
across the globe can be reconstructed based on the seven phylogeographical lineages 
of M. tuberculosis (4). Strains from each of these specific lineages continue to show 
increased transmissibility among their geographically associated human population, 
indicating optimal host adaptation (5).
During the Neolithic demographic transition around 10.000 years ago, agricultural 
advances and animal domestication gradually replaced our hunter-gatherer lifestyle, 
which resulted in massive population expansions. This steered M. tuberculosis co-
evolution from a slowly progressive disease that benefits from host survival into a 
‘crowd disease’ in which pathogen transmissibility equals evolutionary success and host 
survival becomes less important (4).
M. tuberculosis virulence increased throughout history. It burdened Egyptians around 
5000 years ago (6) and plagued ancient Greeks in the form of ‘phthisis’ according to Hip-
pocrates’ Of the epidemics around 2500 year ago. It reached devastating proportions in 
Europe during the industrial revolution between the 18th and 19th century. Overcrowded 
cities, poor hygiene and smog exposure created a perfect combination for TB to thrive 
and no less than one in five human deaths was caused by it (7). Rich and poor alike 
were slowly dying of ‘consumption’, a mysterious disease with no cure that killed young 
people in the prime of their life.
The disease was viewed upon as a romantic disease that inspired artists through ‘spes 
phthisica’, a phenomenon in which the physically wasting body inspired the creative 
soul and turned prosaic humans into poets (8). A famous example of this was John Keats 
with poems such as ‘Ode to a Nightingale’. The romantic aspects of TB quickly vanished 
after Robert Koch identified the bacterium M. tuberculosis in 1882 as its causative agent. 
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In a relatively short period of time TB was degraded from a poet’s disease to a contagious 
pathogen that was associated with ‘the poor man’s sputum’.
Despite the identification of its cause in 1882, an effective cure for TB remained to be 
found and treatment was limited to a combination of liver cod, sunlight and (perhaps 
most importantly) isolation from society in sanatoria (9). This changed from the 1950s 
onwards with the discovery and use of effective antibiotics. Streptomycin and para-
aminosalicylic acid (PAS) were the first agents with moderate antimycobacterial efficacy 
(10). While promising, the first clinical report on these drugs already encountered two 
important aspects of TB treatment which still apply today: drug resistance and treatment 
side effects (10). A cure became possible with the discovery of isoniazid as TB drug (11). 
For over a decade, treatment with oral isoniazid and PAS for 18 to 24 months combined 
with intramuscular injections of streptomycin during the first 6 months became the 
standard TB treatment (12). The introduction of agents such as pyrazinamide in 1955, 
ethambutol in 1961 and rifampicin in 1966 further improved cure rates, while reducing 
treatment duration (12). Eventually, in 1979, a six months treatment course with the oral 
antibiotics isoniazid, rifampicin, pyrazinamide and ethambutol became, and still is, the 
standard of care in TB treatment (9, 13).
Unfortunately, the progression in TB treatment was overshadowed by an infectious 
disease crisis that started in the 1980’s. The Human Immunodeficiency Virus (HIV) 
manifested itself and caused mortality on an unprecedented scale. Where TB caused 
approximately 20% mortality among affected individuals in Europe during the industrial 
revolution, HIV was accountable for over 50% of adult mortality in most African countries 
during the early 90’s (14). HIV-induced immunodeficiency was quickly recognized to act 
as a TB-catalyzer and vice versa. The coinfection of the two diseases was termed ‘the 
cursed duet’ (14). An immunocompetent, latently infected individual has a 5-10% life-
time risk of progressing to active TB (15). These chances increase substantially when this 
same individual is also infected with HIV, which is now the most important predisposing 
factor for the development of active TB disease (16). The increased progression and 
transmission of TB amongst HIV-infected individuals caused an increase in TB incidence 
in sub-Saharan Africa between 1990 and 2005, while stabilization or steady decrease of 
TB incidences was observed in countries outside Africa during this period (17).
Another impact of HIV on TB is of a more indirect nature. During the last 30 years, 
enormous global efforts have resulted in rapid development and implementation of 
anti-retroviral HIV therapy. Unfortunately, these efforts appear to have been at the cost 
of funds for TB treatment, as TB treatment has remained virtually unchanged compared 
to pre-HIV times. In 2016, TB claimed more victims than HIV and malaria combined (18). 
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Nevertheless, the global fund disbursed 40.4% of its funding for HIV, 29.7% for malaria 
and 22.4% for tuberculosis (19). In absolute terms: in 2016 a worldwide total of 19.1 
billion dollar was available for HIV treatment and prevention compared to 6.3 billion for 
TB (18, 20). A potential explanation for this discrepancy is best embodied by the words 
of the director of the WHO global TB program, stating that “HIV is a disease that involves 
one of the most important aspects of life – sex. Tuberculosis involves the sputum of poor 
people, and the poor are without voice in most societies” (21).
Nowadays, TB treatment, in combination with improved sanitation, housing and nutri-
tion, screening programs and outbreak prevention measures has resulted in a decline of 
TB incidence in developed countries. Nevertheless, in the developing world TB still has 
a profound impact and claimed an estimated 1.7 million lives in 2016 (18). This makes 
TB one of the top 10 causes of death worldwide and places it above road injuries. New 
threats are present on the horizon in the form of more extensive drug resistance and the 
emergence of M. tuberculosis genotypes with increased virulence. Combined with the 
current major funding gaps for TB diagnosis, treatment and research, it remains to be 
seen how long our 1979 drug regimen can contain this evolutionary giant.
From the microbe’s point of view: the template for success
M. tuberculosis is a slow-growing, rod-shaped, facultative intracellular bacterium that is 
primarily spread through aerosols coughed up by infected individuals. Detailed descrip-
tion of the evolutionary success of M. tuberculosis can be divided into three different 
categories: mycobacterial factors, host factors and treatment factors, which will be 
described in more detail.
mycobacterial factors in m. tuberculosis’ evolutionary success
The unique features of M. tuberculosis start with the composition of its cell wall. The thick, 
lipid-rich combination of mycolic acids, lipomannan arabinogalactan and peptidogly-
cans prevents regular Gram staining and requires specific stains such as Ziehl-Neelsen 
(acid-fast) or auramine-rhodamine staining for identification (22). The composition of 
the mycobacterial wall stimulates rapid contact with innate leukocytes such as macro-
phages and subsequent phagocytosis (15). The unique inflammation-inducing capacity 
of the mycobacterial cell wall is best exemplified by complete Freund’s adjuvant, a com-
mon immunopotentiator used to enhance vaccination efficacy in experimental animals, 
which primarily consists of inactivated mycobacteria. Upon phagocytosis, M. tuberculosis 
prevents acidification of the phagosomal compartment caused by phagolysosomal fu-
sion (15). Subsequently, pore-forming virulence factors such as early secreted antigenic 
target 6 kDa (ESAT-6) enable translocation to the cytosol (23). It has been demonstrated 
that in the intracellular compartment, M. tuberculosis can prevent further degradation 
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and use the macrophage as a shielded niche for survival, replication and persistence 
(15).
Under influence of environmental stress factors such as antibiotic pressure or adaptive 
immunity, M. tuberculosis can further alter the composition of its cell wall as part of a 
transition into a slow-growing, non-replicating state in which it is highly resistant to 
host responses and antibiotics (24, 25). The ability of M. tuberculosis to progress to this 
resilient state is one of the main reasons for the long treatments, as metabolism is low 
and the thickened cell wall prevents entry of antibiotics into the bacterium (26). In its 
persistent state, M. tuberculosis is also able to effectively circumvent immunity and cause 
the clinical phenomenon termed ‘latent TB’ in which mycobacteria are present in the 
body, but do not cause active disease at that moment (15).
Mycobacterial strain variance is a virulence factor in TB pathogenesis that is gaining in-
terest among TB researchers. Due to its slow-growing character, M. tuberculosis was ini-
tially viewed upon as a genetically conserved organism for which strain variation played 
a minor role in disease outcome (27). This assumption could be one of the reasons why 
the mycobacterial H37Rv strain, isolated from a patient in 1905 remains one of the most 
commonly used strains in preclinical TB research to date (28). Advances in genotyping 
technologies and clinical observations over the last two decades have proven this as-
sumption to be false. H37Rv is deemed a laboratory strain as it is no longer isolated 
from patients, while strains from other genotypes have emerged at an alarming rate 
(29, 30). The best example of this is the Beijing genotype, identified in 1995 (31). Strains 
of the Beijing genotype show increased virulence and drug resistance compared to 
strains from other lineages, as illustrated by exceptionally high rates of drug resistance 
in Eurasia (32-40). Given the current high TB incidences in East-Asian countries, Beijing 
genotype strains are the second-most common strains responsible for TB after strains 
from the East-African Indian (EAI) genotype (29). Thus, an important consequence of 
strain variance that will also be discussed in this thesis is that the strains that currently 
cause the major burden of TB in patients are clearly distinct from those most frequently 
used for screening of novel anti-mycobacterial drugs in preclinical TB models.
Host factors in m. tuberculosis’ evolutionary success
Worldwide, a huge human reservoir of latently infected individuals exists of which most 
will most likely never progress to active TB. Latent TB poses a significant challenge to the 
global eradication of TB as an estimated 30% of the world population can be classified 
as having latent TB (15). However, an immune-compromised state significantly increases 
the risk of TB reactivation (15). In developing countries this is best exemplified by HIV 
co-infection as discussed above. In the developed world, major risk factors for TB include 
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type 2 diabetes, alcohol use and smoking (41). Another increasing population of indi-
viduals at risk for TB reactivation comprise those receiving deliberate immunosuppres-
sion for treatment of auto-immune diseases, malignancies and organ transplants (16). A 
notorious example is the introduction of anti-TNF-α monoclonal antibody therapies for 
rheumatoid arthritis, which caused increased rates of TB reactivation in latently infected 
individuals (42). The association of such specific interventions like anti-TNF-α with TB 
reactivation does provide insight into their role in TB pathogenesis (43). Another classic 
example is the discovery of genetic defects as observed in Mendelian Susceptibility to 
Mycobacterial Disease (MSMD) (44). Patients with MSMD have genetic mutations result-
ing in defective IL-12 production or IFN-γ responsiveness, which renders them extremely 
susceptible for mycobacterial disease (44).
Anti-TNF-α treatment and MSMD highlight the importance of an intact IL-12 / T-helper 
1 immune response/ IFN-γ in TB. However, this axis alone is not sufficient for an optimal 
host response. The current vaccine for TB, Bacillus Calmette-Guérin (BCG), induces a 
strong Th1 response but provides highly variable protection between 0-80% due to 
unknown causes (41, 45, 46). Further boosting of the Th1-inducing potential of BCG 
by using a modified Ankara virus did not improve efficacy (47, 48). BCG offers higher 
protection rates in young children. In adults, however, BCG vaccination not only has a 
lower efficacy for protection against TB, but might even have been a selective force con-
tributing to the spread of virulent Beijing strains, which circumvent vaccine-mediated 
immunity more efficiently (41, 49). With increasing incidences of Beijing strain infections, 
this might even call for more selective vaccination strategies. Also, the basic principle of 
vaccination is that once the immune system has encountered a pathogen, it will form a 
more effective and efficient adaptive immune response upon re-infection. In the case of 
TB, it should be noted that reinfection after successful TB treatment frequently occurs 
and actually increases the chances of developing active TB instead of offering protec-
tive immunity (50, 51). Thus, in contrast to most other infectious diseases, survival after 
primary infection provides limited protection against future exposure. Combined with 
the variable efficacy of BCG, this indicates the complexity of TB immunology and the 
need for better understanding and identification of protective host responses.
Immune-compromised individuals have an increased risk of developing active TB, but 
the vast majority of TB patients are non-immune compromised adults, capable of in-
ducing robust host responses (18). Thus, a final important host factor to consider is the 
contribution of our own immune system to disease progression. In other words: To what 
extent does our own immune system contribute to a detrimental course of TB? Gene 
expression signatures in TB have greater overlap with auto-immune diseases than with 
other infectious diseases (52). Also, preclinical studies show that boosting protective 
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T-cell-mediated IFN-γ production in TB promotes disease progression due to hyper-
inflammation (53). So it appears that both immune suppression and stimulation can 
cause disease progression in TB. Unraveling the exact host factors and immunological 
mechanisms responsible is crucial for the development of host-directed therapies as 
possible adjunct to antibiotic treatment.
Treatment factors in m. tuberculosis’ evolutionary success
Current strategies for global TB treatment revolve around DOTS, i.e. ‘Directly Observed 
Treatment, Short course’. The success of DOTS depends on five distinct elements: (i) sus-
tained political and financial commitment, (ii) diagnosis by quality-ensured microscopy 
services, (iii) a secured supply of high quality TB drugs, (iv) standardized recording and of 
course (v) Directly Observed Treatment (DOT) (18). DOT has been proven to be important 
to complete the 6-months treatment course successfully. TB treatment eliminates nearly 
all mycobacteria and most of the clinical symptoms in the first 2 months of treatment. 
However, longer treatment durations are required to eliminate persistent populations of 
mycobacteria. In these last 4 months, in which low numbers of persistent mycobacteria 
are treated, compliance to therapy is essential to prevent the development of drug-
resistant TB. Drug resistance currently occurs in 4.1% of all new TB cases and 19% of pre-
viously treated cases (18). The impact of drug resistance in TB is substantial: treatment of 
drug-susceptible TB comprises a 6-months course with daily oral first line TB drugs, has a 
cure rate of approximately 83% and costs around 1200 dollar (18). In contrast, treatment 
of multi-drug resistant TB requires at least 18 months of treatment with second-line TB 
drugs, has a cure rate of approximately 55% and costs almost 10.000 dollar (18, 54, 55).
Probably one of the best ways to increase compliance and prevent drug resistance is 
to shorten treatment duration, but chemotherapeutic advancements that may shorten 
TB treatment have been scarce. After 40 years of silence, delamanid and bedaquiline 
have recently been approved as new agents for TB treatment, but remain reserved for 
the treatment of drug-resistant forms of TB (56, 57). Fortunately, the need for new TB 
treatment has been recognized and the current clinical pipeline for new TB drugs looks 
more promising than ever (41). Meanwhile, reducing duration of TB treatment through 
repurposing of other chemotherapeutic agents proved difficult. In 2014, a large phase 
III clinical trial to reduce treatment duration to 4 months through implementation of 
moxifloxacin in the multidrug regimen essentially failed (58). Although this clinical 
trial did not achieve treatment reduction of TB, it did provide essential information to 
rethink current methods and improve future drug development programs. It showed 
that early surrogates for treatment efficacy assessments as measured in clinical phase 
IIa/b trials are unreliable predictors for cure in TB (59, 60). More relevant for this thesis, it 
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also pointed out that current preclinical TB models require further optimization in order 
to increase their translational value (61).
Current research on new drugs, drug regimens and treatment duration primarily occurs 
in mouse TB models (62). These are readily available models that allow testing in large 
groups, but have the drawback that infected mice do not develop necrotizing granulo-
mas. These structures are the hallmark for disease in human TB and are believed to play 
a central role in mycobacterial persistence (62, 63). For the experiments described in this 
thesis we use the BALB/c mouse model, because, despite the absence of necrotizing 
granulomas, the course of infection and treatment in the BALB/c mice resembles the 
clinical situation remarkably (64). After several months of treatment no mycobacteria 
can be cultured from the lungs, but a full 6-months course with the current TB drug 
regime is necessary to eradicate persistent mycobacteria and prevent relapse of disease 
(64). Eradicating these persistent mycobacteria more efficiently is the key to shortening 
treatment duration and their proven presence in the BALB/c mouse model indicates its 
usefulness as preclinical model.
OuTlinE OF THis THEsis
The aim of this thesis is to increase our understanding of TB pathogenesis and improve 
its treatment. Therefore, mycobacterial-, host-, and treatment factors are studied.
mycobacterial factors
To what degree does mycobacterial strain diversity influences treatment outcome and 
host responses in mouse TB models? The mycobacterial strain H37Rv is still commonly 
used in preclinical TB research, but it is more than 100 years old and no longer isolated 
from patients, can we therefore still use it as model organism? In chapter 3 we analyze 
host-responses against H37Rv compared to two recently isolated clinical strains from the 
Beijing and East-African Indian genotype to evaluate how currently circulating strains 
evade protective immunity more efficiently. To evaluate the impact of strain diversity 
on TB treatment, we assess bactericidal drug activity and treatment outcome against 
recent clinical isolates in chapter 5.
Host factors
Both impaired host responses and boosting immunity can result in disease progression 
in TB, indicating the duality and importance of our immune system in TB pathogenesis. 
In the current paradigm, IL-12 stimulates IFN-γ-mediated macrophage activation and 
mycobacterial killing, which is essential in TB as observed in patients with MSMD. How-
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ever, this does not explain the recently identified functional role of antibodies and B-cells 
in TB (65, 66). Also the emerging s of type 1 interferons and/or Th17 immunity in patients 
need to be incorporated into our current understanding of TB pathogenesis. Therefore 
we have performed a review of the current literature on these factors in chapter 2. We 
also evaluate the feasibility of altering host responses through host-directed therapy 
adjunct to antibiotic treatment to improve treatment outcome in chapter 4.
Treatment factors
Poor outcomes of recent clinical phase III trials evaluating novel TB treatment regi-
mens have shown that the predictive value of preclinical models needs to be further 
optimized (58). In chapter 5 we validate the efficacy of conventional TB drugs in our 
own mouse TB model using a mycobacterial Beijing genotype strain and assess the 
predictive value of early bactericidal activity, i.e. during the first months of treatment, 
on treatment outcome. Finally, in chapter 6 we present a new approach for treatment 
outcome evaluation by combining observational data with mathematical modeling in 
order to evaluate the potency of (new) TB drug regimens.
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absTRacT
The classical paradigm of TB immunity, with a central protective role for Th1 responses 
and IFN-γ-stimulated cellular responses, has been challenged by unsatisfactory results 
of vaccine strategies aimed at enhancing Th1 immunity. Moreover, preclinical TB models 
have shown that increasing IFN-γ responses in the lungs is more damaging to the host 
than to the pathogen. Type 1 interferon signaling and altered Th17 responses have also 
been associated with active TB, but their functional roles in TB pathogenesis remain 
to be established. These two host responses have been studied in more detail in auto-
immune diseases and show functional interactions that are of potential interest in TB 
immunity. In this review we first identify the roles type 1 interferons and Th17 immunity 
in TB, followed by an overview of interactions between these responses observed in 
systemic auto-immune diseases. We discuss (i) the effects of GM-CSF-secreting Th17.1 
cells and type 1 interferons on CCR2+ monocytes; (ii) convergence of IL-17 and type 1 
interferon signaling on stimulating B-cell activating factor (BAFF) production and the 
central role of neutrophils in this process; (iii) synergy between IL-17 and type 1 interfer-
ons in the generation and function of tertiary lymphoid structures and the associated 
follicular helper T-cell responses. Evaluation of these auto-immune-related pathways in 
TB pathogenesis provides a new perspective on recent developments in TB research.
27
Type 1 interferons and the Th17 response in TB
1. inTROducTiOn
Tuberculosis (TB) has been responsible for an estimated one billion deaths worldwide 
over the last 200 years (1), which is more than any other infectious disease caused by a 
single pathogen. Given its global magnitude, it has been hypothesized that TB particu-
larly contributed to the genetic selective pressure that predisposes for development of 
auto-immune diseases (AID) (2). This is supported by polymorphism studies of the TNF 
gene, which show an opposite association between susceptibility to TB versus suscep-
tibility to several AID (3). Additionally, a gender-dependent predisposition to either TB 
or AID exists with a male predominance among TB patients (4) opposed to increased 
AID incidences in women (5). The general concept of an inverse relation between infec-
tious diseases and AID is best described by the hygiene hypothesis, which states that 
diminished exposure to infectious pathogens during childhood increases the chances of 
developing auto-immune diseases (AID) and allergies (6) (7). Also, epidemiologically, the 
decline in burden of infectious diseases over the last century in industrialized countries 
is accompanied by increasing rates of auto-immune diseases (AID) (8).
Despite support for an inverse relation, similarities between TB and AID have also been 
identified. TB is even hypothesized to be an infection-induced AID based on the ob-
servation that diverse clinical autoimmune phenomena frequently occur in TB patients 
(9, 10). Furthermore, up to 32% of patients with active TB have elevated autoantibody 
titers (11, 12). Rational explanations for these findings could be that either TB and AID 
activate common immunological pathways (10), or protective immunity in TB increases 
the chance to develop AID (2). In both scenarios, key findings in AID immunology could 
potentially contribute to our understanding of TB pathogenesis.
The current paradigm of the host response to Mtb infection is summarized in Fig. 1. The 
indispensable role of IL-12/IFN-γ-mediated Th1 immunity against Mtb has long been 
recognized (13). However, stimulating Th1 immunity in TB can also result in excessive 
inflammation (see box 1). More recently the contributions of additional immune path-
ways have been explored, especially the role of T1-IFNs, Th17 immunity (14, 15) and 
unconventional T cell immunity (16-18). Little is known about the potential interaction 
between T1-IFNs and Th17 responses in TB, but interesting observations in this regard 
have been reported for multiple AID (19-21). To determine if these findings are relevant 
for the understanding of TB pathogenesis, we first review the separate involvements of 
T1-IFNs and Th17 responses in TB pathogenesis in section 2 and section 3, respectively. 
Next, their known interactions in AID are discussed in section 4. Lastly, in section 5 the 
potential relevance of these interacting pathways in TB is assessed and integrated into 
the current understanding of TB pathogenesis.
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Figure 1. The phases and cell types involved in the immune response to Tb in the lungs
1) Inhaled Mtb-containing aerosols are deposited deep into the lung, reaching the alveoli (24). Within the 
alveoli, Mtb are phagocytosed by alveolar macrophages (Alv. Mɸ) or infect alveolar epithelial cells prior 
to ending up in alveolar macrophages (25). Within Alv. Mɸ, the bacteria are able to inhibit phagosome-
lysosome fusion and replicate until cell lysis ensues, which takes approximately 3-5 days (26). 2) After the 
initial contact, Mtb encounters infiltrating myeloid cells of which inflammatory dendritic cells (iDC) and 
PMN are most readily infected (13, 27). During these early phases, invariate natural killer (iNK)-cells and 
type 1 innate lymphoid cells (ILC1) produce IFN-γ in response to IL-12 and stimulate myeloid cells to kill 
phagocytosed Mtb. In addition, γδ T-cells and ILC3 produce IL-17. There is increasing appreciation for the 
role of tertiary lymphoid structures that arise under influence of IL-17 and facilitate optimal activation of 
myeloid cells and efficient recall-responses. During this process loosely aggregated ‘innate granulomas’ are 
already formed (28). It should be noted that the roles of ILC1s and ILC3s are based on their general function, 
which has not yet been formally demonstrated in TB (29). 3) Onset of adaptive immunity in Mtb infection 
is delayed to circa 14 days in mice and up to 6 weeks in humans (13, 24). At this point distinct T-cell subsets 
and B-cells migrate to the site of infection and execute their different effector functions. 4) After onset of 
adaptive immunity, 90-97% of infected individuals develop sustained infection without clinical symptoms 
termed ‘latent TB infection’ (LTBI) (13). LTBI was initially considered a static phase, but it is now known that 
this stage is hallmarked by the presence of granulomas in various stages (caseous, non-caseous, fibrotic) 
and an ongoing balance between anti-mycobacterial activity and regulatory mechanisms to minimize im-
munopathology (13, 30). Cell phenotypes are as present in mouse TB models.
29
Type 1 interferons and the Th17 response in TB
2. TyPE-i inTERFEROn in Tb
Type I interferons (T1-IFNs) comprise a family of 13 IFN-α subtypes, IFN-β, IFN-ε, IFN-κ, and 
IFN-ω, which have the shared ability to bind to the IFN-α/β receptor (IFNAR) (22). Other 
interferons include the single type II interferon, interferon-γ, and the type III interferon 
family covering three IFN-δ types. All nucleated cell types are capable of both producing 
T1-IFNs and responding to them, while type II/III interferons are mostly produced by 
leukocytes (22). The main function of T1-IFNs is to ‘interfere’ with intracellular infections. 
Therefore, T1-IFN expression is primarily induced through cytoplasmic pattern recogni-
tion receptors (PRRs) and endosomal Toll-like receptors (TLRs), which activate distinct 
interferon regulatory factors (IRFs) that act as transcription factors enabling expression 
of interferon-responsivegenes (23). In contrast, extracellular pathogens trigger surface-
bound TLRs that preferentially induce IL-1β and TNF-α through activation of NF-κB.
The role of T1-IFNs in infectious diseases is complex (15, 31-33). T1-IFNs boost the im-
mune system upon pathogen encounter by activating dendritic cells and NK-cells and by 
stimulating both B-cell responses and CD4+/CD8+ T-cell responses. However, T1-IFNs can 
also induce anti-inflammatory responses to control immune-mediated tissue damage 
during chronic infections. These contradictory effects of T1-IFNs in different situations 
can likely be ascribed to the heterogeneity of the T1-IFNs family, downstream activation 
of different STAT homo/heterodimers after binding to IFNAR (23, 34) and to differential 
priming of cells prior to induction of T1-IFN signaling (35).
2.1. T1-iFns in human Tb
When recombinant or purified T1-IFNs became available as therapeutic agents in the 
1980s, different applications have been established based on their antiviral, immune-
stimulating and -suppressive effects. These include treatment of viral infections (e.g. 
IFN-α treatment of hepatitis B/C infections), auto-immune diseases (e.g. IFN-β treatment 
for multiple sclerosis) and various malignancies (44). Based on their well-described 
immune-stimulating effect, the use of T1-IFNs as adjuvant to antibiotic treatment 
for patients with active TB has also been explored (see Table 1). All studies found a 
positive influence of adjuvant T1-IFN therapy on clinical outcomes in active TB (45-49). 
Conversely, IFN-α treatment without concomitant antibiotic treatment, e.g. for hepatitis 
C, has been described to cause reactivation of latent TB (50-57). While reactivation of 
latent TB and treatment of active TB are two distinct clinical situations, the latter finding 
suggests an unfavorable role for T1-IFNs in TB pathogenesis
In 2010, an interferon-inducible transcriptional signature was reported in circulating 
leukocytes of TB patients, thus linking increased T1-IFN signaling with active disease 
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(58). This finding has been validated in several independent studies (59-62). A meta-
analysis confirmed statistical significance but found a less dominant role for T1-IFN-
related genes than expected (63). This is ascribed to the involvement of signaling 
components downstream of the T1-IFNs receptor in multiple overlapping intracellular 
pathways. Also, association studies do not necessarily implicate a causally detrimental 
effect of T1-IFNs in TB pathogenesis. In line with this, T1-IFN responses show potential as 
biomarkers or diagnostic tool for risk of active disease, but their functional involvement 
during TB progression in patients is not yet understood (62).
2.2.  Preclinical studies in mice support a detrimental role of T1-iFns during 
acute Tb
A causal relationship between T1-IFN signaling and TB disease severity was first sug-
gested in 2001 when IFN-α levels in the lungs of Mtb-infected mice were shown to be 
associated with Mtb strain virulence (64). Several approaches have been used to verify 
this relationship between increased T1-IFN signaling and unfavorable disease outcome. 
Blocking the T1-IFN signaling pathway through use of IFN-α/β receptor knockout (IF-
NAR-/-) improves survival, but only when applied on the background of mouse strains 
in which acute TB is lethal, such as the A129 strain (65). In IFNAR-/- mice with a relatively 
TB-resistant C57BL/6 background, survival rates were similar to wildtype mice, but my-
cobacterial loads in the lungs were lower(66-69). One study actually observed increased 
loads in the lungs (70) (Table 2).
box 1. The dual faces of iFn-γ in Tb immunity
In the current paradigm of a successful host response, lung DCs migrate to the draining lymph node after 
Mtb contact and induce a robust IL-12-mediated Th1 response (13). This results in migration of IFN-γ-
producing CD4+ T-cells to the site of infection. Subsequently, activation of macrophages by IFN-γ results 
in killing of intracellular Mtb, while activated CD8+ T-cells lyse infected host cells. Conversely, unsuccess-
ful clearance of infection is due to poor activation of adaptive immunity. This can result from insuffi-
cient antigen presentation (36), or from the action of regulatory factors that interfere with Th1 responses 
such as IL-10 or PDL1-PD1 interaction (13). Paradoxically, the current vaccine Bacillus Calmette-Guérin 
(BCG) induces a strong Th1 response, but is only partially effective in protecting against TB (37). Boost-
ing the Th1-inducing potential of BCG by using a modified Ankara virus also has yielded disappointing 
results (38, 39). Thus, solely stimulating Th1 immunity might not be the solution in TB prevention. This 
is confirmed in a mouse TB study showing that increasing IFN-γ production by T-cells in the lungs is 
detrimental to the host due to hyper-inflammation that requires PD-1- mediated suppression to limit 
pathology (40). In line with this, Mtb-infected mice deficient in PD-1, or mice in which PD-1 is selectively 
inhibited display excessive inflammation and disease progression (41, 42). Lastly, ex vivo studies in hu-
man monocyte-derived macrophages show that protective effects of IFN-γ are dependent on multiple 
factors including time of contact, concentration, and the magnitude of the ensuing microbial challenge 
(43). Based on these observations it can be concluded that boosting IFN-γ production and Th1 immunity 
in TB, besides potentially enhancing protection, can also result in unbalanced inflammation in the lungs 
that is more harmful to the host than to the pathogen. This emphasizes the need for involvement of ad-
ditional immunological pathways for optimal protection.
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In a second approach Mtb-infected mice were supplemented with T1-IFNs after start of 
infection or treated with the TLR3-ligand poly-ICLC, which stimulates T1-IFN production 
and signaling (64, 71). Both studies showed increased mortality and higher mycobacte-
rial loads in the supplemented groups, which were not observed when T1-IFNs or poly-
ICLC were administered to Mtb-infected IFNAR-/- mice. Lastly, in a third approach, mice 
were primed with a T1-IFN-inducing influenza virus prior to TB infection, which led to 
enhanced mycobacterial growth and reduced survival (72).
Table 1. Effect of T1-iFn supplementation in human Tb
study design Regimen Outcome side effects Ref
Open parallel, 
susceptible Mtb 
strain, HIV(-), N=20 
(2x10),
2 mo treated
HRZE vs. 
HRZE+
IFN-α
- Less fever on d3&4 after start treatment in 
HRZE+IFNα group
- Increases in total lymphocytes and HLA DR1+ 
cells after 2 months only in HRZE+IFN-α group
- Reduction in HRCT-score only in HRZE+IFN-α 
group
- Stronger reduction of pro-inflammatory 
cytokines in BALF after 2 months treatment in 
HRZE+IFN-α group
No adverse effects 
reported
(45)
Patients treated 
prior for 3-12 years, 
MDR strain, HIV(+),
N=5, 12 wks treated
Anti-TB 
treatment 
+IFN-α
- 2/5 complete response
- 1/5 partial response
- 2/5 no response
- Increase of NK (% cytotoxicity) in all patients 
after 12 weeks
Flu-like symptoms 
in 4/5 patients, not 
needing treatment
(46)
Patients treated 
prior for 6 mo, MDR 
strain, HIV (-)
N=7, 9 wks treated
DOT+
IFN-α
- Significant drop (p = 0.02) in Mtb-loads at the 
end of a 9-weeks IFN-α treatment course
- Significant increase (p = 0.03) in Mtb-loads after 
stop of IFN-α treatment
- Significant drop in IL-1β, IL-6, TNF-α and IFN-γ 
proinflammatory cytokines; IL-4 & IL-10 showed 
inconsistent changes.
No adverse effects 
reported
(47)
Parallel, patients 
treated prior for 6 
mo with DOT, MDR 
strain, HIV (-)
N=12 (2x6), 8 wks 
treated
1. DOT
2. DOT
+ IFN-α
- After 8 weeks, all five subjects of the case group 
became sputum smear-negative; the control 
group remained smear-positive (p = 0.012)
- Evaluation of smear results after 6 months 
showed two smear-negative subjects in the case 
group while all controls were smear-positive (p 
= 0.132)
4 subjects mild 
arthralgia and 
myalgia, flu-like 
symptoms in all 
subjects
(48)
Case report, MDR 
strain, HIV (-), N=1, 
2 mo treated
HRZE+ 
IFN-α
- Two months after initiation of therapy, sputum 
smears became negative, the patient’s clinical 
and radiological findings strikingly improved. 
During 4-year follow-up, all consecutive sputum 
cultures remained negative.
No adverse effects 
reported
(49)
BALF= Bronchoalveolar lavage fluid, DOT= Directly Observed Therapy (antibiotic TB treatment), HRCT= 
high-resolution Computed Tomography, HRZE= Isoniazid, Rifampicin, Pyrazinamid & Ethambutol, MDR= 
Multi-drug resistant, Mo= months.
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Enigmatically, reduced mycobacterial loads in IFNAR-/- mice are primarily observed in 
the acute phase of infection in which T1-IFNs are considered immune stimulating. No 
differences in survival or long term control of infection were found in C57BL/6 IFNAR-/- 
mice compared to wild-type. In support of this notion, T-cell analyses in several of the 
above-mentioned studies convincingly excluded an effect of increased or decreased 
T1-IFN signaling on the adaptive immune response (68, 69, 71). Notably, none of these 
studies addressed the effect of T1-IFNs as adjunct treatment to antibiotics, which was 
shown to be beneficial in TB patients (Table 1).
2.3. mtb actively induces T1-iFns
Multiple studies indicate that Mtb employs both active and passive mechanisms to 
induce T1-IFNs (74-76). The mycobacterial ESAT-6 secretion system (ESX-1) and its 6 
kDa early secretory antigenic target (ESAT-6) are essential in this process, as mycobac-
Table 2. interference with T1-iFn signaling in preclinical Tb studies
mouse 
back
ground
intervention mtb strain survival mtb load Ref
A129 IFNAR-/- HN878, W4, CDC1551, 
100-200 CFU, aerosol
Better survival against 
CDC1551.
Trend towards better 
survival against HN878
No data (65)
B6D2/
F1
anti-IFN-α/β 
antibody
HN878, 100-200 CFU, 
aerosol
Better survival against 
HN878
No differences up to d.100 (65)
B6/129 IFNAR-/- H37Rv, HN878, CSU 
93, CSU 123 50-100 
CFU, aerosol
No differences in 
survival after infection 
with all strains
Lower Mtb loads in lungs 
after infection with all 
strains up to d.150
(66)
B6 IFNAR-/- Erdman, 106 CFU, i.v. 
injection
No data No differences in lung 
until d.20
Lower Mtb loads in spleen 
at d.10 and d.20
(67)
B6 IFNAR-/- H37Rv, 100 CFU, 
aerosol
No differences up to 
d.70
Lower Mtb loads in lungs 
at d.18,
no differences at d.25
(68)
129S2 IFNAR-/- H37Rv, 200 CFU, 
aerosol
Improved survival Lower Mtb loads at d.21 (69)
B6 IFNAR-/- H37Rv, 500 CFU, 
aerosol
No differences in 
survival up to d.90
Lower Mtb loads at d.21 (69)
B6.SJL IFNAR-/- H37Rv, 100-150 CFU, 
aerosol
No differences in 
survival up to d.90
No data (73)
B6/129 IFNAR-/- Erdman, 100 CFU, 
aerosol
No data Higher Mtb loads in lungs 
on d.10, d.20 and d.40. 
Equal loads at d.80.
(70)
i.v.: intravenous
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teria lacking ESX-1 fail to induce T1-IFN production (67, 77-81). ESAT-6 can disrupt the 
phagosomal membrane, which allows translocation of mycobacteria and mycobacterial 
products from the phagosome into the cytosol (78, 82).
Mycobacteria actively secrete several T1-IFN-inducing compounds, including double-
stranded (ds)DNA and the bacterial second messenger cyclic-di-AMP (83). These 
compounds are recognized by different cytosolic PRRs, including cGAS (81), IFI-204 (78), 
AIM2 (84) and possibly NOD2 (77), although data on the latter are conflicting (67, 78). 
Activation of these cytosolic PRRs converges to activate ‘STimulator of INterferon Genes’ 
(STING), which subsequently forms a complex with TANK-binding Kinase 1 (TBK-1) (79). 
This STING-TBK1 complex activates IRF3, leading to IFN-β production in mice (80) as well 
as human dendritic cells (74). IRF3-/- mice are poor producers of IFN-β and more resistant 
to Mtb infection, which supports a negative role for T1-IFNs in TB pathogenesis (78).
However, the overall picture is more complex. IRF3-/- mice are more resistant to Mtb in-
fection, but mice deficient in the cytosolic PRR cGAS, upstream of IRF3, show diminished 
control of chronic Mtb infection (79). This can be traced back to a concomitant reduction 
in autophagy, which is also dependent on the cGAS-induced activation of the STING-
TBK1 axis, but independent of IRF3. In line with this, mice infected with an Mtb-strain that 
induces higher amounts of cyclic-di-AMP, thus stimulating both IRF3-mediated IFN-β 
production and STING-TBK1-mediated autophagy, show improved survival compared 
despite increased IFN-β levels (83). Taken together, this suggests that pro-mycobacterial 
effects of stimulating the cytosolic PRR/STING/IRF3/IFN-β-axis by mycobacteria might 
be outweighed by the anti-mycobacterial effects of the PRR/STING/autophagy pathway.
Autocrine or paracrine IFN-β-signaling induces IRF-7 and leads to the production of 
IFN-α in human dendritic cells (74). In line with this, injection of recombinant IFN-β in 
mice induces IFN-α production (85). Alternatively, myeloid cells and particularly plas-
macytoid dendritic (pDC) cells are capable of directly activating IRF7-mediated IFN-α 
production after recognition of Mtb, particularly by endosomal TLR9 (86). In TB, this 
TLR9-IRF7 pathway is studied to lesser extent than the cytosolic PRR-IRF3 axis (87). This 
is possibly due to the dependence of T1-IFN-mediated pathogenic effects in mice on 
ESX1, which induces IRF3 rather than IRF7 as explained above (67). However, IRF7 is 
recognized as commonly induced transcription factor by multiple clinical Mtb strains 
in alveolar epithelial cells (88). Moreover, TLR9-/- mice succumb earlier to high-dose Mtb 
infection than wildtype mice, which suggests a role for the TLR9/IRF7/IFN-α-axis in TB as 
well (89).
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2.4.  T1-iFns drive the influx of mtb-permissive myeloid cells during acute 
infection
Most studies in mouse TB models found significant functional effects of T1-IFNs spe-
cifically on CD11b+Gr1int myeloid cell populations (68, 69, 71). This population com-
prises monocyte-derived Ly6ChighCD11c-CCR2high inflammatory macrophages (iM) and 
Ly6CintCD11c+CCR2int inflammatory dendritic cells (iDC), but not CD11b+Gr1high PMN (90). 
This is an important distinction, as T1-IFNs actively inhibit PMN influx, as discussed in 
more detail below in paragraph 2.4.3.
iM and iDC have been identified as major contributors to disease progression in mouse 
TB models (91-93). Several lines of evidence suggest that T1-IFNs regulate the influx of 
these cells and play a role in their functional impairment to resist Mtb. This interference 
with protective immunity is multifaceted and concerns four important interactions, 
which will be reviewed separately:
1) T1-IFNs mediate the influx of iM and iDC. 2) T1-IFNs inhibit IL-1β responses by these 
cells, which are essential in the initial host-responses to Mtb. 3) Prolonged IL-1β signaling 
can also cause excessive inflammation and thus requires regulation during later phases. 
This can be mediated by T1-IFNs, but also by IFN-γ through functionally different routes. 
4) T1-IFNs and IFN-γ show a complex interplay in the activation of iM and iDC.
2.4.1.	 T1-IFNs	mediate	the	influx	of	iM	and	iDC
Mtb-infected mice treated with the T1-IFN-inducing compound poly-ICLC show in-
creased numbers of iM and iDC in the lungs, which are ten times more permissive to 
Mtb infection than their counterparts in PBS-treated mice (71). Others confirmed that 
signaling through IFNAR indeed augments the recruitment of Mtb-permissive iM and 
iDC into the lungs (69). Mechanistically, IFNAR-dependent expression of the chemokine 
CCL2 mediates the influx of CCR2+ monocytes that differentiate into iM and iDC (71). 
Both myeloid and parenchymal cells can produce CCL2 in response to T1-IFNs, but pa-
renchymal cells appear the main source of this chemokine (94-96). Expression of CCL2 is 
reduced in the lungs of IFNAR-/- mice and the pathogenic effects of poly-ICLC treatment 
are absent in Mtb-infected CCR2-/- mice (71). Thus, preclinical TB studies indicate that 
T1-IFNs stimulate the influx of CCR2+ monocytes, but not PMN, to the site of infection in 
a CCR2-dependent way via the induction of CCL2 in parenchymal cells (74-76).
2.4.2.	 T1-IFNs	inhibit	IL-1β	responses	during	acute	TB
T1-IFNs not only stimulate the influx of CCR2+ monocytes, but also stimulate their dif-
ferentiation into Mtb-permissive iM and iDC (71, 75, 76). This can be traced back to a 
crosstalk between T1-IFNs and IL-1β (73, 90). iM and iDC are the major sources of IL-1β 
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in the lungs Mtb-infected mice and IL-1β plays a crucial role in the acute host response 
to Mtb-infection (73, 90). IL-1β augments TNF-α-stimulated Mtb-killing and increases 
prostaglandin E2 (PGE2) production by upregulating cyclooxygenase-2 (COX2/PTGS2) 
(73, 97, 98). PGE2 is involved in control of intracellular Mtb replication, but also prevents 
necrotic host cell death (99). In accordance, Ptgs2-/- mice, unable to produce PGE2, are 
more susceptible to Mtb infection than wild type mice, but to a lesser degree than IL1-/- 
mice. Further information on PGE2 in TB is given in box 2.
T1-IFNs inhibit the expression and production of IL-1β and simultaneously increase the 
expression of 5-lipoxygenase (5-LO), which is a competitive enzyme for COX2 in the 
arachidonic acid metabolism (73, 90, 114, 115). As a result, IFNAR signaling causes a 
shift from COX2-mediated PGE2 production to an increase in the 5-lipoxygenase (5-LO) 
products such as lipoxin A4 (LXA4) and leukotriene B4 (LTB4), which render cells more 
susceptible to necrotic cell death (73, 116). Pharmacological intervention in this process 
by administrating the 5-LO inhibitor Zileuton to Mtb-infected mice, improved disease 
outcomes during acute infection to similar extent as observed in IFNAR-/- mice(73). An 
overview on the balance between IL-1β and T1-IFNs is given in Figure 2.
2.4.3.	 	Prolonged	IL-1β	signaling	causes	PMN-mediated	tissue	damage	and	is	
regulated	by	both	T1-IFNs	and	IFN-γ.
The cross-talk between T1-IFNs and IL-1β influences disease outcome in TB (73). How-
ever, this does not fully explain the harmful effects of T1-IFNs observed in TB. Most 
importantly, although IL-1β production is essential for protective immunity in the acute 
phase of disease in TB, it requires strict regulation as unchecked IL-1β signaling in TB can 
result in excessive PMN-mediated tissue damage (120, 123). Also, as explained in box 2, 
IL-1β-mediated PGE2 production is protective during acute disease, but appears to have 
a detrimental effect during chronic disease. Lastly, inflammatory mediators associated 
with continuing infection, e.g. GM-CSF, predispose for IL-1β production over T1-IFNs by 
iM and iDC (43, 94, 124-126). This reflects an increasing need over time to limit IL-1β-
mediated inflammatory responses.
To prevent PMN-mediated inflammation caused by excessive IL-1β signaling, the expres-
sion and production of IL-1β is inhibited not only by T1-IFNs, but also by IFN-γ (90, 120). 
In line with this, both T1-IFNs and IFN-γ can inhibit PMN influx (127-131). T1-IFNs and 
IFN-γ can both reduce pro-IL-1β gene expression and increase the expression of soluble 
antagonists for the IL-1 receptor (114, 132).
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Despite the above mentioned functional similarities between T1-IFNs and IFN-γ in IL-
1β inhibition, mechanistic differences exist between these IFN types in mediating this 
effect.
Ex vivo studies in human iM and iDC demonstrate that IFN-β inhibits IL-1β production 
more potently than IFN-γ (90, 114). One explanation might be that IFN-γ inhibits IL-10, 
while T1-IFNs induce IL-10, which contributes to the inhibition of IL-1β production (90, 
Figure 2. inflammatory responses during acute infection in naïve inflammatory macrophages and 
dendritic cells
Green text indicates a beneficial host effect during Mtb infection, red indicates a detrimental effect. Mtb: 
Mycobacterium tuberculosis, PRR: Pattern recognition receptor, STING: Stimulator of interferon genes, TBK1: 
Tank-binding kinase 1, IRF3: interferon regulatory factor 3, 5-LO: 5-lipoxygenase, COX-2: cyclo-oxygenase 2, 
PGE2: Prostaglandin E2, EP2: Prostaglandin E2 receptor 2. ILC3: Innate Lymphoid Cells type 3. 1(97), 2(116), 
3(107), 4(98), 5(117), 6(106),7(118) 8(119), 9(120), 10(80), 11(94), 12(73), 13(71), 14(121), 15(122), 16(64), 17(65), 18(90).
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114, 115). Additionally, an IL-10-independent inhibition of IL-1β by T1-IFNs was recently 
identified (129). T1-IFNs induce cholesterol 25-hydroxylase, which potently reduces IL-
1β transcription and broadly represses IL-1-activating inflammasomes. In contrast, IFN-γ 
inhibits Il-1β by increasing intracellular nitric oxide (NO) in an iNOS-dependent way 
(120)., 2013). This prevents NLRP3 inflammasome activation and cleavage of pro-Il-1β 
into IL-1β. In contrast to the mechanisms exerted by T1-IFNs, IFN-γ-induced iNOS not 
only limits IL-1β-mediated inflammation, but also markedly enhances the bactericidal 
potential of iM (120). Conversely, T1-IFNs suppress iNOS production (90). Based on the 
stimulation of iNOS by IFN-γ and the inhibition of iNOS by T1-IFNs, it appears that iDC 
are more sensitive to T1-IFN signaling and iM to IFN-γ when both types of interferon 
are present. T1-IFN-mediated inhibition of iNOS appears to occur primarily in iDC, since 
iDC only expressed iNOS in IFNAR-/- mice during viral infection, while iM appear more 
sensitive to IFN-γ and are the main source of iNOS in wild-type mice (131).
When taken together, these data suggest that IL-1β inhibition by either T1-IFNs or IFN-γ 
has strong implications on the bactericidal potential of iM and iDC. Furthermore, T1-IFNs 
interfere with the induction of iNOS by IFN-γ, particularly in iDC. This fits the observation 
that IFN-γ only inhibits IL-1β production by iM but not iDC in mouse TB models (90). 
Notably, iDC are the most readily infected cells in the lungs of Mtb-infected mice (27) 
and are present in larger numbers than iM during Mtb infection (71, 133).
box 2. The dual faces of PGE2 in Tb immunity
PGE2 is generally considered a pro-inflammatory mediator and indispensable for the induction of fever, 
which is a hallmark symptom of active TB (100, 101). The anti-inflammatory effects of prostaglandin syn-
thase (COX-) inhibitors such as NSAIDs underline this notion. However, high levels of PGE2 can also exert 
immunosuppressive effects as they stimulate alternative activation of macrophages (102), inhibit bacte-
ricidal activity (103) and promote production of IL-10 (104). Moreover, high PGE2 levels can stimulate the 
development of myeloid-derived suppressor cells (MDSC) with inhibitory effects on adaptive immune 
cells (104, 105). Lastly, PGE2 inhibits IL-12 production by DCs and IFN-γ production by T-cells, thereby 
promoting Th2/Th17 immunity (106, 107). In the serum and broncho-alveolar lavage fluid of TB patients 
PGE2 levels were found to be elevated (73, 108, 109) and polymorphisms in the PGE2 receptor EP2 are 
associated with TB-susceptibility (110). Experimentally, one mouse study showed that low PGE2 levels 
in the acute phase of infection are essential for iNOS-mediated control of Mtb (111). Also, PGE2 plays an 
important role during acute TB since the PGE2-producing enzyme COX2 competes for arachidonic acid 
substrate with 5-lipoxygenase, which produces leukotrienes and lipoxins. Hereby, PGE2 prevents necrotic 
cell death thus benefiting the host (73). Opposed to the protective role of low PGE2 levels during acute 
disease, PGE2 levels are higher during the chronic phase of TB and these concentrations contribute to 
disease by suppressing IFN-γ, TNF-α and iNOS (111). Notably, the cellular source of PGE2 appears to differ 
between acute and chronic TB. During the acute phase of infection inflammatory myeloid cells are the 
main source of PGE2, while foamy macrophages are strong producers of PGE2 during the chronic phase 
of disease (112). In line with a detrimental effect of high PGE2 levels in the chronic phase, foamy macro-
phages are typically associated with disease progression(113).
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2.4.5.	 The	interplay	between	T1-IFNs	and	IFN-γ
During direct contact with Mtb through Toll-like receptors , endogenous T1-IFN signal-
ing through IRF3 promotes IL-12 production by iDC over IL-23 (see also: Fig. 2 and box 3) 
(94, 134, 135). This early IL-12 signaling is required to induce IFN-γ production by innate 
lymphoid cells (ILC) such as NK-cells and possibly ILC1s (136, 137). However, exogenous 
T1-IFNs or T1-IFN signaling in the absence of TLR stimulation can also inhibit IL-12 pro-
duction by iDC (115, 138). This inhibition of IL-12 by T1-IFNs occurs particularly through 
induction of IL-10 (15). T1-IFNs also inhibit the responsiveness of iDC to IFN-γ-mediated 
activation, which is required for Mtb-killing. This occurs partially by reducing the expres-
sion level of IFN-γ-receptor on the cell surface, but primarily through induction of an 
IL-10high regulatory phenotype in which antimicrobial pathways by IFN-γ are not readily 
activated, as discussed below (90, 115, 131, 139-141).
Recent findings might explain the mechanism behind this paradox where T1-IFNs initial-
ly support IL-12-mediated IFN-γ production by NK-cells, but can also induce an IL-10high 
phenotype in iDC, which interferes with IL-12 production and prevents IFN-γ-mediated 
activation. It has been observed in different mouse models, including Mtb-infected mice, 
that T1-IFNs can only induce an IL-10high regulatory phenotype in monocyte-derived DCs 
(iregDC) if these cells have been primed previously by IFN-γ (35). IFN-γ-primed DCs that 
did not receive T1-IFN signaling differentiated into iDC that stimulated robust T-cell 
responses. This phenomenon of monocyte-priming by IFN-γ has been demonstrated 
to occur in the bone marrow (142). During gut infections, local production of IL-12 in 
mucosa-associated lymphoid tissue stimulates bone-marrow resident NK-cells to pro-
duce IFN-γ as early as 3 days post infection (142). This results in a uniform presence of an 
IFN-γ-primed signature of Ly6Chigh monocytes in the circulation at day 6. Furthermore, 
box 3. il-12 or il-23 production by dendritic cells?
IL-12 and IL-23 are heterodimeric cytokines composed of a common p40 subunit, coupled with either a 
p35 subunit in IL-12 or a p19 subunit in IL-23. Both IL-12 and IL-23 are produced in particular by stimu-
lated dendritic cells and to lesser degree by macrophages. The preferential production of IL-12 or IL-23 
by these cells is multifactorial. Increased levels of PGE2 support IL-23 production over IL-12 (106, 107, 
143). Activation of TLR-2 and TLR-4 also stimulates IL-23 production over IL-12, especially when NOD2 
is simultaneously activated (144, 145). On the other hand, TLR9 and TLR3 agonists preferentially induce 
IL-12 (134, 146, 147). Downstream of PRRs, activation of IRF 4 and 5 favor induction of IL-23, while IRF 1, 3 
and 7 induce IL-12 (134, 148). In line with this, T1-IFN-mediated IRF-3 activation and IFN-γ-mediated IRF-
1-activation both favor IL-12 production (94, 134, 149).IL-4 also favors IL-12 production and inhibits IL-23 
production, especially in combination with IFN-γ or GM-CSF (150, 151). Lastly, an important pathway that 
promotes IL-12 over IL-23 is ligation of the co-stimulatory molecule CD40 by CD40L on activated T-cells 
or by agonist antibodies (152). Taken together, IL-23 is induced in the presence of pathogens and innate 
signaling in the acute phase of infection, while onset of adaptive immunity with increased levels of IFN-γ 
and/or IL-4 shifts the balance towards IL-12 (153).
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IFN-γ indeed primed these monocytes towards a regulatory phenotype, as they more 
effectively produced IL-10 in response to bacterial ligands (142). We speculate that a 
similar mechanism of IFN-γ priming is likely to be involved in pulmonary infections.
Figure 3. Hypothetical interplay between T1-iFns and iFn-γ in monocyte priming and shaping of the 
immune response in mtb infection
Dotted lines indicate speculations in the context of pulmonary Mtb infection; solid lines indicate shown 
pathways in human and/or in animal models. 1) T1-IFN induces migration of CCR2+ monocytes (iMo) from 
the bone marrow to the lungs of Mtb-infected mice under influence of CCL2 (71). Locally, these cells de-
velop into CD11b+Ly6Chigh inflammatory macrophages (iM) and CD11b+Ly6Cint inflammatory dendritic cells 
(iDC) (35). 2) As shown in Fig. 1, naïve iM and iDC can initiate either IL-1β-mediated inflammation or T1-IFN-
mediated inflammation. Mtb actively triggers intracellular PRRs to induce a T1-IFN-mediated response. 3) 
Additionally, iM and iDC in the naïve situation have differentiated under influence of M-CSF, which makes 
them more responsive to T1-IFN signaling (94). During progression of Mtb-infection, GM-CSF levels rise 
and increase the potential for IL-1β production by iM and iDC (94, 125, 154, 155). 4) Similar to the situation 
in gut infection, we propose that in TB IL-12 production in the lungs stimulates IFN-γ production by bone 
marrow-resident NK-cells, which locally primes monocytes (142). IFN-γ priming of monocyte-derived iDC 
is necessary for T1-IFNs to induce a regulatory (iregDC) phenotype in iDC in the lungs (35). 5) Addition-
ally, IFN-γ stimulates monopoiesis over granulopoiesis by granulocyte/macrophage progenitor cells (128). 
6) As Mtb infection progresses and GM-CSF levels increase, iM and iDC readily produce IL-1β (see also 3) 
(124, 154), which can lead to PMN-mediated inflammatory damage in TB (120). 7) IL-1β production can be 
inhibited in response to either IFN-γ or IFN-β through mechanistically distinct pathways that differently 
affect Mtb-killing 8) Signaling through IFNAR in IFN-γ-primed iDCs induces IL-10 production (35, 115, 131), 
inhibits IL-12 production (115) and makes these cells unresponsive to activation by IFN-γ (35, 115, 141), 
which together interfere with protective immunity during acute Mtb infection.
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These data suggest interplay between T1-IFNs and IFN-γ as proposed in Fig. 3. T1-IFNs 
initially induce IFN-γ responses by promoting IL-12 production in naïve cells as shown 
in Fig. 2. These IL-12 responses stimulate IFN-γ production by innate lymphoid cells not 
only locally, but also systemically, which results in IFN-γ priming of monocytes in the 
bone marrow. Once IFN-γ production is initiated, T1-IFNs mediate a regulatory function 
by inducing an IL-10high phenotype in IFN-γ-primed iDC. This prevents further production 
of IL-12 by these cells, inhibits their activation by IFN-γ and results in an Mtb-permissive 
phenotype.
2.5 summary: The role of T1-iFns in Tb
Several modest clinical successes have been shown with IFN-α supplementation adjunct 
to antibiotic TB treatment (Table 1). However, case reports of TB reactivation under 
IFN-α treatment without concomitant antibiotics have put T1-IFNs in a negative spot-
light (50-57). Furthermore, a T1-IFN transcriptional signature in circulating leukocytes 
is associated with active TB. Nevertheless, the functional role of T1-IFNs in TB patients 
remains to be determined (62).
Preclinical studies in mice support a detrimental role for T1-IFN in the acute phase of Mtb 
infection. T1-IFN signaling was associated with increased mortality in Mtb-susceptible 
mouse strains and higher Mtb loads in the lungs in most studies (Table 2). However, it 
should be noted that most of these preclinical studies do not unequivocally support a 
harmful effect of T1-IFNs during the chronic phase of disease based on mortality, Mtb-
loads or differences in adaptive immunity.
In support of a pathogenic role of T1-IFNs during acute infection, Mycobacteria actively 
induce T1-IFNs by triggering cytosolic PRRs. This leads to IFN-β production in an IRF3-
dependent way. Subsequently, T1-IFNs mediate the CCL2/CCR2-dependent migration of 
iM and iDC into the lungs (71). In these cells, interference of T1-IFNs with IL-1β and PGE2 
as shown in Fig. 2 can lead to an altered metabolism of arachidonic acids that leaves 
cells more vulnerable to necrotic cell death (73). However, sustained IL-1β signaling 
itself carries the risk of excessive inflammation in TB and not only T1-IFNs, but also IFN-γ 
inhibits IL-1β to prevent excessive PMN-mediated inflammation (120). T1-IFNs inhibit 
IL-1β more effectively than IFN-γ, but stimulate an IL-10high Mtb-permissive phenotype 
(71, 90).
Next to their shared ability to inhibit IL-1β, an interesting interplay between T1-IFNs 
and IFN-γ exists in TB as summarized in Fig 3. Two recent findings that are of particular 
interest include the observation that T1-IFNs can only induce an IL-10high phenotype in 
IFN-γ-primed cells (35) and the inductive role of T1-IFNs in early IL-12 signaling, which is 
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required for IFN-γ priming in the bone marrow (142). Further research into this complex 
interplay between T1-IFNs and IFN-γ during early host responses in TB would be highly 
interesting given the T1-IFN-inducing capacities of Mtb and the shaping effect of early 
T1-IFN or IFN-γ signaling on the ensuing immune response.
3. THE TH17 REsPOnsE in Tb
As discussed in the previous paragraph, T1-IFNs induce IL-12 production by iDC, while 
IL-1β induces IL-23. Other factors also influence production of IL-12 or IL-23 (see: box 3). 
IL-12 is essential for the induction of IFN-γ responses in TB, but IL-1β is protective during 
acute TB despite inducing IL-23 over IL-12. Similar to the requirement of IL-12 for Th1 
responses, IL-23 is essential for establishing Th17 immunity (156-158). Here we review 
the effect of IL-23 signaling and the Th17 response in TB.
3.1. introduction to the Th17 response
The Th17 response is distinct from classical cell-mediated Th1 immunity or B-cell-
stimulating Th2 responses and is often associated with a potent inflammatory response 
and tissue damage (158). Th17 cells display a high degree of plasticity and their ability 
to express signature markers of other T-helper lineages makes it difficult to establish 
their exact role in disease. Four different subsets of Th17 cells have been described to 
date with ranging inflammatory potential (159). On one side of the spectrum are highly 
inflammatory and often pathogenic IFN-γ /GM-CSF-producing Th17.1 cells that result 
from prolonged IL-1β and IL-23 signaling (Kara et al., 2015). On the other side are IL-
10-producing Th17 cells, which can even trans-differentiate into regulatory T-cells and 
contribute to resolution of inflammation (160).
Despite the plasticity in cytokine production, IL-17 remains the hallmark cytokine of the 
Th17 response. Next to Th17 cells, innate lymphoid cells such as γδ T-cells and ILC3 cells 
can also produce IL-17 in response to IL-23 and IL-1β (29, 117, 161). IL-17 exerts its ef-
fects primarily on nearby parenchymal cells and to lesser extent on hematopoietic cells, 
which is distinct from Th1 and Th2 cytokines like IFN-γ and IL-4 (158). In parenchymal 
cells, IL-17 primarily stimulates the production of the chemokines that attract PMN (162). 
However, it should be noted that IL-17 alone is a poor inducer of these chemokines and 
that synergistic activation by inflammatory ligands such as IL-1β, TNF-α or GM-CSF mark-
edly increases the effects of IL-17 (162, 163).
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3.2. The Th17 response in human Tb infection
The exact role of the Th17 response in human TB remains a topic of debate (13, 14, 164). 
Polymorphisms in genes encoding IL-17 are associated with susceptibility to pulmonary 
TB, which indicates a role for this cytokine in TB (165-168). However, these findings 
could not be reproduced in different demographic settings (169, 170). Analyses of Th17 
responses in peripheral blood mononuclear cells (PBMC) from TB patients do not show 
uniform results either. Direct ex vivo analyses of unstimulated circulating CD4+ T-cells 
show that active TB (ATB) is associated with reduced frequencies of circulating Th17 cells 
compared to latent TB infection (LTBI) (177, 185). However, serum IL-17 levels do not 
differ between ATB and LTBI and IL-17 is undetectable in the broncho-alveolar lavage 
fluid during both stages of disease (174, 177). Different studies report PBMC stimulation 
assays with Mtb-specific antigens showing either increased or reduced Th17 responses 
in ATB compared to LTBI (Table 3). These diverse findings are similar to those observed in 
IFN-γ response assays (IGRA), in which the levels of IFN-γ often also cannot discriminate 
between ATB and LTBI (186, 187). Interestingly, both Th1 and Th17 cells appear function-
ally inhibited in ATB patients by a PD-1-mediated immunosuppressive state (188-191). 
In accord, reductions in PD-1 expression under TB treatment restored both Th1 and Th17 
responses (184).
Taken together, systemic Th17 responses in TB patients demonstrate similar variability 
as observed for IGRA studies. Both are unable to distinguish ATB from LTBI. How these 
systemic responses relate to local host responses in the lungs has not been character-
ized in TB patients.
3.3.  Preclinical studies in mice support a protective role for il-23 and il-17 in Tb
Based on mortality and mycobacterial loads, studies in Mtb-infected mice support a 
protective role for IL-23 and IL-17 in TB, but only during later stages of disease (Table 4). 
Interestingly, these late protective effects result from effects induced during the initial 
phases infection (143, 192). This is due to the essential roles of IL-23 and IL-17 in the local 
formation of tertiary lymphoid structures (TLS) (193, 194). These structures are formed 
during early infection, but can persist for longer periods of time and are associated with 
Table 3. il-17 responses in patients with acute Tb (aTb) compared to latent Tb
increased in aTb no difference Reduced in aTb
% of il-17+cd4+ T-cells
Short incubation (0-48h) (171)* (172, 173) (174, 175)
Long incubation (72-144h) (173, 176) (172, 177) (175, 178)
Ex vivo il-17 production (176, 179) (177, 180, 181) (182-184)
*only in MDR-TB
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protective immunity in Mtb-infected mice (193, 195) (Table 4 / Fig. 4). Furthermore, 
IL-17 and IL-23 increase the expression of the chemokine CXCL13 (196, 197). This che-
mokine stimulates the influx of TLS-associated CXCR5+ follicular helper (Tfh)-cells, which 
facilitate optimal localization of effector T-cell populations within the lung parenchyma, 
thereby promoting efficient T-cell-dependent macrophage activation and intracellular 
Mtb killing (195, 196).
Table 4. Th17-related effects in preclinical Tb studies in mice
mice 
(age, 
wks)
inter-
vention
mtb strain, 
route
survival mtb load
(vs. wildtype mice)
immunological effect Ref
B6
(6-12)
IL23
p19 -/-
H37Rv 
(100 CFU), 
aerosol
No data No difference in 
lungs
1 log higher Mtb load 
in spleen at d.150
No IL-17-producing cells in 
lungs up to
d.150
(157)
B6
(6-12)
IL23
p19 -/-
H37Rv 
(100 CFU), 
aerosol
No data d.120 and onwards, 
0.5-1 log higher Mtb 
load in lungs
Reduced no. of B-cell follicles 
at d.200 (Cxcl13-mediated)
Strongly impaired IL-17, IL-22 
production in lungs up to 
d.250
(196)
B6
(6-12)
IL22 -/- H37Rv 
(100 CFU), 
aerosol
No data No effect up to
d.200
Suboptimal B-cell follicle 
development (Cxcl13-
mediated)
(196)
B6
(6-9)
IL-17
RA-/-
H37Rv (1.103 
CFU), i.t.
higher mortality 
(median 
survival: 18 vs. 
35 wk)
1.5 log higher Mtb 
load at w. 12 and w. 
20 in lungs
Impaired cell recruitment 
(PMN, Lymphocytes, Mo/DC)
Increased IL-1β
Decreased TNF-α, IL-6 & IL-10
(192)
B6
(6-12)
IL-17
RA -/-
H37Rv 
(100 CFU), 
aerosol
No data No effect up to d. 200 Suboptimal B-cell follicle 
development (Cxcl13-
mediated)
(196)
B6
(8-12)
IL-17 -/- H37Rv (1.103 
CFU), i.t
No data 1.5 log higher Mtb 
load
Reduced no. of granulomas 
at d.28
(201)
B6
(6-8)
IL-17 -/- HN878 
(100 CFU), 
aerosol
No data 1 log higher Mtb load 
in lungs at d.30
0.5 log higher Mtb 
load in lungs at d.60
Infection with HN878 
showed robust production 
of IL-1β through TLR2, which 
supported increased IL-17 
production compared to 
H37Rv and CDC1551
(197)
B6
(6-8)
IL-17 -/- H37Rv, 
CDC1551 
(100 CFU), 
aerosol
No data No difference at
d.30 and d.60
(197)
B6
(8-12)
IL-17-/- H37Rv,
(1.103 CFU),
i.t
Higher 
mortality
1.5 log higher Mtb 
loads in lungs at d. 
30, 1 log higher Mtb 
loads at d.60 d.120
Impaired granuloma 
formation, γδ T-cells primary 
source of IL-17
(200)
CFU: Colony forming Units, IL-17RA: IL-17 receptor A, i.t: intra-tracheal instillation.
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On account of their ability to induce TLS formation, boosting IL-23 and IL-17 production 
is also an interesting strategy for vaccine-induced protection against TB. In this regard, 
IL-17 production by Th17 cells during recall responses is indeed dependent on IL-23 and 
could reduce mycobacterial loads in the lungs of Mtb-infected mice (198). Th17 cells 
preferentially migrate to the lungs and are better contained in the lungs compared to 
Th1 cells upon adoptive transfer to naïve mice (198, 199). The developmental flexibility 
of Th17 cells is illustrated in experiments where Mtb-antigen-primed Th17 cells have 
Figure 4. The il-23/il-17 axis in acute Tb
When iDC recognize Mtb through membrane-bound TLRs, they can secrete IL-1β, IL-23 and PGE2 (see: Fig. 
1). This occurs more efficiently if iDC are activated through contact with Mtb-infected PMN, which also stim-
ulates their migratory capacity to TLS and promotes recall immunity (202-206). 2) The combination of IL-1β 
and IL-23 induces IL-17 production by γδ T-cells and possibly ILC3 (29, 117). 3) Activation of parenchymal 
cells by IL-17 in combination with IL-1β or other inflammatory mediators ultimately results in PMN influx. 4) 
PMN contribute to inflammation when stimulated by extracellular Mtb or inflammatory cytokines. 5) Acti-
vated PMN readily cause tissue damage through production of ROS and proteases; this effect is suppressed 
by activated iDC in a PGE2-dependent way (112, 207, 208). 6) IL-23 and IL-17 stimulate the local production 
of CXCL13 by stromal cells (193, 196). This promotes TLS formation and follicular helper T-cell migration to 
the site of infection. 7) CD40 ligation in the interaction between (i)DC and CD4+ T-cells is a strong stimulus 
for IL-12 production over IL-23 (box 3) and leads to Th1 formation and IFN-γ production. 8) IFN-γ inhibits IL-
1β production and shifts IL-23 production to IL-12, thus inhibiting Il-17 production and reinforcing the Th1 
response (209). 9) In the absence of inflammatory stimuli, PMN can produce IL-10 and undergo apoptosis. 
Phagocytosis of apoptotic PMN induces an IL-10-producing regulatory M2c phenotype in macrophages 
and further contributes to resolution of inflammation.
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been adoptively transferred to naïve mice (198). Initially, these Th17 cells produce 
IL-17. However, upon recall immunity against Mtb, they primarily produce IFN-γ, with 
or without IL-17. Paradoxically, the latter switch results in a less effective reduction in 
bacterial loads compared to IL-17-producing Th17 cells that are adoptively transferred 
from IFN-γ-/- mice. This tendency of Th17 cells to produce IFN-γ instead of IL-17 during 
recall responses might explain the observation that IL-17 production during later phases 
of Mtb infection is dominated by γδ T-cells rather than CD4+ cells (117, 200).
When taken together, initial shaping of the local inflammatory environment by IL-17 and 
IL-23 during acute infection stimulates local TLS formation. This facilitates the develop-
ment of more robust Th1 responses by improving contact between antigen-presenting 
cells and lymphoid cells (Fig. 4). Furthermore, Th17 cells confer protective immunity 
during recall responses by their enhanced capacity to migrate to the lungs and stimulate 
Tfh responses compared to other CD4+ T-helper cell populations.
3.4. The Th17 response, Pmn and inflammatory damage
IL-17 stimulates granulopoiesis in the bone marrow and increases PMN influx to the site 
of infection by inducing G-CSF, CXCL1, CXCL3 and CXCL5 expression by parenchymal 
cells in mice or G-CSF and IL-8 in humans (158). These effects of IL-17 are markedly en-
hanced through synergistic activation by inflammatory mediators such as IL-1β, TNF-α 
or GM-CSF (162, 210, 211). In this regard, IL-17 is not a strong inducer of inflammation by 
itself, but rather amplifies pre-existing inflammation.
This IL-17-mediated ‘inflammatory boost’ can positively shape adaptive immunity, but 
prolonged or repeated antigen exposure can also lead to PMN-mediated pathological 
inflammation (212). Since IL-17 signaling is inevitably linked to PMN influx, the role of 
PMN in TB provides an additional perspective on the effects of IL-17 signaling in TB.
Review of available literature on the role of PMN in TB yields a complex picture with 
seemingly conflicting effects (14, 164, 213). In patients with active TB, PMN are the 
predominantly infected cells in the airways and provide a permissive site for a burst of 
active mycobacterial replication prior to transmission (214). On the other hand, PMN 
from healthy individuals, especially when stimulated with TNF-α, show a strong bacte-
ricidal effect (215). In preclinical TB models, highly susceptible mouse strains such as I/
St, CBA/J or DBA/2 show an enhanced influx of apoptosis-resistant, highly phagocytic 
neutrophils that negatively affect survival compared to more TB-resistant C57BL/6 and 
BALB/c mice (216-218). Moreover, PMN are poor producers of essential cytokines such 
as IL-1α/β and IL-12p40 in the anti-TB response (90, 219). These effects in preclinical 
models primarily suggest a negative contribution of PMN to acute disease. However, 
Chapter 2
46
increasing evidence suggests a supportive role for PMN in protective immunity. PMN 
can indirectly augment IL-1β-mediated inflammatory responses in macrophages after 
contact with Mtb (202, 204, 205). Also, and consistent with Th17 responses, PMN play 
an essential role in generation of protective recall responses in Mtb-infected mice (192, 
206, 220). Early, but not late PMN recruitment is essential for IL-17-mediated long-term 
control of Mtb infection (192). This can be explained by the finding that DCs that acquire 
Mtb through uptake of infected PMN are better able to activate T-cells (203, 220). The 
importance of this mechanism is recently highlighted in Mtb-infected mice, showing 
that PMN-depletion during vaccination prevented the generation of specific Th1 and 
Th17 responses (206).
A second emerging protective role of PMN is their contribution to initiating inflam-
mation resolution (221). In mouse TB models, PMN are the main producers of IL-10 in 
the lungs and can dampen inflammatory damage (222). In this regulatory role, PMN 
inhibit Th17 responses, but do not interfere with IFN-γ-mediated Th1 immunity due to 
relative insensitivity of Th1 cells to IL-10 (222, 223). Another regulatory effect of PMN 
concerns their apoptosis and subsequent phagocytosis by macrophages in the absence 
of extracellular Mtb. This inhibits IL-23 production by these macrophages and induces a 
regulatory IL-10high M2c phenotype under influence of IL-17 and IL-10 (see Fig. 4) (224, 
225). IL-17 can further contribute to this process by attenuating the anti-apoptotic effect 
of GM-CSF on PMN and by stimulating PMN apoptosis (226, 227).
Taken together, PMN recruitment to the site of infection is largely dependent on IL-17, 
but only in synergy with innate inflammatory cytokines such as IL-1β. Locally, these re-
cruited PMN contribute to inflammation if pathogens are still present, improve dendritic 
cell function and contribute to the formation of recall responses, or initiate resolution of 
inflammation in the absence of inflammatory or microbial stimuli.
3.5. summary: The role of Th17 immunity in Tb
The roles of IL-23 and IL-17 in TB are more subtle than the effects of Th1-related cytokines 
or T1-IFNs. Patient data are mostly limited to studies in PBMC. These show inconclusive 
results that are possibly confounded by the dynamics and heterogeneity of the Th17 
response, which can range from highly pro-inflammatory IFN-γ/GM-CSF-producing 
Th17.1 cells to IL-10-producing regulatory Th17 cells.
Preclinical mouse TB models provide evidence for a protective role of the Th17 cytokines 
IL-23 and IL-17 in TB. These protective effects become apparent in the chronic phase 
of infection, but result from IL-23/IL-17-mediated effects in the earlier, acute phase 
of infection. This is associated with early protective effects of IL-1β, which is a strong 
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inducer of IL-23 and IL-17 (Fig. 4). Mechanistically, evidence for the protective effects 
of IL-17 and IL-23 primarily points towards their role in the development of TLS during 
the acute phase of disease, which provide protective effects during later stages (193, 
228). Additionally, IL-23 and IL-17 induce CXCL13 expression that mediates the influx 
of TLS-associated Tfh cells. TLS and Tfh responses facilitate optimal interactions between 
adaptive and innate immunity, contribute to granuloma formation and improve the 
quality of T-cell recall responses in TB (195). In TB patients, TLS have also been associated 
with immune control, but more in-depth research is needed to establish their exact 
functional role and contribution to protective immunity (195).
Next to TLS formation and function, IL-23 and IL-17 mediate the influx of PMN into the 
lungs and the contribution of these cells to protective immunity in TB is increasingly 
recognized (206). Early, but not late PMN recruitment is essential for IL-17-mediated 
long-term control of Mtb infection (192) and DCs that acquire Mtb through uptake of 
infected PMN are better able to activate T-cells than DCs that directly interact with Mtb 
themselves (203, 220). The ability of IL-17 to induce the production of PMN-attracting 
chemokines in parenchymal cells is markedly improved when IL-17 signals in synergy 
with inflammatory mediators such as IL-1β, which again indicates synergy between IL-1β 
and IL-17 responses during acute TB. Prolonged activation of IL-1β and IL-17 responses 
can lead to massive accumulation of PMN and their local necrotic death can also be 
damaging to the host. However, in the absence of inflammatory stimuli, PMN are an 
important source of IL-10 in the lungs and can initiate resolution of inflammation (Fig. 
4).
4.  T1-iFns, THE TH17 REsPOnsE and THEiR inTERacTiOns in 
auTOimmunE disEasE
AID comprise a wide range of organ-specific and systemic disorders. Most systemic AID 
are considered classical B cell-mediated diseases, typified by circulating autoreactive 
antibodies against intracellular self-antigens. The clinical presentation of different AID 
varies, but evidence from genome-wide association studies points towards common 
immunogenetic mechanisms, as many systemic AID share disease-associated genes 
(229). Another trait particularly shared amongst different antibody-driven AID is the 
expression of a T1-IFN signature in both blood and disease-affected tissue (230-232), 
the strength of which generally correlates with disease activity and severity (233-236). 
Vice versa, T1-IFN immunotherapy as treatment for other diseases is known to cause 
symptoms similar to those observed in AID, such as development of psoriatic lesions in 
multiple sclerosis (MS) or hepatitis C-infected patients (237, 238).
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T-cells also have a major impact on the development and progression of AID and increas-
ing evidence points towards crucial involvement of the Th17 response in the pathogen-
esis of multiple AID (159, 239) (Martin et al., 2014;Lubberts, 2015). Th17 cells have been 
shown to be critical in the pathogenesis of MS and rheumatoid arthritis (RA) (19, 159). 
However, Th17 cells have also been associated with disease severity in autoimmune dis-
eases characterized by a T1-IFN signature, such as systemic lupus erythematosus (SLE), 
(20, 231, 240, 241). Since T1-IFN signatures and Th17 responses are both associated with 
disease in AID, the question arises whether these two pathways act in concert to sustain 
and amplify autoimmune responses, or control each other (20, 21, 242). Therefore, we 
will discuss below the involvement of the T1-IFN and Th17 responses in AID individually 
as well as their interaction. We refer readers who are familiar with the contributions of 
T1-IFN and Th17 in AID to continue at paragraph 4.3 where we discuss the interaction 
between these pathways.
4.1. The contribution of T1-iFns to the pathogenesis of aid
Most insight into the role of T1-IFNs in the pathogenesis of AID has been obtained in SLE, 
which was the first disease in which a T1-IFN transcriptional signature was identified in 
2003 (233). Since then it has become clear that 60-80% of adult SLE patients and nearly 
100% of pediatric SLE patients express a T1-IFN signature in their blood (243). Several 
mechanisms through which T1-IFNs contribute to disease in SLE, outlined below, have 
been elucidated.
4.1.1.	 Induction	of	T1-IFNs	in	AID
Specifically IFN-α appears to play a central role in SLE pathogenesis (243, 244). As men-
tioned in paragraph 2.3, IFN-α is produced in an IRF7-dependent way by pDC and other 
myeloid cell types. In accordance, pDC have been found to be a major source of T1-IFNs 
in SLE (245, 246). Immune complexes (IC), consisting of antibodies bound to self-DNA, 
are a major trigger for IFN-α production by pDC in AID (247) . However, pDC are not acti-
vated by self-DNA under steady state conditions, which indicates that additional stimuli 
are required. One such stimulus is the PMN-derived antimicrobial peptide LL37 (247), 
which converts inert self-DNA into a potent activator of endosomal TLR9 (248). Another 
stimulus is the nuclear protein High Mobility Group Box 1 protein (HMGB1), which is 
secreted by activated myeloid cells and passively released by necrotic, but not apoptotic 
cells (249). HMGB1 binds DNA and the formed complexes bind with high affinity to RAGE 
(receptor for advanced glycation end-products), which facilitates internalization into 
the endosome where TLR-9 can be activated (247). Extracellular HMGB1 also triggers 
the recruitment of PMN and stimulates their formation of Neutrophil Extracellular Traps 
(NETs) (250). NETs contain large amounts of nucleic acids and LL37, and are also a major 
driving factor behind chronic pDC activation and IFN-α production in SLE (251).
49
Type 1 interferons and the Th17 response in TB
It deserves mention that NET-formation is driven by reactive oxygen species (ROS), 
which in PMN are particularly produced by NADPH-oxidase and subsequently processed 
by myeloperoxidase (252). Paradoxically, despite the capacity of NETs to induce T1-IFNs 
and the pathogenic role of T1-IFNs in SLE, NADPH oxidase appears to be protective in 
SLE (253). Lupus-prone mice deficient in NADPH-oxidase develop more severe SLE (253). 
Moreover, autoimmunity with T1-IFN signatures can still develop in individuals with 
chronic granulomatous disease, who lack NADPH-oxidase activity (254). This seeming 
contradiction has been partially explained by the observation that IgG auto-antibody-
mediated NETosis, which is most relevant in SLE, is specifically reliant on mitochondrial 
ROS, while NETosis induced by e.g. TLR4 signaling is NADPH-dependent (254). In line 
with this, NETs from SLE patients have been shown to contain mitochondrial DNA (254). 
Thus the way NETs are induced and the type of DNA that is present on NETs probably 
also influences their ability to induce T1-IFNs and their role in disease.
Taken together, TLR9-mediated IFN-α production by pDC in response to immune 
complexes and NETs appears the major driving factor behind T1-IFN production in 
autoantibody-mediated AID. Additionally, the way NETs are induced and the type of 
DNA present on NETs can influence disease outcomes.
4.1.2.	 Disease-promoting	effects	of	T1-IFN	in	AID
T1-IFNs exert a detrimental effect in AID through different pathways. In monocyte-
derived cells T1-IFNs stimulate maturation, increase phagocytic capacities (255) and 
increase the expression of co-stimulatory molecules (256). Also, T1-IFNs have a direct 
stimulating effect on T-cells. Together these effects promote the generation of autoreac-
tive T-cells which support autoreactive B-cell responses (255, 257).
At cytokine level, T1-IFNs can induce the production of B-cell Activating Factor (BAFF) 
by myeloid cells (236, 258, 259). BAFF induction confers a significant proportion of T1-
IFN-mediated damage in SLE as supported by the observation that IFN-α administration 
induces disease in SLE-prone mice, but fails to do so in B-cell-deficient and BAFF-defi-
cient mice on the same background (260). BAFF plays a central role in the development 
and selection of autoreactive B-cells (258). In line with this, increased BAFF expression 
correlates with disease severity in SLE (21, 258, 261). BAFF also induces class switch 
recombination in B-cells, leading to preferential expression of IgG and IgA over IgM, 
which is important for Fc-receptor-mediated NETosis induction in PMN (262). The clinical 
relevance of BAFF in SLE pathogenesis is illustrated by the current use of Belimumab, a 
monoclonal antibody against BAFF, as treatment for SLE (263). Interestingly, targeting 
BAFF is effective in SLE patients, while B-cell depleting therapies using CD-20-targeting 
Rituximab show disappointing results in phase III clinical trials (264, 265). This suggests 
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effector functions of BAFF other than B-cell activation. In this regard, BAFF can act as a 
co-stimulatory molecule for T-cells and promote Th17 development (266, 267). BAFF can 
also directly activate plasma cells, which are not depleted by rituximab (268, 269).
4.2. The contribution of Th17 in the pathogenesis of aid
4.2.1.	 GM-CSF-secreting	Th17.1	cells
Pathogenic effects of Th17-mediated immunity in AID have been studied most detailed 
in MS and RA and their respective mouse models, experimental autoimmune encepha-
litis (EAE) and collagen-induced arthritis (CIA) (159, 240). MS was long believed to be 
primarily driven by an IL-12/Th1 response, but this concept was challenged by obser-
vations in the EAE mouse model for MS showing that the IL-23p19 subunit instead of 
IL-12p35 (see box 3) caused disease (270). In addition, the classic cytokines of Th1 and 
Th17 immunity, i.e. IFN-γ and IL-17, respectively, were found dispensable in EAE and 
instead GM-CSF appeared to be the effector cytokine responsible for IL-23-induced en-
cephalopathy (118). Notably, while most studies agree on a central pathogenic role for 
GM-CSF in MS, conflicting results are reported regarding its cellular source (19, 271-273). 
One study shows that GM-CSF expression in MS patients is promoted by the IL-12/T-bet/
Th1 axis, instead of IL-23 as observed in mouse EAE (271). Other publications report that 
B-cells are a major source of GM-CSF and specifically act in concert with Th17 cells (272, 
274). In accord with these discrepant results, MS is shown to be a heterogeneous disease 
that can be driven by either Th1 or Th17 immunity (240), which also has implications for 
therapy as will be discussed in paragraph 4.3.1.
One interesting observation in this regard is the development of ‘hybrid’ Th17.1 cells 
that express markers of both Th17 cells and Th1 cells. Naïve CD4+ T-cells in both mice and 
man do not express the IL-23 receptor and can either differentiate into T-bet+ Th1 cells 
under influence of IL-12 or differentiate into CCR6+ Th17 cells under influence of IL-6 and 
TGF-β (275). These IL-6/TGF-β-differentiated Th17 cells have low inflammatory potential 
and are prone to adopt an IL-10-producing regulatory phenotype. However, IL-6 also 
induces STAT3-dependent upregulation of IL-23 receptor (276). Subsequent (re)activa-
tion of such IL-6-primed Th17 cells by IL-23 increases Th1-associated T-bet expression 
and generates inflammatory IFN-γ/GM-CSF-producing Th17.1 cells (275). These cells can 
also switch their chemokine receptor profile and become CCR2+ instead of CCR6+ (275). 
Expression of CCR2 by Th17.1 cells can contribute to their inflammatory potential as it 
can divert their migration to sites without concomitant influx of regulatory T-cells, which 
depend on CCR6 for their migration (277).
Mechanistically, it was shown in a mouse EAE model that GM-CSF exerted its pathogenic 
effector function by stimulating IL-1β production by monocyte-derived cells (278). This 
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Figure 5. interactions between T1-iFn and Th17 immunity in aid
The color grading in the figure indicates the level of involvement of either Th17 immunity or T1-IFN-associated 
signaling. 1) T1-IFNs, primarily produced by pDC, but also by iDC and PMN, prime the latter cells towards a 
T1-IFN/BAFF-producing phenotype, promote NETosis by PMN and stimulate monocyte migration by inducing 
CCL2 production. 2) BAFF activates B-cells, stimulates TLS formation together with CXCL13, directly promotes 
Th17 differentiation (not shown) and stimulates the release of IL-1β by iDC. 3) TLS facilitate optimal interac-
tion between activated B-cells and antigen presenting cells (APC), while necrosis, NETs and T1-IFN increase 
the chance that these APC present self-antigens. Subsequent germinal center (GC) reactions within these 
TLS result in B-cells differentiating into plasma cells that produce large quantities of auto-antibodies. These 
auto-antibodies can mediate tissue damage and sustain a self-amplifying loop by inducing NETosis through 
binding the Fc-receptor on PMN. B-cells can also contribute to Th17 immunity by their ability to secrete IL-6 
and GM-CSF (not shown and uncertain if this is BAFF-dependent). 4) NETs trap antibodies. This facilitates their 
Fc-receptor-mediated internalization by pDC in which they stimulate T1-IFN production through endosomal 
TLR9 activation. Circulating NETs also stimulate IL-1β production by iDC and can mediate tissue damage. 
5) In a pro-inflammatory feedback loop, IL-23 stimulates the development of GM-CSF-producing Th17 cells 
(Th17.1), which in turn, together with BAFF and/or NETs stimulate an inflammatory phenotype in iDC. 6) IL-
1β and IL-23 stimulate IL-17 production by γδ T-cells, while concomitant stimulation with IL-1β and TNF-α is 
required for IL-17-induced G-CSF and chemokine production in parenchymal cells. 7) IL-1β and TNF-α activate 
PMN to release reactive oxygen species (ROS) and proteases that cause tissue damage. Furthermore, GM-CSF 
increases longevity of PMN (not shown). Lastly, the priming of PMN and monocytes prior to entering the site 
of disease is important for their eventual effector function. For monocytes this is shown in more detail in Fig. 3.
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suggests a positive inflammatory feedback loop, since IL-1β in turn promotes IL-23 pro-
duction and development of Th17.1 cells (118). A similar pathogenic Th17.1 response 
is observed in RA, which was the first AID in which IL-1β inhibition was approved for 
clinical use (279). Also, regarding the distinction between Th17 and Th17.1 responses in 
RA, it should be noted that anti-GM-CSF therapy shows more promise than anti-IL-17 in 
clinical phase I/II trials (159, 280).
4.2.2.	 The	contribution	of	IL-17-producing	Th17	cells	to	AID	pathogenesis
Next to GM-CSF-secreting Th17.1 cells, regular Il-17-producing Th17 cells also have been 
identified as pathogenic in other AID. This is best exemplified by the clinical successes 
of targeting IL-17 in psoriasis (281). Th17-associated pathogenic effects in SLE also ap-
pear to be driven by IL-17 rather than GM-CSF (21, 282). This is further supported by the 
specific contribution of PMN to disease in SLE, which is dependent on IL-17, opposed to 
GM-CSF which primarily influences the inflammatory potential of monocytes in MS and 
RA.
4.3. interactions between T1-iFns and the Th17 response in aid
SLE and other auto-antibody-mediated AID show a pathogenic role for T1-IFNs, while 
T-cell-mediated AID, such as MS, are driven primarily by GM-CSF-stimulated IL-1β 
production. With the functional dichotomy of IL-1β and T1-IFNs in mind, as shown in 
Fig. 2, MS and SLE seem to be opposite ends of the disease spectrum in AID instead 
of demonstrating interactions between T1-IFNs and the Th17 response. However, the 
existence of different Th17 subsets might explain this seeming disparity and suggest 
roles for GM-CSF-producing Th17.1 cells in MS and regular IL-17-producing Th17 cells in 
SLE. Both Th17 responses interact differently with T1-IFNs as will be discussed here. We 
identify three relevant interactions: 1) Th17.1 responses are fueled by T1-IFN-stimulated 
influx of CCR2+ inflammatory monocytes; 2) a pathological IL-17/T1-IFN/BAFF axis driven 
by NET-forming PMN; and 3) Th17 immunity and T1-IFNs collaborate in the generation 
and function of TLS. An overview of these pathways is presented in Fig. 5.
4.3.1.	 T1-IFNs	can	contribute	to	Th17.1-mediated	AID
Among MS patients treated with IFN-β, approximately 30-50% do not respond favorably 
to treatment (283). It was shown that IFN-β suppresses Th1-mediated inflammation in 
MS, but is ineffective and may even exacerbate Th17-mediated inflammation (19). This is 
one of the first studies that report a detrimental interaction between T1-IFNs and Th17 
responses. Given the importance of Th17.1 cells in MS, this negative outcome might be 
explained by the observation that IFN-β therapy in MS increases CCL2 production (284). 
Expression of this chemokine in the brain recruits inflammatory CCR2+ monocytes as 
well as Th17.1 cells, which switch their chemokine receptor profile from CCR6+ to CCR2+ 
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upon terminal differentiation (275). Moreover, Th17.1 cells stimulate IL-1β production 
in CCR2+ monocytes (278, 285). Inflammatory monocytes may differentiate locally into 
dendritic cells further stimulating Th17 responses (286). Thus, a strongly pro-inflamma-
tory condition is created in Th17.1-mediated MS. Since regulatory T lymphocytes rely 
on CCR6 rather than CCR2 (278), recruitment of these anti-inflammatory cells does not 
appear to hold pace with the influx of inflammatory monocytes and Th17.1 cells in MS.
4.3.2.	 A	pathological	IL-17/T1-IFNs/BAFF	axis	in	AID
IL-17 induces PMN influx through induction of G-CSF and chemokines (section 3.4), 
which contribute to the production of IFN-α by pDC via the NETosis process (section 
4.1.1). However, increasing evidence suggests a more prominent contribution of IL-17 
and PMN to T1-IFN-mediated disease in SLE. Firstly, besides being major inducers of 
IFN-α production by pDC upon NETosis, PMN also appear to be a significant source of 
IFN-α themselves (287, 288). This was related to their sheer numbers, as circulating pDC 
were 27 times more efficient in secreting IFN-α, but PMN were 100 times more frequent 
(287). Secondly, both T1-IFNs and IL-17-induced G-CSF prime PMN for NETosis (248, 289). 
In accord, circulating PMN of SLE-patients are also the main cells expressing the tran-
scriptional T1-IFN signature and release more NETs than PMN from healthy individuals 
(248, 251, 287, 288, 290, 291). Thirdly, T1-IFNs stimulate BAFF production, which is es-
sential for T1-IFN-mediated pathogenic effects in mouse SLE (259, 260, 292). It is recently 
shown that IL-17 also induces BAFF production and that IL-17-driven, G-CSF-dependent 
PMN recruitment drives plasma cell responses during emergency granulopoiesis in a 
BAFF-dependent way (268).
Also, therapeutically administered G-CSF, which is physiologically induced by IL-17, 
increases BAFF production by PMN (293). These interactions indicate a prominent role 
for IL-17-mediated PMN influx in T1-IFN-production and induction AID and synergistic 
induction of BAFF production by IL-17 and T1-IFNs. In support of this, IL-17 and Th17 cells 
are associated with disease severity in SLE to similar extent as T1-IFNs (20, 21, 239, 242). 
In turn, BAFF can promote Th17 responses (266, 267). This further suggests an inflam-
matory loop with a central role for PMN in which IL-17, T1-IFNs and BAFF continuously 
increase each other’s production and contribute to auto-antibody-mediated responses.
4.3.3.	 T1-IFNs,	Th17	responses	and	TLS
Lastly, T1-IFNs and Th17 responses converge onto the development and functioning of 
TLS. In these structures, Tfh cells support germinal center reactions in which B-cells differ-
entiate into antibody-producing plasma cells and memory cells (294). As expected from 
their function, TLS and Tfh cells are essential components in the pathogenesis of multiple 
auto-antibody-mediated AID (295-302). The cytokines IL-17 and IL-22 secreted by ILC3, 
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γδ T-cells and Th17 cells are required for local TLS-formation (193, 228, 303). T1-IFN and 
IL-17-induced BAFF promotes the formation and integrity of germinal centers within 
TLS and stimulates Tfh development (304, 305). T1-IFNs directly induce the expression 
of the Tfh-markers CXCR5 and PD-1 on T cells (306, 307). Also, T1-IFNs promote the sur-
vival of aberrantly selected B-cells in the GC reactions during SLE directly and indirectly 
through BAFF-induction as discussed in 4.2.2. Thus, it appears that by stimulating TLS 
development, the Th17 response facilitates an environment that promotes selection of 
autoreactive B-cells under influence of T1-IFNs and BAFF.
Taken together, several lines of evidence exist for interactions between the Th17 response 
and T1-IFNs in systemic AID. Current data support a scenario in which Th17 immunity fu-
els T1-IFN-related pathology by mediating PMN influx and driving TLS formation, which 
facilitates T1-IFN/BAFF-mediated plasma cell responses and auto-antibody production. 
In turn, T1-IFNs can support pathogenic Th17.1 responses in AID by driving the influx of 
CCR2+ inflammatory monocytes and potentially CCR2+ Th17.1 cells themselves, which 
locally drive IL-1β mediated inflammation. An overview of these interacting pathways 
is shown in Fig. 5.
Figure 6. Th17.1 responses in Tb
1) T1-IFNs induce CCL2 production in parenchymal cells and MDM, but not GMDM. This induces the influx 
of CCR2+ monocytes that mediate detrimental effects in TB as Mtb-permissive cells develop upon T1-IFN 
stimulation. 2) GM-CSF increases IL-1β production, limits responsiveness to T1-IFNs and increases Mtb-
killing potential. However, the exact cellular source of GM-CSF in TB is unknown. 3) Patients with active 
TB overexpress TGF-β, which may drive Th17 development over Th17.1 in the presence of IL-1β and IL-23. 
Dotted lines implicate mechanisms shown in AID that have not been confirmed in TB.
Outstanding questions:
1) What is (are) the cellular source(s) of T1-IFNs in TB?
2) What is the ratio between different Th17 subsets in TB?
3) Do T-cells contribute to GM-CSF production in TB?
55
Type 1 interferons and the Th17 response in TB
5. inTERacTiOns bETwEEn T1-iFns and TH17 immuniTy in Tb
In the previous section we have outlined how T1-IFNs and Th17 immunity interact in AID 
(illustrated in Fig. 5). These interactions primarily concern 1) Th17.1 responses fueled by 
T1-IFN-stimulated influx of CCR2+ monocytes; 2) The IL-17/T1-IFNs/BAFF axis driven by 
NET-forming PMN; and 3) Synergism between Th17 immunity and T1-IFNs in TLS forma-
tion and function. In this section we assess the relevance of these three pathways in TB 
based on cell types and effector molecules involved. Each subsection contains a part of 
Fig. 5, supplemented with relevant finding and outstanding questions in TB.
5.1. Th17.1 responses in Tb
Studies in MS and RA emphasize the difference between GM-CSF/IFN-γ-producing 
Th17.1 cells and regular IL-17-producing Th17 cells. The former primarily increase the 
inflammatory potential of monocytes (Fig. 7), while the latter are more closely associ-
ated with PMN. Data on subtypes of Th17 cells and particularly Th17.1 cells in human TB 
Figure 7. The il-17/T1-iFns/baFF axis in Tb
Mtb actively induces NET formation by PMN, but subsequent activation of IFN-α production by pDC appears 
less relevant in TB than in AID. IL-17 levels from TB patients vary (Table 3), but preclinical models support a 
protective role. Dotted lines implicate mechanisms present in AID that have not been confirmed in TB.
Outstanding questions:
1) What are the specific contributions of IFN-α vs. IFN-β to disease in the different phases of TB?
2) Do BAFF and T1-IFNs promote the observed auto-immune phenomena in TB?
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are limited. One study shows that circulating GM-CSF+ T-cells are not increased in ATB 
compared to LTBI, but it is unclear if this concerns Th17.1 cells or Th1 cells (308). Interest-
ingly, GM-CSF production by both granuloma-associated T-cells and circulating CD4+ 
T-cells in TB patients only occurs after mycobacterial antigen stimulation (308, 309). In 
mice, adoptively transferred Mtb-primed Th17 cells that produce IL-17 upon transfer, 
predominantly produce IFN-γ upon subsequent contact with Mtb, which is suggestive 
of a Th17.1 phenotype (198).
Th17.1 cells in AID result from prolonged innate IL-1β and IL-23 signaling. With regard to 
the role of IL-1β and IL-23 in human TB, IL-1β is essential for the expansion of both IFN-γ- 
IL-17+ Th17 cells and IFN-γ+ IL-17+ Th17 cells (310, 311). IL-23 promotes the development 
of IFN-γ+ IL-17+ Th17 cells, but promotes IFN-γ- IL-17+ Th17 cells if TGF-β is concomitantly 
present (310). Since active TB is associated with elevated TGF-b levels (188, 312, 313), it 
is possible that Th17.1 cell differentiation does not play a major role, but this remains to 
be demonstrated.
Th17.1-derived GM-CSF exerts a pathogenic effect in AID by stimulating IL-1β produc-
tion in CCR2+ monocytes. Although the role of Th17.1 cells in TB is uncertain, other cells 
such as NK-cells and Th1 cells can also produce GM-CSF in TB and during the course of 
infection GM-CSF levels progressively increase in the lungs of Mtb-infected mice (125, 
314). The functional role of GM-CSF is of interest in TB, because it importantly impacts 
on CCR2+ monocytes, which play a central role in T1-IFN-mediated pathogenic effects. 
T1-IFNs stimulate the influx of inflammatory CCR2+ monocytes, but inhibit their IL-1β 
production and stimulate their differentiation into Mtb-permissive cells (see: Fig. 3). In 
contrast, GM-CSF is protective during acute TB, which is in line with the protective effects 
of IL-1β in this phase of disease. Mice deficient in GM-CSF succumb rapidly to infection 
due to their inability to mount Th1 responses (315, 316). Transgenic mice that overex-
press GM-CSF in the lungs, but are GM-CSF-deficient in all other organs can develop Th1 
responses, but still succumb to infection more rapidly than wild-type mice due to their 
inability to develop a normal granulomatous response (315, 316). Evidence from in vitro 
studies suggests that GM-CSF exerts its protective effect in TB by countering the effects 
of T1-IFNs in CCR2+ monocytes (43, 94). Under physiological conditions monocytes dif-
ferentiate under influence of M-CSF into monocyte-derived macrophages (MDM). These 
MDM have a CCR2low phenotype, readily produce CCL2 and IL-10 in response to T1-IFNs 
and have a low Mtb-killing capacity (94, 155, 317, 318). Conversely, monocytes that dif-
ferentiate under influence of GM-CSF (GMDM) are CCR2high, relatively unresponsive to 
T1-IFN signaling, produce small amounts of CCL2 and IL-10 and have better Mtb-killing 
capacities than MDM in response to activation by IFN-γ (43, 126).
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The relative unresponsiveness of GMDM to T1-IFNs might explain why preclinical stud-
ies primarily show effects of T1-IFNs during acute TB when the GM-CSF/M-CSF ratio 
in the lungs is relatively low, but less pronounced effects during later stages when 
GM-CSF-levels progressively increase (section 2.4.3 / Fig. 3) (125). However, similar to 
IL-1β, prolonged GM-CSF signaling also appears detrimental in TB. In particular, GM-CSF 
contributes to foamy macrophage development during later stages of infection, which 
can sustain persistent mycobacteria and contribute to inflammation (125, 319).
In summary, relatively few data are available on Th17.1 cells or T-cell-derived GM-CSF in 
TB. The requirement for antigen stimulation of T-cells to induce expression of GM-CSF is 
interesting. However, elevated TGF-β levels in TB patients suggest a limited contribution 
of Th17.1 cells to disease, as TGF-β favors the development of regular IL-17-producing 
Th17 cells. Regardless of its cellular source, preclinical TB studies support a protective role 
for GM-CSF during acute infection. GM-CSF causes monocytes to differentiate into cells 
with decreased T1-IFN responsiveness and increased Mtb-killing potential compared to 
Figure 8. Tertiary lymphoid structures in Tb
TLS, Tfh cells, B-cells and antibodies are all associated with protective immunity in TB. Preclinical TB models 
show that TLS induction and CXCL13 production are driven by IL-17 and IL-23. T1-IFNs and BAFF support 
TLS function and Tfh responses in AID. In TB, T1-IFNs and BAFF are associated with active disease, but their 
functional role remains to be identified. Dotted lines implicate mechanisms present in AID that have not 
been confirmed in TB.
Outstanding question:
1) What are the functional roles of T1-IFNs and BAFF in TLS function and humoral immunity in Mtb infection?
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their M-CSF-differentiated counterparts. However, during chronic Mtb infection, high 
GM-CSF levels appear detrimental as they stimulate foamy macrophage development 
and inflammation.
5.2. The il-17/T1-iFns/baFF axis in Tb
In the previous paragraph it was discussed that regular IL-17-producing T-cells are more 
likely to play a role in TB than Th17.1 cells. Opposed to Th17.1 cells, regular Th17 cells 
exert their effect primarily through PMN instead of CCR2+ monocytes in AID. Particularly 
in SLE, this was shown to be part of a pathogenic axis together with T1-IFNs and BAFF. 
The roles of T1-IFNs and IL-17 in TB have been discussed already in section 2 & 3. In this 
section we assess the roles of the other components of the IL-17/T1-IFNs/BAFF axis in TB, 
which include PMN-derived NETs, pDC and BAFF (Fig. 7).
5.2.1.	 PMN,	NETs	and	pDC	in	TB
PMN isolated from SLE patients are the primary cells that express the transcriptional 
T1-IFN signature. Furthermore, a specific subclass of PMN, termed low-density granu-
locytes (LDG) have been identified in SLE that express a pro-inflammatory phenotype, 
have increased T1-IFN-production and more readily form NETs than PMN from healthy 
individuals (290, 291). Similar to SLE, the transcriptional T1-IFN signature in TB patients 
is mostly expressed in PMN (58). Moreover, LDG are also present in TB patients and cor-
relate with disease severity, but it is unclear if these cells also have a similarly increased 
tendency for NETosis as their SLE counterparts (320). Nevertheless, NETosis does occurs 
in TB, as Mtb readily induces NETosis itself in PMN in an ESX-1-dependent way and can 
even stimulate extracellular trap formation in macrophages (205, 321-323).
NETs are strong inducers of IFN-α production in pDC in SLE (254). Conversely, pDC pro-
duce only small amounts of IFN-α and appear of minor clinical significance in TB (324). In 
accord, circulating pDC are elevated in SLE (325), but reduced in TB patients (326).
Final support for a limited role of pDC in TB pathogenesis comes from the observation 
that pDC produce IFN-α after endosomal TLR-activation, while it is shown that Mtb 
primarily induces IFN-β through activation of cytoplasmic PRRs (see section 2.3) (80, 
248). While both IFN-α and IFN-β signal through IFNAR, this diversification in cellular 
source and type of T1-IFN that is induced can have important consequences for TB 
pathogenesis (see: box 4).
5.2.2.	 BAFF	in	TB
Both T1-IFNs and IL-17 can induce BAFF expression, which contributes to disease in SLE 
as illustrated by the clinical successes of BAFF-inhibition (259, 268, 327). BAFF increases 
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B-cell numbers and antibody titers (292, 328) and treatment with anti-BAFF in SLE 
patients reduces serum IgG levels (327). The role of BAFF in TB has been explored to a 
much lesser extent, with currently one paper demonstrating BAFF levels to be elevated 
in patients with active TB without elaborating on its functional contribution to the host-
response (329).
box 4: iFn-α or iFn-β: which is relevant in Tb?
IFN-α and IFN-β both exert their effect by binding to IFNAR, but increasing evidence from AID and viral 
infections suggests divergent effector functions (336, 337). In AID this is illustrated by the pathogenicity 
of IFN-α in SLE opposed to the therapeutic application of IFN-β as immunosuppressive treatment in MS. 
Recently, these different immunoregulatory roles of IFN-α and IFN-β in SLE and MS have been confirmed 
by more detailed analysis of blood transcriptional profiles in patients (338). The molecular explanation 
for the differential function of IFN-α and IFN-β traces back to subtle differences in receptor binding, 
signaling cascades and feedback mechanisms initiated, and has been reviewed in detail elsewhere (30, 
339).
The specific contributions of IFN-α and IFN-β to the host response in infectious disease have been stud-
ied particularly in mice infected with lymphocytic choriomeningitis virus (LCMV). This work supports an 
immune-stimulating, antiviral role for IFN-α as opposed to an immunosuppressive effect by IFN-β (336, 
339, 340). IFN-β specifically inhibits anti-viral T-cell responses and promotes viral persistence (339). In 
contrast, IFN-α-signaling associates with tissue damage and antiviral activity (339, 340).
In TB, evidence for the involvement of both T1-IFNs is present. Reactivation of TB has been reported 
specifically after treatment of patients with IFN-α, but not IFN-β(50-57). Also, mice infected with viru-
lent Mtb strains specifically show higher IFN-α levels in the lungs compared to less virulent strains (64, 
65). However, IFN-α-producing pDC seem to be of minor significance in TB patients (324, 326) and pre-
clinical studies show that Mtb preferentially induces IFN-β through cytoplasmic PRRs and IRF3 instead of 
IFN-α through endosomal TLRs and IRF7 (79-81). Mycobacterial persistence in patients with TB is a major 
clinical problem and in line with the immunosuppressed state in active TB primarily supports a role for 
IFN-β (188, 341). However, exaggerated innate responses are also observed in TB where IFN-α might be 
involved. This is supported by recent evidence showing that IRF7 drives excessive innate inflammation 
during bacterial infections and provides an interesting therapeutic target (342). Taken together, little is 
known about the separate effects of IFN-α and IFN-β in TB, but clinical and preclinical studies support a 
role for both in different disease contexts. The diversification of IFN-α and IFN-β responses in transcrip-
tional signatures observed in AID patients and the distinct effects of IFN-α and IFN-β in experimental 
LMCV infection therefore provide highly interesting perspectives for TB.
The functional role of BAFF in TB might be of particular interest given its stimulation 
of humoral immunity and the recently demonstrated protective effects of antibody-
mediated immunity in TB patients (330, 331). Next to antibody-mediated protection, 
B-cells also essentially support T-cell responses in TB, but circulating B-cells are dysfunc-
tional and reduced in absolute numbers in patients with active TB (332). The protective 
effects of Mtb-specific antibodies and B cells in TB suggest that increased BAFF levels 
may supports host responses by stimulating antibody production and perhaps other B 
cell functions such as stimulating T cell responses (330). However, high BAFF levels also 
predispose for the development of autoreactive B-cells in AID (333). Thus, elevated BAFF 
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levels in TB could relate to the observation that up to 32% of patients with active TB have 
elevated auto-antibody levels (12). Such correlations between elevated BAFF-levels and 
autoimmunity have been demonstrated in other chronic infections (334).
Additional support for a supposed protective role in BAFF in TB comes from its interac-
tion with IL-17, which shows protective effects in preclinical early infection phase TB 
models, as discussed in section 3. IL-17 stimulates the migration of PMN to lymphoid 
structures where they can produce large quantities of BAFF that directly drive plasma 
cell responses. Also, IL-17-induced G-CSF primes PMN for BAFF-production upon activa-
tion (268, 293). Vice versa, elevated BAFF levels have been reported to increase Th17 
immunity in AID and infection (266, 267, 335).
Taken together, preliminary pieces of evidence support the presence of interactions be-
tween IL-17, T1-IFNs and BAFF in TB, similar to those demonstrated in AID. This primarily 
includes the presence of NETs and elevated BAFF levels. However, despite the T1-IFN 
signature observed in TB, NET-induced IFN-α production by pDC appears less relevant 
in TB than in AID, and the specific contributions of IFN-α and IFN-β are of high interest 
in TB, but currently largely unknown. Studies in TB patients show protective effects of 
antibody-mediated immunity, but also elevated titers of autoantibodies. This supports a 
view in which BAFF is protective in TB, but excessive BAFF levels, driven by either T1-IFNs 
or IL-17 can also increase the chances of developing auto-immunity in TB patients.
5.3. Tertiary lymphoid structures in Tb
As a third place of interaction, IL-17, T1-IFNs and BAFF converge in the local formation 
and functioning of TLS. In these structures, Tfh cells support germinal center reactions 
in which B-cells differentiate into plasma cells and memory cells (294). As discussed 
in section 4.3.4 observations in AID suggest that Th17 responses drive TLS develop-
ment and facilitate an environment that promotes development of autoreactive B-cells 
under influence of T1-IFNs and BAFF. Conversely, both TLS and Tfh cells are associated 
with immune control in TB patients and preclinical TB models, which is in line with the 
protective role of humoral immunity in TB discussed in the previous section (195, 196, 
343, 344). Here we discuss how TLS and Tfh responses are associated with protective im-
munity in TB and how interactions between IL-17, T1-IFNs and BAFF may contribute to 
this immune response.
Migration of CXCR5+ Tfh-cells into TLS is largely dependent on CXCL13, which is primarily 
induced by IL-23 and IL-17 in mouse TB models, but can also be induced by T1-IFNs, 
as demonstrated in viral infections (196, 345). Mechanistically, CXCR5+ Tfh-cells medi-
ate their protective effect in Mtb-infected mice by facilitating optimal localization of 
61
Type 1 interferons and the Th17 response in TB
effector T-cell populations within the lung parenchyma, thereby promoting efficient 
T-cell-dependent macrophage activation and intracellular Mtb killing (195, 196).
Another interesting observation regarding Tfh responses concerns the induction of 
PD-L1 expression on antigen-presenting cells and PD1 on T-cells by T1-IFNs (35, 136, 
306). In TB circulating PMN primarily express the T1-IFN signature, but also overexpress 
PD-L1 (58, 346). The interaction of PD-L1 with PD1 on CD4+ T-cells is a key immuno-
logical checkpoint in TB that limits excessive T-helper responses (40, 42). In line with 
this, PD1-deficient mice are extraordinarily susceptible to TB (41). Tfh cells constitutively 
express PD1+, which distinguishes them from conventional CD4+ Th cells. Interestingly, 
while increased PD1/PD-L1 interaction suppresses conventional T-helper responses, 
the opposite is observed for Tfh responses (347). Interaction between PD1+ Tfh cells with 
PD-L1 has a stronger suppressive effect on the regulatory subset of Tfh cells than on 
stimulatory Tfh cells and results in a net increase of Tfh activity (347).
Taken together, IL-17, T1-IFNs and BAFF act in concert to drive TLS formation and Tfh 
responses. These responses support the development of autoreactive B-cells and the 
subsequent production of autoantibodies in AID, but confer protective immunity in TB 
by improving the interaction between adaptive and innate cells and facilitating antibody 
production, while simultaneously inhibiting excessive inflammation by conventional 
CD4+ T-cell responses.
cOncludinG REmaRks
The notion that complex mechanisms beyond Th1 immunity are at play in TB immunity 
is supported by 1) the unsatisfactory results of vaccine strategies aimed at boosting Th1 
immunity in TB patients (38); 2) The inflammatory damage associated with increasing 
IFN-γ production by T-cells in the lungs of Mtb-infected mice (40); and 3) The host-
detrimental effect of targeting the Th1-inhibiting PD1/PD-L1 interaction in mice (41, 42).
Patients with active TB express a T1-IFN transcriptional signature in their circulating 
leukocytes, but the exact identity and functional role of T1-IFNs in patients remains to 
be elucidated (62). Others have speculated that deleterious effects of T1-IFN-signaling 
during bacterial infections are tolerated because of their ability to suppress myeloid cell 
responses (31). This review highlights two additional aspects of T1-IFNs that are of inter-
est in TB. The first concerns the preconditioning of myeloid cells prior to their contact 
with T1-IFNs. IFN-γ priming appears essential for the induction of an Mtb-permissive 
phenotype, and monocytes that differentiate under GM-CSF are less responsive to T1-
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IFNs than their M-CSF-differentiated counterparts (Fig. 3) (35, 94). The second aspect 
is the diversification of IFN-α and IFN-β responses on a transcriptional and functional 
level as explained in box 4. We propose that the inflammatory effects of IRF7-mediated 
IFN-α might contribute to excessive innate inflammatory responses in TB, while the im-
munosuppressive effects of IFN-β are more likely to support mycobacterial persistence.
Determination of the role of the Th17 response in TB is impeded by its heterogeneity, 
reflected in the presence of different of Th17 subsets with ranging inflammatory poten-
tials. Observations in AID emphasize the difference between IFN-γ/GM-CSF-producing 
Th17.1 cells and regular IL-17-producing Th17 cells. The exact role of T-cell-derived GM-
CSF in TB remains to be determined, but preclinical TB studies show a protective role for 
GM-CSF on monocyte differentiation in the acute phase of TB. In contrast, IL-17 and PMN 
appear more relevant in chronic control of Mtb-infection and recall immunity.
Immunological similarities between TB and AID may result from commonly activated 
pathogenic pathways. Alternatively, compensatory mechanisms induced by one disease 
might predispose for the development of the other. Interactions between IL-17, T1-IFNs 
and BAFF form a pathological axis in AID that promotes autoantibody-mediated autoim-
munity.
The newly appreciated functional roles of antibodies, B-cells and Tfh cells in TB provide 
suggestive evidence that pathogenic mechanisms in AID confer protective immunity to 
TB. Further insight into these mechanisms as discussed in Fig 6-8 may generate leads 
for immune-directed therapies adjunct to current and newly developed antimicrobial 
treatment protocols.
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absTRacT
To identify how virulence among different Mycobacterium tuberculosis lineages can 
influence host responses, we infected BALB/c mice with Beijing-1585, EAI-1627 or the 
less virulent laboratory strain H37Rv. Disease progression was monitored up to 28 days 
post infection. Beijing-1585 and EAI-1672 infection resulted in higher mycobacterial 
loads at earlier time points. They induced a marked influx of B-cells and elevated IL-4 
protein levels in the lungs compared to H37Rv, which induced a T-cell influx with higher 
γγ and IL-17 levels. During infection with Beijing-1585 and EAI-1627, myeloid cells in the 
lungs appeared functionally impaired with reduced iNOS and IL-12 expression levels 
compared to H37Rv infection. In the bone marrow of mice infected with Beijing-1585 
and EAI-1627 we found reduced expression of IFN-γ, TNF-α and IFN-β, essential for 
myeloid cell priming, from the third day post infection onwards. Our findings indicate 
that the increased virulence of two clinical isolates compared to H37Rv is characterized 
by a fundamentally different systemic immune response, which already can be detected 
early during infection.
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inTROducTiOn
Tuberculosis (TB) is a leading cause of death among infectious diseases worldwide and 
claimed more victims in 2015 than HIV and malaria combined (1). While global efforts 
have resulted in a steady decline in TB-related deaths over the years, new threats are 
present in the form of drug resistance and the emergence of more virulent Mycobacte-
rium tuberculosis (Mtb) genotypes (1-3).
Mycobacterial strains belonging to the Beijing genotype particularly have shown an 
aggressive global spread over the last century and have been associated with higher 
rates of treatment failure and disease relapse compared to other genotypes (4-10). One 
major explanation for this clinical impact of the Beijing genotypes seems to be their 
increased capacity to acquire drug resistance (11). A less well-defined characteristic 
concerns their hypervirulence (12-14). Clinical studies on immunology and pathogenic-
ity of strains belonging to the Beijing genotype are challenging due to varying outcome 
parameter definitions (15, 16). Nonetheless, Beijing strains cause higher mycobacterial 
loads, more lung damage and earlier mortality compared to strains from other lineages 
in preclinical TB models (13, 17, 18). Mechanistic studies have suggested that Beijing 
strains have enhanced capacity to inhibit protective immunity in the lungs through in-
duction of higher levels of type-I interferons, leading to lower IL-12 and TNF-α levels and 
reduced T-cell activation (19, 20). Increased Beijing virulence also has been attributed 
to bacterial phenolic glycolipid (PGL)-production, which suppresses the production of 
IL-12, IL-6 and TNF-α by host immune cells (21, 22). Lastly, Beijing strains may induce a 
stronger regulatory T-cell response compared to other strains, thereby down-regulating 
protective immunity (17, 23).
One factor hampering Beijing genotype-specific immunological characterization is the 
genetic diversity among Beijing strains, which can substantially affect virulence (3, 24). 
In this study we evaluate the host response during acute infection against the well-
defined, highly virulent Beijing-1585 strain. This strain has previously demonstrated 
similar infection and mortality kinetics as other virulent Beijing strains (18, 24). Further-
more, Beijing-1585 was found associated with drug resistance and treatment failure (18, 
25). We compare Beijing-1585 with a clinical isolate from the East-African/Indian (EAI) 
lineage that displays similar virulence as Beijing-1585 in our model (18), and with the 
less virulent laboratory strain H37Rv (26).
Previous studies in our (BALB/c) mouse TB model showed that mice infected with the 
laboratory strain H37Rv reach maximal mycobacterial loads and start developing pro-
gressive pneumonia 28 days post infection (dpi). Next, they enter a phase of chronic 
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infection and become moribund between 22 and 38 weeks post infection (26). In 
contrast, mice infected with Beijing-1585 or EAI-1627 reach peak infection at 14 dpi 
with histopathological signs of pneumonia comparable to H37Rv at 28 dpi and rapidly 
become moribund between three to five weeks post infection if left untreated (26, 27). 
In this study we aim to identify the underlying host responses that might contribute to 
this marked difference in virulence.
maTERials and mETHOds
mycobacterial strains
We used the Mycobacterium tuberculosis H37Rv strain (ATCC 27294) and two strains 
isolated from patients in Vietnam in 2002, Beijing-1585 and EAI-1627, as representatives 
for their respective lineage based on genotyping results (27).
mice and infection
Female specific pathogen-free BALB/c mice aged 10-11 weeks and weighing 22-24 
grams (Charles River, Les Oncins, France) were infected by intra-tracheal instillation 
under general anesthesia as described previously (25). Inoculum sizes were confirmed 
by plating and were 1.0.105 colony forming units (CFU) for Beijing-1585, 1.3.105 CFU for 
EAI-1627 and 1.8.105 CFU for H37Rv. Mice infected with Beijing-1585 or EAI-1627 rapidly 
become moribund between 3-5 weeks (18), therefore mycobacterial loads and other 
parameters for these two clinical strains were measured up to the peak of infection at 
14 dpi, while measurements on H37Rv-infected animals were continued up to peak of 
infection at 28 dpi. All protocols were approved by the institutional animal ethics com-
mittee (DEC number 117-12-13, EMC-number 3005) and adhered to the rules laid down 
in the Dutch Animal Experimentation Act and the EU Animal Directive 201/63/EU.
determination of mycobacterial load
Lungs and spleens were removed aseptically and homogenized in 2 mL PBS using the 
gentleMACS Octo Dissociator (Miltenyi Biotec BV, Leiden, the Netherlands) according to 
the manufacturer’s protocol. From each tissue homogenate 10-fold serial dilutions were 
made. Next, 200 µL aliquots were plated on 7H10 agar culture plates supplemented with 
10% OADC. Plates were incubated for up to 42 days at 37 °C and 5% CO2 before colonies 
were counted.
Flow cytometry, Real-time quantitative PcR and cytokine assessment
The flow cytometry protocol, fluorescent antibody panels, Real-time quantitative PCR 
and Cytokine assessment were essentially as described previously (29). An additional 
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fluorescent antibody panel used in this study is described in supplementary Table 1. 
Primer sequences and manufacturers are listed in supplementary Table 2.
data analysis and statistics
Flow cytometry data were analyzed using Flowjo 7.6.5. Analyses were done and graphs 
were made using PRISM Graphpad 7. All data are expressed as mean ± SEM. Student’s 
t-test, followed by Bonferroni correction for multiple comparisons where applicable, 
was used to calculate significance, except for Fig. 7b. Here we used two-way, repeated 
measure ANOVA. P-values less than 0.05 were considered statistically significant.
REsulTs
beijing-1585 and Eai-1627 lead to higher mycobacterial loads than H37Rv at 
earlier time points
We found no significant differences in mycobacterial load between Beijing-1585, EAI-
1627 and H37Rv at 1 dpi and 3 dpi, indicating that all groups received a similar inoculum 
of mycobacteria (Fig. 1a). At 7 dpi, mice infected with Beijing-1585 had significantly 
higher mycobacterial loads than mice infected with EAI-1627 or H37Rv and at 14 dpi, 
Beijing-1585 and EAI-1627 caused almost 2 log higher loads than H37Rv. Mycobacterial 
loads for H37Rv at peak infection (28 dpi) were still 1 log lower than those observed 
for Beijing-1585 and EAI-1627 at 14 dpi. These findings are in agreement with previous 
studies monitoring mycobacterial loads for Beijing strains and H37Rv (13, 28).
To check whether the higher mycobacterial loads in the lungs caused by Beijing-1585 
and EAI-1627 were associated with more rapid dissemination to other organs, we deter-
mined mycobacterial loads in the spleen (Fig. 1b). No significant differences in culture-
conversion were found. At 7 dpi the Beijing-1585 group did show culture-positive 
spleens in all mice with higher loads compared to other groups.
beijing-1585 and Eai-1627 induce lung influx of b-cells, while H37Rv induces 
T-cell influx
To explore whether the distinct mycobacterial growth profiles in our model correlated 
with differences in adaptive immune responses, we evaluated the numbers of B- and 
T-cells recruited to the lungs by the three different strains. Most notably, Beijing-1585 
and EAI-1627 induced a strong influx of B-cells at 14 dpi, which was not observed for 
H37Rv at either 14 dpi or 28 dpi (Fig. 2a). In contrast, H37Rv induced the recruitment 
of CD4+ and CD8+ T-cells at 28 dpi, which was not observed upon infection with the 
clinical strains (Fig. 2b/c). Despite the marked T-cell increase in the H37Rv group at 28 
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dpi, Foxp3+ regulatory T-cells percentages of total lung single cell suspension remained 
lower compared to Beijing-1585 and EAI-1627 at 14 dpi (Fig. 2d). The total lung single 
cell suspension included parenchymal cells, which function as an internal control as it is 
reasonable to assume that their numbers remain constant during infection.
Figure 3 shows the associated cytokine protein levels in the lungs for each time point 
and genotype strain. In accordance with the increase in B-cells, Beijing-1585 and EAI-
1627-infected mice showed elevated protein levels of IL-4 at 14 dpi, which were 4-5 
fold higher than IL-4 levels observed for H37Rv at 14 and 28 dpi (Fig. 3a). Although 
Beijing-1585 and EAI-1627 also caused elevated protein levels of IFN-γ and IL-17a at 14 
dpi, these remained 2-fold and 6-fold lower respectively, compared to the H37Rv group 
at 28 dpi (Fig. 3b/c).
TNF-α protein levels in the lungs closely correlated with strain-dependent differences 
in mycobacterial loads over time. At 7 dpi, TNF-α levels were significantly induced only 
in mice infected with Beijing-1585- and EAI-1627, which were almost 2-fold higher at 
14 dpi compared to H37Rv at 28 dpi (Fig. 3d). This is in line with the role of TNF-α as 
general inflammation marker. In support of this, the inflammation marker IL-6 showed 
similar kinetics as TNF-α over time (Fig s1). IL-10 and IL-23 levels were also measured 
in the lung homogenates, but were below the limit of detection of our assay (data not 
Figure 1. mycobacterial loads in lungs and spleen
a) Mycobacterial loads in the lungs after intratracheal infection with Beijing-1585 (black bars), EAI-1627 
(open bars) or H37Rv (grey bars). At 14 dpi, Beijing-1585 and EAI-1627 cause higher loads than H37Rv at 
either 14 dpi or 28 dpi (peak infection H37Rv). After 14 days Beijing-1585 and EAI-1627-infected mice rap-
idly become moribund, therefore no later analyses for these strains are possible. b) Mycobacterial loads in 
the spleen. Dissemination rates from the lungs to the spleens are not significantly different. Beijing-1585-
infected mice showed higher loads at 7 dpi and 14 dpi compared to the other strains. Three mice were 
used for each group at 1 dpi and 6 mice for each group at the remaining time points. Inoculum sizes were 
1.0.105 CFU for Beijing, 1.3.105 CFU for EAI and 1.8.105 CFU for H37Rv. * p < 0.05 ** p <0.01 *** p<0.001 after 
Bonferroni correction.
93
Strain-related virulence in TB
shown). Quantitative PCR measurements of IFN-γ, IL-17a TNF-α, IL-6 in the lungs were 
also performed with outcomes comparable to those on protein level as shown in Figure 
3 (Fig. s2). IL-10 expression levels were above the lower limit of detection, but did not 
show strain-specific differences (Fig. s2).
Figure 2. lymphoid cell populations in the lungs of mice infected with different mtb strains
Lymphoid cells were determined in the lungs of mice infected with Beijing-1585 (black bars), EAI-1627 
(open bars) or H37Rv (grey bars) and compared to healthy control mice (HC, striped bars). a) B-cells are sig-
nificantly higher for Beijing-1585 and EAI-1627 at 14 dpi compared with H37Rv at 14 and 28 dpi. b/c) Only 
H37Rv shows an increase in both CD4+ and CD8+ T-cells at 28 dpi. d) Despite the increase in T-cells caused 
by H37Rv infection at 28 dpi, Foxp3+ regulatory T-cells are significantly lower compared to Beijing-1585- 
and EAI-1627-infected mice at 14 dpi. Gating strategies were similar as described previously (29). N=6 mice 
per group per time point, * p < 0.05, ** p < 0.01, *** p < 0.001 after Bonferroni correction. Data are shown 
as % of total lung single cell suspension including parenchymal cells. These cells function as an internal 
control as it is reasonable to assume that their numbers remain constant during infection.
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beijing-1585 and Eai-1627 induce a qualitatively impaired myeloid response 
compared to H37Rv.
Next, we evaluated potential differences in CD11b+ myeloid cells in the lungs that could 
explain the observed differences in lymphoid cell responses and cytokine levels. Lung 
polymorphonuclear leukocytes (PMN) percentages were increased in the Beijing-1585 
and EAI-1627 group compared to H37Rv at 7 dpi and 14 dpi, which was in line with 
the elevated mycobacterial loads and inflammation markers TNF-α and IL-6 at these 
time points (Fig. 4a). However, at 28 dpi the PMN frequency in the H37Rv group was 
comparable with that in the Beijing-1585 group and EAI-1627 group at 14 dpi.
Inflammatory macrophages / dendritic cells (iM/DC) showed a similar trend as PMN 
(Fig. 4b). Monocyte-like cells were present to a lesser extent than PMN and iM/DC, and 
were only higher in the EAI-1627 group at 14 dpi compared to the H37Rv group at 28 
dpi (Fig. 4c). Alveolar macrophages (AM) were reduced over time in all groups, associ-
ated with inflammatory cell influx, but most prominently at 14 dpi in the Beijing-1585 
and EAI-1627 groups compared to the H37Rv group (Fig. 4d). We also evaluated lung 
eosinophils in each group since these cells are known IL-4 producers, but levels of these 
cells were not elevated in the Beijing-1585 and EAI-1627 groups compared to the H37Rv 
group at any time point evaluated (Fig. s3).
AM and iM/DC are important cellular sources of IL-12 in the lungs (30), which is essen-
tial for initiation of T-cell responses (31). To determine potential functional differences 
between the infiltrating iM/DC and the lung-resident AM in the different groups, we 
measured the expression of IL-12p35 and IL-12p40. Most notably, Beijing-1585 caused 
the strongest down-regulation of IL-12p35 in the lungs compared to healthy control 
mice and did not induce any IL-12p40 expression at all time points evaluated (Fig 5a 
and 5b).
We also measured the expression of inducible nitric oxide synthase (iNOS) in both cell 
populations at each time point evaluated. iNOS expression is induced by IFN-γ and 
TNF-α and associates with bactericidal activity (30, 32). The AM from mice infected 
with Beijing-1585 failed to up-regulate iNOS at any point during the course of infec-
tion (Fig. 5c). In contrast, iNOS expression was already significantly higher in AM from 
H37Rv-infected mice at 3 dpi and its expression continued to increase up to 14 dpi. The 
expression of iNOS could not be determined in AM of H37Rv-infected mice at 28 dpi as 
the AM-population at this point was too small to be clearly separated from other cell 
populations (Fig 4d/ Fig s4a).
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iM/DC in lungs of mice infected with Beijing-1585 or EAI-1627 also showed significantly 
lower iNOS expression compared to H37Rv-infected mice at 3 dpi and 7 dpi (Fig 5d). At 
14 dpi, when IFN-γ and TNF-α levels were high in the lungs of mice from the Beijing-1585 
and EAI-1627 group (Fig. 3c), iNOS expression by iM/DC was increased accordingly. 
Nevertheless, iNOS expression by iM/DC in H37Rv-infected mice was significantly higher 
at 14 dpi despite lower levels of IFN-γ and TNF-α in the lungs compared to Beijing-1585- 
and EAI-1627-infected mice and iNOS expression levels increased even further at 28 dpi.
Figure 3. cytokine protein levels in the lungs of mice infected with different mtb strains
Protein levels were determined in lung tissue homogenates of mice infected with Beijing-1585 (black dots), 
EAI-1627 (open circles) or H37Rv (grey squares). a) IL-4 levels are 4-5 fold higher for Beijing-1585 and EAI-
1627 at 14 dpi compared to H37Rv at 14 dpi or 28 dpi. b) IFN-γ levels are elevated for Beijing-1585 and 
EAI-1627 at 14 dpi, but are 2-fold lower compared to H37Rv at 28 dpi. c) Beijing-1585 and EAI-1627 induced 
circa 7-fold lower levels of IL-17a at 14 dpi compared to H37Rv at 28 dpi. d) TNF-α levels are circa 2-fold 
higher for Beijing-1585 and EAI-1627 at 14 dpi compared to H37Rv at 28 dpi. N=6 mice per group per time 
point, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 after Bonferroni correction.
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infection with beijing-1585 induces less expression of inflammatory cytokines 
in the bone marrow compared to H37Rv
To assess if iM/DC from the H37Rv-infected group were primed differently at an earlier 
developmental stage, we determined cytokine mRNA expression in the bone marrow in 
the course of infection.
Similar to the lungs, IL-12p35 mRNA expression in the bone marrow was down-
regulated most effectively by Beijing-1585 infection compared to uninfected mice at all 
time points evaluated (Fig. 6a). Interestingly, Beijing-1585 infection also showed a lack 
of induction, or even reduced expression of inflammatory cytokines IFN-γ, IL-17a and 
Figure 4. myeloid cell populations in the lungs of mice infected with different mtb strains
CD11b+ cells were distinguished as PMN, iM/DC, monocyte-like cells (Mo-like) and AM in the lungs of mice 
infected with Beijing-1585 (black bars), EAI-1627 (open bars) or H37Rv (grey bars) compared to healthy con-
trol mice (HC, striped bars). a) PMN (CD11b+Ly6Ghigh) cells showed a more rapid increase for Beijng-1585 and 
EAI-1627 compared to H37Rv. b) iM/DC (CD11b+Ly6CintCD11chigh) showed kinetics comparable to PMN for 
the different groups. c) Monocyte-like cells (CD11b+Ly6ChighCD11clow) are only higher in the EAI-1627 group 
at 14 dpi compared to the H37Rv group at 28 dpi. d) Lung alveolar macrophages (CD11bintCD11chighSiglec-
F+) are lower in the Beijing-1585 and EAI-1627 group compared to the H37Rv group at 14 dpi. N=6 mice per 
group per time point, * p < 0.05, ** p < 0.01, *** p < 0.001 after Bonferroni correction.
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TNF-α compared to H37Rv as early as 3 dpi (Fig. 6b-d). Especially for TNF-a, expression 
levels differed markedly between BM cells from Beijing-1585- and H37Rv-infected mice 
over time with a decreased expression for Beijing-1585 at 14 dpi compared to 3 dpi, as 
opposed to a 34-fold increase for H37Rv. Measurement results for the EAI-1627 group 
consistently were intermediate between those for the Beijing-1585 and H37Rv groups, 
but tended to be more similar to results from Beijing-infected mice.
Figure 5. il-12 production and myeloid cell populations inOs expression in the lungs of mtb-infect-
ed mice
IL-12 mRNA expression in total lung homogenate (a,b) and iNOS expression in alveolar macrophages 
(AM) and inflammatory macrophages/dendritic cells (iM/DC) in the lungs (c,d) of mice infected with 
Beijing-1585 (black bars/dots), EAI-1627 (open bars/dots) or H37Rv (grey bars/squares) are compared to 
healthy control mice (HC, striped bars/open diamonds). a) IL-12p35 expression levels are lower in the Bei-
jing-1585 group compared to the EAI-1627 and H37Rv group. b) IL-12p40 expression is induced in EAI-
1627- and H37Rv-infected mice, and reached its peak for both strains at 14 dpi with higher expression in the 
H37Rv group. Beijing-1585 does not induce any notable expression of either IL-12p35 or IL-12p40 at all time 
points evaluated. c) AM in the lungs of Beijing-1585-infected mice fail to induce iNOS expression beyond 
levels observed in healthy control mice. d) iM/DC in H37Rv-infected mice show higher iNOS expression 
than iM/DC in the lungs of mice from the Beijing-1585 or EAI-1627 group at all time point evaluated. N=6 
mice per group per time point, * p < 0.05, ** p < 0.01, *** p < 0.001 after Bonferroni correction. For experi-
ments depicted in this figure, iM/DC are defined as CD11bhighCD11chighMHC-II+ cells and AM were defined as 
CD11bintCD11c+F4/80+CD200R+ cells (gating strategies: Fig. s4a), based on a distinct panel of antibodies. 
Population frequencies through this gating were highly comparable to those in Figure 4 (Fig. s4b).
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induction of type 1 iFn signature genes in the lungs of infected mice essentially 
correlates with expression of iFn-β
Lastly, we tested the mRNA expression of IFN-α genes (subtypes 1,2,5,6 and 7) in the 
lungs with methods described by Manca et al (20). We only found a limited expression of 
the tested IFN-α genes at 3 dpi for all strains, which decreased upon progressing infec-
tion and showed no significant inter-strain differences (Fig. 7a).
Since IFN-α and IFN-β share the ability to bind to, and signal via the IFN-α/β receptor, we 
evaluated IFN-β mRNA expression in the lungs. IFN-β expression in the H37Rv group was 
significantly higher than that in the EAI-1627 group at 3 dpi, and also higher than that in 
the Beijing-1585 group, but without statistical significance (Fig. 7b).
Figure 6. cytokine mRna expression levels in the bone marrow of mice infected with different mtb 
strains.
Expression levels of target cytokine mRNA are shown relative to Gapdh in the bone marrow of mice infected 
with Beijing-1585 (black dots), EAI-1627 (open circles) or H37Rv (grey squares). a) IL-12p35 expression at 3 
dpi and 7 dpi was lower in the Beijing-1585 group compared to H37Rv. b) IFN-γ expression was lower for 
Beijing-1585 at 3 dpi compared to H37Rv. c) IL-17a levels were markedly lower in the Beijing-1585 group 
compared to the H37Rv group (mean of 0.26 vs. 26.7), but without statistical significance (p= 0.06 after 
Bonferroni correction) due to the high spread in the H37Rv group (5.3 – 71.8). d) TNF-α levels were higher in 
the bone marrow of H37Rv-infected mice compared to Beijing-1585-infected mice at all time points evalu-
ated. EAI-1585 consistently showed intermediate results between Beijing-1585 and H37Rv for all cytokines. 
N=6 mice per group per time point, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 after Bonferroni 
correction.
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Type I interferons comprise several more subtypes than those for which we could test 
expression by qPCR and their expression is often transient. Therefore we decided to 
test the type 1 interferon response, represented by expression of Mx1, IFI44 and CCL2, 
which are known type 1 interferon-inducible genes (33-35). Expression levels of such 
genes can be combined into a type 1 interferon signature, which provides an indica-
tion of type 1 interferon responsiveness in a tissue (36). Our type 1 interferon signature 
showed different kinetics between Beijing-1585 and H37Rv, with EAI-1627 again show-
ing intermediate results (Figure 7c, see Fig s5 for individual graphs). Most notably, 
the Beijing-1585 group showed the strongest induction of type 1 interferon inducible 
Figure 7. Expression of iFn-α, iFn-β and type 1 interferon-inducible genes in lung and bm during 
infection with different mtb strains.
a) Combined expression of IFN-α 1,2,5,6,7 mRNA in lung homogenate did not show significant differences 
between groups b) Expression of IFN-β mRNA in lung homogenate is higher in the lungs of H37Rv-infected 
mice compared to EAI-1627-infected mice at 3 dpi. Other differences did not reach significance. c) Com-
bined expression in the lungs of type 1 interferon-inducible genes Mx1 (black), IFI44 (light grey) and CCL2 
(dark grey), represented in a type 1 interferon signature, showed the highest level in the Beijing-1585 group 
at 7 dpi and in the H37Rv group at 14 dpi. d) Expression of IFN-β in the bone marrow is higher in the H37Rv 
group compared to Beijing-1585 at 3 dpi. N=6 mice per group per time point, * p < 0.05, ** p < 0.01, *** p 
< 0.001 after Bonferroni correction. Two-way, repeated measure ANOVA followed by Bonferroni correction 
was used to calculate significance for Figure 7C.
Chapter 3
100
genes in the lungs at 7 dpi, while H37Rv-infected mice showed a higher peak induction 
at 14 dpi. The observed kinetics for the type 1 interferon-inducible genes at 7 dpi and 
14 dpi closely matched the trends observed for IFN-β expression at these time points, 
and not IFN-α, except for the absence of a type 1 interferon signature in the lungs of 
mice infected with H37Rv 4 days before. This suggests that in this model IFN-β is more 
relevant for the induction of type 1 IFN-regulated genes during acute infection than the 
tested IFN-α subtypes.
To compare the findings on IFN-β in the lungs at 3 dpi with differential systemic effects 
observed previously in the bone marrow, we measured IFN-β mRNA expression in the 
bone marrow. This showed a significantly increased expression of IFN-β in the H37Rv 
group compared to the Beijing-1585 group at 3 dpi (Fig. 7d).
discussiOn
This study shows that infections with two clinical isolates of Mycobacterium tuberculosis 
belonging to the Beijing and EAI lineages is characterized in the lungs by an influx of B-
cells, higher IL-4 protein levels and recruitment of myeloid cells that appear functionally 
impaired with low IL-12 and iNOS expression levels. Moreover, especially Beijing-1585 
infection is associated with a reduced expression of inflammatory cytokines in the bone 
marrow as early as from 3 dpi onwards, suggesting the hampered priming of developing 
myeloid cells for subsequent responses.
Our model suggests a pathogenic effect of B-cells during acute infection, thereby con-
trasting an earlier study that showed that B-cells reduced neutrophilia by limiting IL-17 
responses (37). We found lower IL-17 protein levels in the lungs of Beijing-1585- and 
EAI-1627-infected mice compared to H37Rv and a similar influx of PMN into the lungs 
at peak infection. These findings were in line with more recent studies demonstrating 
a protective effect of IL-17 during acute infection, particularly against Beijing strains 
(38, 39). Another study in non-human primates showed that B-cell depletion resulted in 
lower levels of inflammation and increased bacterial burdens during acute infection (40). 
Similarly, we found that the higher percentages of B-cells were associated with higher 
levels of inflammation, as expressed by inflammation markers TNF-α and IL-6, but also 
with higher bacterial burdens. Potential interactions between B-cells, IL-17 and inflam-
mation during acute TB are complex and reviewed elsewhere (41). However, based on 
our data it appears that the combination of a B-cell influx and high IL-17 protein levels in 
the lungs during acute infection causes excessive inflammatory damage without having 
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an effective bactericidal effect. Interestingly, during chronic infection a protective role 
was recently demonstrated for B-cells and antibodies in TB patients (42, 43).
Beijing-1585 and EAI-1627 infection elicited significant IL-4 protein levels in the lungs, 
thus matching the observed increase in B-cells. The presence of IL-4 was previously 
shown to exert a pathogenic effect during Mtb infection by diverting the role of TNF-α 
from myeloid cell activator to tissue damage mediator (44). In line with this, in vitro 
studies showed that Beijing-HN878, another highly virulent Beijing strain, preferentially 
induced IL-4 expression in human peripheral blood mononuclear cells compared to the 
CDC1551 strain (45), and that virulent Beijing strains induced higher IL-4 mRNA expres-
sion levels in the lungs of mice at 14 dpi compared to non-virulent Beijing strains (24). 
This adds to the support for a negative role of IL-4 and B-cell responses during acute 
infection.
The lack of T-cell influx into the lungs observed for Beijing-1585 and EAI-1627 compared 
to H37Rv can potentially be explained by differences found in IL-12 expression, which is 
essential for dendritic cell migration from the lungs to the lymph node and the initiation 
of T-cell responses (31, 46). Our findings that Beijing-1585 induced lower lung IL-12p35 
and IL-12p40 mRNA expression levels compared to H37Rv, are in line with previous stud-
ies (20, 21, 45, 47). Also the observed lower iNOS-expression levels in AM and iM/DC of 
mice infected with Beijing-1585 compared to H37Rv were described previously (13, 24, 
48). However, these earlier studies found that low iNOS expression was accompanied by 
low expression levels of iNOS-inducing IFN-γ and TNF-α mRNA (32). In sharp contrast, 
we observed lower iNOS expression by iM/DC in the lungs at 14 dpi in Beijing-1585- and 
EAI-1627-infected mice accompanied with significantly higher lung protein levels IFN-γ 
and TNF-α compared to H37Rv.
Low iNOS expression in AM and iM/DC in the lungs despite high IFN-γ protein levels 
could be due to inhibition or prevention of iNOS induction at the site of infection. Alter-
natively, these myeloid cells recruited to the lung might have been primed differently 
in an earlier stage of development. Gut mucosal immunology studies have shown how 
local IL-12 production can exert a systemic effect by stimulating bone marrow resident 
NK-cells to produce IFN-γ early during infection, thereby priming immature myeloid 
cells to inhibit pathological inflammatory responses in the periphery (49). We have 
previously reasoned that a similar mechanism might be present in TB (41). In the current 
study we provide experimental evidence that reduced IL-12 expression in the lungs of 
Beijing-1585-infected mice is associated in the bone marrow with reduced IL-12 and 
IFN-γ, as well as reduced IL-17a and TNF-α expression. This occurs already in the early 
stage of infection before widespread bacterial dissemination. While not conclusive, this 
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suggests that IL-12-mediated differential bone marrow priming of myeloid cells might 
be an important factor early during infection with Mycobacterium tuberculosis. In this 
case, lung IL-12 present for H37Rv, but absent for the clinical strains, could cause IFN-γ 
mediated myeloid cell development in the bone marrow towards a regulatory pheno-
type that prevents excessive innate inflammatory damage upon their migration to the 
lungs, while concomitantly stimulating protective adaptive responses.
Next to differential expression of IFN-γ in the bone marrow, we also found significant 
differences in type 1 interferon expression and responses in both bone marrow and 
lung. Manca et al. have associated virulent Beijing-HN878 infection with elevated IFN-α 
mRNA expression in the lungs at 28 dpi in a low-dose BALB/c infection model (19, 20). 
We were unable to reproduce this preferential increase in IFN-α mRNA upon infection 
with the virulent Beijing strain in the lungs, which could be due to using a high-dose in-
fection model and/or measurements at different time points. In our subsequent analysis 
of IFN-β expression and type 1 interferon-inducible genes we found lower expression 
levels for Beijing-1585 and EAI-1627 compared to H37Rv, thus refuting the association 
of type 1 interferon activity and Mtb virulence in our model.
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absTRacT
Rationale
Immune-modulating drugs that target myeloid-derived suppressor cells or stimulate 
Natural Killer T-cells have been shown to reduce mycobacterial loads in tuberculosis. 
We aimed to determine if a combination of these drugs as adjunct immunotherapy 
to conventional antibiotic treatment could also increase therapeutic efficacy against 
tuberculosis.
methods
In our model of pulmonary tuberculosis in mice, we applied treatment with isoniazid, 
rifampicin and pyrazinamide for 13 weeks alone or combined with immunotherapy 
consisting of all-trans-retinoic acid, 1,25(OH)2-vitamin D3 and α-galactosylceramide. 
Outcome parameters were mycobacterial load during treatment (therapeutic activity) 
and 13 weeks after termination of treatment (therapeutic efficacy). Moreover, cellular 
changes were analyzed using flow cytometry and cytokine expression was assessed at 
mRNA and protein level.
Results
Addition of immunotherapy was associated with lower mycobacterial loads after 5 weeks 
of treatment and significantly reduced relapse of disease after a shortened 13-weeks 
treatment course compared to antibiotic treatment alone. This was accompanied by 
reduced accumulation of immature myeloid cells in the lungs at the end of treatment 
and increased TNF-α protein levels throughout the treatment period.
conclusion
We demonstrate in a mouse model of pulmonary tuberculosis that immunotherapy 
consisting of three clinically approved drugs can improve the therapeutic efficacy of 
standard antibiotic treatment.
Published in the American Journal of Respiratory Cell and Molecular Biology
2017 Feb;56(2):233-241. doi: 10.1165/rcmb.2016-0185OC.
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inTROducTiOn
Annually, an estimated 9 million people worldwide develop active tuberculosis (TB) and 
rates of multidrug-resistant and extensively drug-resistant TB continue to rise (1). In the 
search for improved and shortened treatment regimens to counter the TB pandemic, 
immunotherapy as an adjunct to antibiotic treatment is gaining interest (2).
Several strategies in this regard are currently being explored, including the use of 
immunoglobulins, statins and metformin (3). Another option that may contribute to 
anti-TB treatment is targeted inhibition of myeloid-derived suppressor cells (MDSC) (4). 
MDSC are immature myeloid cells that accumulate during pathological inflammatory 
conditions and have the functional ability to suppress T-cell proliferation and to inhibit 
IFN-g production (5). In mice, MDSC are broadly defined as CD11b+ Gr1+ cells. However, 
as they phenotypically resemble their non-suppressive counterparts developing under 
steady state conditions, MDSC can only be identified unequivocally based on functional 
testing (5, 6).
The detrimental function of MDSC in TB has been demonstrated in both mouse models 
(4, 7-9) and in patient populations (10, 11). Moreover, in mouse TB, MDSC that infiltrated 
the lungs phagocytosed Mycobacterium tuberculosis, thereby creating a potential 
niche for pathogen survival.
The inhibitory function of MDSC can be targeted with all-trans-retinoic acid (ATRA) 
(12). This vitamin A-derivative was shown to induce maturation and thereby functional 
depletion of MDSC (13). In experimental TB in mice and rats, ATRA therapy reduced 
the number of MDSC (4), lowered mycobacterial loads in the lungs in vivo (4, 14), and 
stimulated antimicrobial activity against Mycobacterium tuberculosis (Mtb) in vitro (15, 
16). The maturation effect of ATRA on MDSC could be enhanced by adding 1,25(OH)2-
vitamin D3 (DiOH-VD3) (17), which in itself also stimulated antimicrobial activity against 
Mtb that is mechanistically distinct from ATRA’s mode of action (15).
Lastly, ATRA increased the expression of CD1d on antigen presenting cells, which is re-
quired for activation of Natural Killer T-cells (NKT cells) (18). CD1d-dependent activation 
of NKT cells with the CD1d ligand α-GalactosylCeramide (α-GalCer) reduced mycobacte-
rial loads and improved survival in mice with TB (19). Since the combination of ATRA and 
α-GalCer has been found to convert MDSC into immunogenic antigen-presenting cells 
(20), we added α-GalCer to our treatment so as to combine differentiation therapy with 
activation of CD1d-restricted NKT cells.
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The contributions ATRA and α-GalCer to therapy in TB are limited to therapeutic activ-
ity studies, determining reduction in mycobacterial load (4, 19). However, therapeutic 
activity was shown to be a poor predictor of therapeutic efficacy in TB, which can be 
determined by survival or relapse studies (21, 22). Therefore, to test the above-men-
tioned therapeutics in a setting more similar to clinical conditions, we determined if a 
combination of ATRA, DiOH-VD3 and α-GalCer could increase the therapeutic efficacy of 
antibiotic treatment, allowing shortening of TB treatment duration from 26 weeks to 13 
weeks. We performed these studies in our model of pulmonary TB in mice, optimized to 
simulate the full course of TB treatment in humans according to WHO recommendations 
(23, 24).
maTERials and mETHOds
mice, bacteria and infection
Female specific pathogen-free BALB/c mice aged 10-11 weeks and weighing 22-24 
grams (Charles River, Les Oncins, FR) were infected with the H37Rv Mtb strain (ATCC 
27294) by intra-tracheal instillation of 1.0-2.9x105 mycobacteria under general anesthe-
sia as described previously (25). Inoculum sizes were confirmed by plating. All protocols 
were approved by the institutional animal ethics committee and adhered to the rules 
laid down in the Dutch Animal Experimentation Act and the EU Animal Directive 201/63/
EU, DEC number 117-12-07, EMC-number 2737.
Treatment regimens
Choice of antibiotic drugs and dosage schedules were in accordance with the WHO 
guidelines for treatment of TB as described previously (25). In short, treatment started 
4 weeks post infection (p.i.) and consisted of isoniazid (H, 25 mg/kg), rifampicin (R, 10 
mg/kg) and pyrazinamide (Z, 150 mg/kg) administered subcutaneously in the neck once 
daily for five days a week (Mo-Fri). The DiOH-VD3 (Sigma Chemical Co, St. Louis, MO, 
USA) was frozen as 10% stock solution in 100% ethanol and was diluted in sterile 0.9% 
NaCl prior to administration. DiOH-VD3 was injected intraperitoneally in a volume of 
500 μL containing 0.05 μg DiOH-VD3 three days per week (Mo-We-Fri). Dose and route 
of administration resulted in human pharmacokinetic equivalent dosage (26). α-GalCer 
(Tebu-bio, Le Perray-en-Yvelines, France) was dissolved as described previously (27) 
and was injected intraperitoneally at 500 μg/kg in a total volume of 300 μL at day 1 of 
treatment and subsequently once every 30 days conform to treatment of TB in an earlier 
study (19). ATRA was administered using slow release drug pellets (4 or 10 mg, 90-days 
sustained release pellets; Innovative Research of America, Sarasota, FL, USA). Pellets 
were implanted subcutaneously in the flank under general anesthesia.
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Real-time quantitative PcR
RNA from mouse lung homogenate was purified and processed as described previously 
(28). Sequences for primers and reference numbers for probes (Universal Probe Library; 
Roche Applied Science) are listed in Table E1 in the supplementary data. RNA levels 
were calculated relative to RNA levels of household gene Gapdh.
Flow cytometry
The flow cytometry protocol is explained in detail in the online data supplement. To 
eliminate live mycobacteria prior to flow cytometry analysis, cell suspensions were fixed 
for 30 min in fix/perm solution (Ebioscience, Vienna, AT). Cells were stained with differ-
ent mAb mixes as described in Table E2 in the supplementary data and measured on a 
FACS Canto II flow cytometer (BD Biosciences, Breda, NL).
data analysis and statistics
Flow cytometry data were analyzed using Flowjo 7.6.5. Analyses were done and graphs 
were made using PRISM Graphpad 6. All data are expressed as mean ± SEM. Student’s 
t-test, followed by Bonferroni correction where applicable, was used to calculate sig-
nificance unless stated otherwise. P-values less than 0.05 were considered statistically 
significant.
supplemental data
Tissue handling, mycobacterial load determination, ATRA and Ca2+ serum level quantifi-
cation and lung supernatant cytokine level quantification are described in detail in the 
online data supplement.
REsulTs
Tb leads to increased aTRa serum concentration during treatment
Since ATRA has a narrow therapeutic window (29), we first performed dose finding in 
uninfected mice with ATRA as single adjunct to treatment with isoniazid, rifampicin and 
pyrazinamide (HRZ) before starting combination therapy. Based on loss of bodyweight 
and supported by animal wellbeing scores, ATRA therapy in a dose of 5 mg/kg/day 
(10 mg pellets) was well tolerated and addition of HRZ did not influence ATRA serum 
concentrations in uninfected mice (Fig. 1a). However, in Mtb-infected mice we found 
ATRA serum concentrations 2-3-fold higher compared to uninfected ATRA-treated mice, 
which was associated with excessive weight loss (Fig. 1b). A lower ATRA dose of 2 mg/
kg/day (4 mg pellets) was well tolerated by Mtb-infected mice and was still associated 
with a 10-fold increase of physiological ATRA serum concentrations to 11.9 ± 0.2 pmol/
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ml (Fig. E1 in the supplementary data). Therefore, ATRA was applied in this lower dose 
in our experiments.
adjunct immunotherapy is well tolerated and marginally increases therapeutic 
activity
Next, we determined the therapeutic activity of immunotherapy consisting of ATRA, 
DiOH-VD3 and α-GalCer (ADG) adjunct to antibiotic treatment with isoniazid, rifampicin 
and pyrazinamide (HRZ). To this aim, we used the BALB/c mouse model of Mtb infection. 
In this model, mice reach the peak of infection at 4 weeks post infection with Mtb loads 
of 106-108 in the lungs and of 104-106 in spleen and liver. Mycobacterial loads subse-
quently stabilize and untreated mice become moribund between 22 and 38 weeks after 
infection (25).
At the peak of infection treatment was initiated with HRZ or HRZ+ADG for a period of 
5 weeks. After termination of treatment, HRZ+ADG-treated mice had three-fold lower 
mycobacterial loads in the spleen (p<0.05) and showed a trend towards lower mycobac-
terial loads in the lungs (2.7-fold lower, p=0.08) compared to HRZ-treated mice (Fig. 2a).
Figure 1. aTRa serum concentrations increase upon aTRa-treatment during mtb infection and are 
associated with excessive body weight loss.
a) After 25 days of treatment, ATRA serum concentrations were measured in uninfected and Mtb-infected 
mice treated with ATRA, eventually supplemented with antibiotics (HRZ). ATRA was applied as 10 mg, 90-
days release pellets. ATRA serum concentrations were not affected by addition of HRZ, but were signifi-
cantly increased when treatment was started 4 weeks after infection with Mtb (***p < 0.001). b) Pooled data 
from different experiments for ATRA serum concentrations versus body weight loss in Mtb-infected mice 
after 21 to 35 days of treatment with ATRA+HRZ using 10 mg 90-days sustained release pellets. ATRA serum 
concentration was strongly correlated with body weight loss (R2: 0.88).
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Regarding tolerability, HRZ+ADG-treated mice weighing >20 grams at start of treatment 
transiently lost weight compared to HRZ-treated mice (Fig. 2b). However, mice weighing 
≤20 gram 4 weeks p.i. showed excessive weight loss in the first week of treatment and 
had to be euthanized as they had reached humane endpoints. Therefore, mice weighing 
≤20 gram at start of treatment were excluded in both treatment groups (2 mice from 
each group).
Treatment with ATRA- or DiOH-VD3, but also TB itself, can all cause hypercalcaemia. 
Therefore, serum Ca2+ was determined at end of treatment. The Ca2+ levels in both HRZ 
or HRZ+ADG treatment groups were significantly higher than in uninfected mice, but 
did not differ between the two treatment groups (Fig. 2c).
adjunct immunotherapy reduces relapse of disease
In order to determine the effect of ADG adjunct therapy on therapeutic efficacy, our 
next step was to measure relapse of TB. In previous experiments in our mouse TB 
model, mycobacterial loads in infected tissues became undetectable after 13 weeks of 
HRZ treatment (25). However, when treatment was terminated at this point instead of 
completing the WHO-recommended 26 weeks period, relapse of disease still occurred 
leading to mycobacterial loads of circa 103 CFU in the lungs (25). To determine the ef-
fect of ADG therapy against these persistent Mtb populations responsible for relapse of 
Figure 2. addition of adG to HRZ therapy is well tolerated and enhances mycobacterial killing dur-
ing active disease.
a) Mycobacterial loads in the lungs and spleen after 5 weeks of treatment (9 weeks p.i.) with HRZ (grey 
triangles) or HRZ+ADG (black dots), n=5 mice per group. b) Bodyweight in grams during infection and 
treatment. c) Serum concentrations of Ca2+ in Mtb-infected mice treated with HRZ or HRZ+ADG after 5 
weeks of treatment (9 weeks p.i.) compared to healthy controls. In untreated mice mycobacterial loads in 
the lungs and spleen at 9 weeks p.i. are 107 and 105 respectively (published earlier in (25).Data are derived 
from a single experiment and shown as mean ± SEM. Mycobacterial loads in antibiotic-treated mice are 
in agreement with previous historic controls (25). *** p < 0.001, **p < 0.01, *p < 0.05. HC=healthy control, 
HRZ= isoniazid, rifampicin and pyrazinamide, ADG= ATRA, DiOH-VD3 and α-GalCer.
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disease, we treated Mtb-infected mice for 13 weeks with HRZ or HRZ+ADG. Next, at 13 
weeks after termination of treatment, i.e. at 30 weeks p.i., we measured mycobacterial 
loads in lungs and spleen (Fig. 3a). We validated our data with regard to infection kinet-
ics by comparing it to earlier findings in this model. In line with previous findings, mice 
from both groups had low or undetectable mycobacterial loads in the lungs after 13 
weeks of treatment (25). At 30 weeks p.i., relapse of disease with mycobacterial loads of 
103 in the lungs was observed in only 1 out of 8 HRZ+ADG-treated mice versus 6 out of 8 
HRZ-treated mice (p < 0.05). In addition, one HRZ-treated mouse had Mtb in the spleen 
(102.4 CFU, data not shown) versus none of the HRZ+ADG-treated mice. In 3 mice from 
the HRZ+ADG-treated group, minimal mycobacterial loads were still detectable at 30 
weeks p.i., but none exceeded those found 17 weeks p.i. (Fig. 3b). Interestingly, serum 
Ca2+ levels in the HRZ+ADG-treated group were significantly lower than in HRZ-treated 
mice at the end of the post-treatment period, but still higher than in healthy control 
mice (Fig. 3c).
Figure 3. addition of adG to HRZ therapy significantly reduces relapse of disease.
a) Outline of the experimental design. b) Mice were treated with HRZ (grey triangles) or HRZ+ADG (black 
dots) starting 4 weeks p.i. (open diamonds). Lung mycobacterial loads were determined by plating. At 17 
weeks p.i. both treatment groups still had 1 mouse with a detectable mycobacterial load in the lungs (HRZ 
only: 101.4 HRZ+ADG: 101.1). At 30 weeks p.i. 3 mice from the HRZ+ADG treated group had detectable my-
cobacterial loads (all: 101.1). Fisher’s exact test was used to calculate significance between relapse vs. no re-
lapse at 30 weeks p.i. Of note: in untreated mice mycobacterial loads in the lungs remain constant between 
106-108 from week 4 up to week 30 (25) c) Serum concentrations of Ca2+ at each time point as shown in b in 
both treatment groups compared to healthy controls (open circles). Data are derived from a single experi-
ment and shown as mean ± SEM, n=5 mice per group at 4 and 17 wk p.i., n=8 mice per group at 30 wk p.i. 
***p < 0.001, **p < 0.01, *p < 0.05, HRZ= isoniazid, rifampicin and pyrazinamide, ADG= ATRA, DiOH-VD3 
and α-GalCer.
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To verify adequate release of ATRA throughout the treatment period the remaining 
amount of ATRA in the pellets of sacrificed mice 17 weeks p.i. was measured. These 
still contained 100 ± 18 μg of ATRA (2.5% of original content). Serum concentrations of 
ATRA at 17 weeks p.i. were elevated compared to concentrations earlier found in healthy 
control mice, but were no longer elevated at 30 weeks p.i. (Fig. E1 in the supplementary 
data). The small amounts of ATRA found in the pellets at 17 weeks p.i. as well as serum 
levels over time suggest an adequate release of the 4 mg ATRA content over the treat-
ment period.
addition of adG to HRZ therapy modulates the cellular immune response in Tb.
To assess the immune-modulating effects associated with ADG we measured the 
composition of immune cell populations in the lungs during infection and treatment. 
Since the components of ADG primarily target myelomonocytic cells, we focused on the 
myeloid populations in the lungs, identified primarily by high level CD11b expression.
First we identified the different CD11b+ cell populations in the lungs during steady 
state and infection (Fig. 4a). These consisted of alveolar macrophages, inflammatory 
macrophages/dendritic cells, PMN-like cells, monocyte (Mo)-like cells and eosinophils 
(see: Table 1). A small CD11b+CD68-Ly6G- population, earlier shown to consist mainly of 
NK-cells and CD11b+ T-cells, was also identified (30). For the non-myeloid cell popula-
tions gating strategies can be found in Fig. E2 in the supplementary data.
In the acute phase of infection until the start of treatment at week 4 p.i. almost all 
myeloid and non-myeloid cell populations increased in the lungs of infected mice 
(Fig. 4b). Focusing on immature myelomonocytic cells as potential MDSC we found a 
strongly diminished expression of Ly6G in our PMN-like population (pop. IV) at 4 weeks 
p.i. compared to healthy controls (Fig. 4c), similar to earlier described MDSC identified 
Table 1. identified cell populations in the lung
cell type identification
CD4+ T-cells CD3+/CD4+
T-reg cells CD3+/CD4+/FoxP3+/CD25+
CD8+ T-cells CD3+/CD8+
B-cells CD45R+/MHC-II+/Ly6C-
Alv. Mɸ CD11bint/Siglec-F+/CD11chigh
iM/DC CD11b+/MHC-II+/CD11cint/Ly6Cint
Mo-like cells CD11b+/MHC-II-/CD11c-/Ly6Chigh
PMN-like cells CD11b+/Ly6G+/Ly6Cint
Eosinophils CD11b+/ Siglec-F+
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as CD11b+ Ly6Gdim cells (7, 8). Upon treatment, Ly6G expression on the PMN-like cells 
increased in both groups, but more rapidly in the HRZ+ADG-treated group than in the 
group receiving only HRZ.
Upon 5 weeks of treatment (9 weeks p.i.) all myeloid cell populations rapidly decreased 
to below their steady state, with the exception of PMN-like cells (Fig. 5a). The latter 
returned to steady state level in the HRZ+ADG-treated group, while being markedly 
reduced in the HRZ-treated group. At the end of treatment (17 weeks p.i.), PMN-like cell 
Figure 4. addition of adG to HRZ therapy is associated with faster recovery of ly6G expression on 
Pmn-like cells
a) Separation of the different CD11b+ cell populations in whole lung single cell suspension in steady state 
and in Mtb-infected mice at 4 weeks p.i. We first separated the AM (I) based on their reduced expression 
of CD11b and high expression of macrosialin (CD68), followed by eosinophils (II) based on their high auto 
fluorescence in the APC channel (CD117), but also based on their expression of Siglec-F (see Fig. E2b in the 
supplementary data). Next, based on their lack of expression of both Ly6G and CD68, a population known 
earlier to exist of T-cells and NK-cells (III) was identified. The PMN-like cells (IV) were separated based on 
Ly6G expression and lack of CD68 expression. Finally the CD68+ population was divided into Mo-like cells 
(V) and iM/DC (VI) based on their differential expression of Ly6C and CD11c. b) Quantitative comparison 
of the different cell populations as shown in Table 1 in whole lung single cell suspension between steady 
state (HC, open bars) and 4 weeks p.i. (striped bars) shows a sharp increase of all inflammatory myeloid 
cells, a reduction in AM and an increase of mainly CD8+ cells and B-cells in the lymphoid cell compart-
ment. c) Ly6G expression on PMN-like cells during infection and under treatment with HRZ (grey bars) 
or HRZ+ADG (Black bars). Cell populations are shown as mean ± SEM, ***p < 0.001, **p < 0.01, *p < 0.05, 
n=5 per group at 9 weeks p.i. and 17 weeks p.i., n=8 per group 30 weeks p.i. Data are from the same mice 
used for experiments shown in Fig. 2-3. HC= healthy controls, AM=alveolar macrophages, Mo= monocytic, 
PMN= polymorphonuclear, iM/DC= inflammatory macrophage/dendritic cells, HRZ= isoniazid, rifampicin 
& pyrazinamide, ADG= ATRA, DiOH-D3 and α-GalCer.
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numbers were similar in both groups. However, at this point the iM/DC and their precur-
sor population of Mo-like cells were reduced in the HRZ+ADG-treated group (Fig. 5b). At 
the end of the post-treatment and potential relapse period (30 weeks p.i.) there were no 
differences in myeloid cell populations between the two treatment groups and healthy 
control mice (Fig. 5c).
Figure 5. addition of adG to HRZ therapy is associated with fewer im/dc at end of treatment and 
more cd8+ T-cells at 30 weeks p.i.
a) Quantitative comparison of the different cell populations as shown in Table 1 in whole lung single cell 
suspension between the two treatment groups at 9 weeks p.i. The PMN-like cells in the HRZ-treated group 
(grey bars) are markedly suppressed compared to HRZ+ADG-treated mice (black bars) and uninfected mice 
(open bars). b) At 17 weeks p.i. iM/DC are reduced in HRZ+ADG-treated mice compared to HRZ-treated 
mice c) At 30 weeks p.i. CD8+ cells are increased in the HRZ+ADG-treated mice compared to HRZ-treated 
mice. Cell populations are shown as mean ± SEM, ***p < 0.001, **p < 0.01, *p < 0.05 after Bonferroni cor-
rection, n=5 per group at 9 weeks p.i. and 17 weeks p.i., n=8 per group at 30 weeks p.i. Data are from the 
same mice used for experiments shown in Fig. 2-3. HC= healthy controls, AM=alveolar macrophages, Mo= 
monocytic, PMN= polymorphonuclear, iM/DC= inflammatory macrophage/dendritic cells, HRZ= isoniazid, 
rifampicin & pyrazinamide, ADG= ATRA, DiOH-D3 and α-GalCer.
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Concerning non-myeloid cells there were no significant differences between the two 
treatment groups during treatment at 9 weeks p.i. (Fig. 5a). At the end of treatment 
T-cells were significantly suppressed in both groups compared to steady state (Fig. 5b). 
At 30 weeks p.i. the HRZ+ADG-treated group had significantly higher percentages of 
CD8+ T-cells compared to the HRZ-treated group (Fig. 5c).
addition of adG to HRZ therapy increases TnF-α protein levels.
To identify the cytokine response associated with ADG adjunct therapy we measured 
cytokine expression at mRNA and protein level during infection and treatment. At the 
peak of infection, 4 weeks p.i., mRNA expression of IFN-g, IL-6 and IL-17a was increased, 
but expression of TNF-α was reduced compared to steady state (Fig. 6a). Protein levels 
Figure 6. addition of adG to HRZ treatment is associated with increased TnF-α protein levels during 
treatment
a) Gene expression analysis of key cytokines in whole lung homogenate normalized to the expression of 
Gapdh. 4 weeks p.i. (black diamonds) compared to steady state (open circles). b) Cytokine protein concen-
tration analysis in whole lung homogenate supernatant 4 weeks p.i., c) TNF-α protein concentrations after 
5 weeks of treatment (9 wks p.i.), 13 weeks of treatment (17 wks p.i.) and 13 weeks after termination of 
treatment (30 wks p.i.) with HRZ (grey triangles) or HRZ+ADG (black dots). Significance for TNF-α was cor-
rected for 1 outlier at 9 wks p.i. (with outlier included: p= 0.03, NS after Bonferroni correction, with outlier 
excluded: p=0.004, * after Bonferroni correction) *** p < 0.001, **p < 0.01, *p < 0.05 after Bonferroni correc-
tion, n=5 per group at 9 weeks p.i. and 17 weeks p.i., n=8 per group 30 weeks p.i. Data are from the same 
mice used for experiments shown in Fig. 2-3.
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correlated with mRNA expression for IFN-g, IL-6 and IL-17a, but TNF-α protein levels 
were substantially increased (Fig. 6b) despite reduced mRNA expression.
During and after treatment, TNF-α mRNA expression did not differ significantly between 
both groups (Fig. E3 in the supplementary data). However, protein levels of TNF-α in 
HRZ+ADG-treated mice were significantly increased compared to HRZ-treated mice at 9 
weeks p.i. and 17 weeks p.i. (Fig. 6c).
Messenger RNA (mRNA) expression of IFN-g, IL-17a and IL-6 remained increased in both 
treatment groups at 9, 17 and 30 weeks p.i., but these increases were not observed at 
protein level and no significant differences were found between the two treatment 
groups (Fig. E3-4 in the supplementary data). IL-4 protein levels were increased 4 weeks 
p.i. (Fig 6b) and persisted at this level throughout the examination period (Fig E4 in the 
supplementary data). Lastly, IL-10 mRNA expression and IL-10 protein levels were both 
below our limit of detection (data not shown).
discussiOn
We determined if adjunct immunotherapy with drugs known to reduce mycobacterial 
loads in the lungs could increase long term therapeutic efficacy of the WHO-recom-
mended antibiotic treatment. In our mouse TB model we have found that a combination 
of ATRA, DiOH-D3 and α-GalCer was tolerated at the given dosage, increased antibiotic-
mediated reduction of mycobacterial loads in infected organs after 5 weeks of treatment, 
reduced the levels of immature myeloid cells in the lungs at the end of treatment, and 
was associated with 10-fold increased levels of TNF-α protein in the lungs throughout 
the treatment period. Even more, addition of ADG significantly reduced relapse of dis-
ease and was associated with nearly twice the levels of CD8+ T-cells, compared to HRZ 
alone 13 weeks after termination of treatment.
To our knowledge, this is the first study in which serum concentrations of ATRA were 
determined when added as a supplement to therapy in TB and we found an important 
association between fulminant TB and pathologically elevated ATRA serum concentra-
tions. This can probably be ascribed to altered ATRA pharmacokinetics during infection. 
In our in vivo TB model, Mtb have already spread from the lungs to the liver 4 weeks p.i. 
(23). Local inflammation and bacterial infection are known to impair CYP450-mediated 
drug metabolism in the liver, resulting in increased ATRA levels (38). The use of ATRA as a 
single therapeutic agent for TB has been tested earlier (4, 14). In those two studies ATRA 
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treatment was started earlier in the course of infection, i.e. before bacterial dissemina-
tion to the liver occurred, and ATRA-associated weight loss was not reported.
Other studies have demonstrated that functionally suppressive MDSC accumulate dur-
ing acute TB in the lungs of mouse strains that are either less or more susceptible than 
the currently used BALB/c mice (4, 7, 9) and that these MDSC could be targeted suc-
cessfully with ATRA (4). These findings inspired us to evaluate the therapeutic efficacy 
of ATRA in TB in combination with two synergistic immune-modulating drugs (17, 20). 
Both ATRA and α-Galcer as single drug therapy earlier lowered mycobacterial loads in 
the lungs with a range between log 0.5 and log 2 after different treatment regimens and 
durations (4, 14, 19). For α-GalCer it has been shown that its effect is CD1d-dependent, 
but ATRA also has a direct bacteriostatic effect that could contribute to the reduced 
mycobacterial loads observed in both the reported (4) and the present study. However, 
this direct bacteriostatic effect was only demonstrated in vitro with ATRA concentra-
tions well above serum concentrations found in our study (16). For α-GalCer it has been 
shown that reductions in CFU persist when isoniazid is concomitantly administered (19). 
We demonstrate that when tested as adjuvant to the full HRZ regimen, a combination 
of ATRA, α-GalCer and DiOH-VD3 marginally improves therapeutic activity. We do not 
consider it likely that this could be of major clinical significance. Elaborating on this, 
clinical studies indicate that anti-mycobacterial activity, as measured in early bacteri-
cidal activity assays (EBA), is a poor predictor of therapeutic efficacy (21, 22).
With regard to therapeutic efficacy, it has been demonstrated previously that α-GalCer 
prolongs survival of Mtb-infected mice (19). However no data are available in the 
context of the most clinically relevant scenario, which is concomitant administration 
adjunct to the current antibiotic anti-TB regimen. Using the BALB/c mouse model as a 
well-recognized experimental approach for efficacy studies (31, 32), our relapse data 
demonstrate that adjunct ADG therapy improved the therapeutic efficacy of HRZ treat-
ment, but was not sufficient to eliminate all Mtb during a 13 week treatment course. This 
is supported by the observation that at 30 weeks p.i., Ca2+ levels, which correlate with 
disease activity in TB (33), were significantly higher in the HRZ-treated group, but also 
remained elevated in the HRZ+ADG-treated group compared to healthy controls. In ad-
dition, both treatment groups showed elevated IFN-g mRNA expression and increased 
IL-4 and TNF-α protein levels compared to steady state 30 weeks p.i. Lastly, mycobacteria 
were still detectable in the lungs of some mice from the HRZ+ADG group that did not 
relapse. Taken together, these observations suggest that HRZ+ADG-treatment was not 
able to clear infection completely in this TB model but did significantly improve contain-
ment of infection compared to treatment with antibiotics only.
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Based on published results of single-drug experiments and synergy reported between 
the individual components (17, 20), we chose ADG to potentiate host immunity, in 
particular targeting MDSC activity. However, we did not prove the latter to be the main 
mechanism of action by performing functional MDSC testing. Hence, we only describe 
correlations between treatment modality and changes in immune parameters. At the 
peak of infection the CD11b+Ly6Gdim PMN-like cells from our model phenotypically re-
sembled the CD11b+Ly6Gdim MDSC population found earlier (7). However, during treat-
ment these immature cells with reduced Ly6G expression could no longer be found. 
Given the sharp reduction of PMN-like cells in the lungs during antibiotic treatment and 
their rapid change in phenotype towards more mature, conventional PMN, we consider 
it likely that functional MDSC activity by the PMN-like cell population is concomitantly 
reduced. In line with this, increased numbers of MDSC have been found in patients after 
recent TB infection and active disease, but successful anti-TB treatment significantly 
reduced MDSC numbers and coincided with increased MDSC maturation (10). On the 
other hand, overall adaptive immune cells are increased at 30 weeks p.i. in mice from 
the HRZ+ADG-treated group with significantly more CD8+ cells in the lungs, but without 
differences in the myeloid compartment or cytokine profile between the two treatment 
groups.. This suggests reduced functional MDSC-activity in the HRZ+ADG-treated 
group, which is supported by studies showing that MDSC inhibit CD8+ T-cells primarily 
in a contact-dependent way and reduce CD8+ T-cell infiltration (5, 34). However, in the 
context of the current study this remains speculative.
Apart from the potential role of MDSC, we observed increased levels of TNF-α protein 
in the HRZ+ADG-treated group during treatment, which could have contributed to the 
improved therapeutic efficacy. TNF-α is a critical immune mediator in TB and holds a 
central protective position in the balance between an adequate anti-TB response, 
excessive inflammation-induced pathology, and reactivation of latent disease (35).. We 
observed discrepancies between TNF-α mRNA expression and protein levels that were 
not found for other cytokines tested. This is likely due to post-transcriptional regulation 
to which TNF-α is exceptionally prone (36), as is also observed in TB (37). If enhancing 
TNF-α production is indeed a key factor mediated by ADG adjunct therapy, treatment 
initiation should be timed carefully, since increased TNF-α levels during the active phase 
of disease might also explain the initial bodyweight loss in the HRZ+ADG-treated group 
in the first 3 weeks of treatment. In support of this ambiguous role of TNF-α, a recent in 
vivo study showed increased therapeutic efficacy of TNF-α inhibition (38), further dem-
onstrating the complexity of the interplay between TB and immune modulation strate-
gies. These data together suggest that it might be more beneficial to treat TB initially 
with antibiotics only and add ADG later in order to increase sterilizing immune activity.
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In conclusion, we have shown that a combination of three clinically approved drugs as 
an adjunct to current HRZ treatment can modulate the immune response and improve 
therapeutic efficacy in TB. This adds to the possibility of adjunct immunotherapy as vi-
able treatment modality in TB. In the current study we demonstrate a proof of principle 
with clinical potential. However, based on the experimental design and data obtained, 
the therapeutic mechanism of ADG on a cellular and molecular level and the role of 
MDSC were not identified unequivocally, which should be addressed in forthcoming 
studies.
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absTRacT
Objectives
Mycobacterium tuberculosis Beijing strains are associated with lower treatment success 
rates in tuberculosis patients. In contrast, laboratory strains such as H37Rv are often 
used in preclinical tuberculosis models. Therefore, we explored the impact of using a 
clinical Beijing strain on treatment outcome in our mouse tuberculosis model. Addition-
ally, the predictive value of bactericidal activity on treatment outcome was assessed.
methods
BALB/c mice were infected with a Beijing strain and treated with one of ten different 
combinations of conventional anti-TB drugs. Bactericidal activity was assessed by de-
termining reductions in mycobacterial load after 7, 14 and 28 days and after 2, 3 and 6 
months of treatment. Treatment outcome was evaluated after a 6-months treatment-
course and was based on lung culture-status 3 months post-treatment.
Results
reatment success rates in Beijing-infected mice were consistently lower than treatment 
success observed for similar anti-TB drug regimens in multiple previous studies using 
H37Rv-infected mice. Treatment outcome depended critically on rifampicin. Four non-
rifampicin-containing regimens showed 0% treatment success compared to success 
rates ranging between 80-95% for six rifampicin-containing regimens. Bactericidal 
activity was only predictive for treatment outcome after 3 months of treatment.
conclusion
Our data advocate the use of Beijing strains to increase the translational value of mouse 
TB models evaluating treatment outcome. Additionally, our findings support the notion 
that bactericidal activity in the first two months of treatment, as measured in clinical 
phase IIa/b trials, has limited predictive value for tuberculosis treatment outcome, thus 
emphasizing the need for better parameters to guide future phase-IIII trials.
Published in Antimicrobial Agents and Chemotherapy
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inTROducTiOn
With 1.8 million deaths in 2015, tuberculosis (TB) surpassed HIV as leading cause of death 
amongst infectious diseases (1). One factor contributing to this ongoing burden of TB is 
the rapid emergence of Mycobacterium tuberculosis strains of the Beijing genotype (2, 3). 
These strains specifically contribute to the spread of drug-resistant TB and are clinically 
associated with increased rates of treatment failure (3-8).
To overcome this new challenge in TB treatment, novel treatment strategies with in-
creased efficacy are urgently needed. However, clinical trials evaluating TB treatment 
outcome are expensive, involve large numbers of patients, and may take up to 10 years 
from drug design to clinical use (9). Moreover, phase IIa and IIb trials, which rely on early 
bactericidal activity (EBA) and surrogate endpoints such as two month sputum culture 
status respectively, cannot predict treatment outcome in phase III trials in TB to a satisfy-
ing degree (9-11).
Phase III trials can also be guided by preclinical testing of anti-TB drugs, which is often 
performed in mouse TB models (12-15). However, recent disappointing results of phase 
III clinical trials on moxifloxacin for anti-TB treatment, which were partly based on 
promising results from mouse experiments, have also raised skepticism regarding the 
predictive value of preclinical TB models and emphasize the need for their improvement 
(9). This has led to the formation of multiple international consortia, such as PreDiCT-TB 
and CPTR, aimed at improving the translational value of preclinical TB models (12).
Approaches that are currently being evaluated include the development of specific in 
vitro models that allow drug activity assessment against Mycobacterium tuberculosis in 
different metabolic states (14), increased appreciation of the pharmacokinetic aspects 
of treatment(9) and the use of mouse models that develop cavitating lesions, thus better 
representing human pathology (12).
Most mouse TB models that evaluate treatment outcomes use Mycobacterium tuberculo-
sis laboratory strains such as H37Rv and Erdman, which are originally derived from clinical 
isolates in 1905 and 1945 respectively, but are no longer found in patients (12, 14).
Given the significant clinical impact of Beijing strain infections on treatment outcome, 
the use of Beijing strains in preclinical mouse TB models should increase their transla-
tional value. Therefore, the primary aim of this study was to assess treatment outcome, 
as measured in clinical phase III trials, in mice infected with an Beijing genotype strain 
(16-18).
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Additionally, we evaluated the predictive value of bactericidal activity-based param-
eters, as measured in clinical phase IIa/b trials, on treatment outcome at multiple time 
points throughout the full 6-months treatment course.
maTERials and mETHOds
bacterial strain
For all experiments, the previously described Beijing VN 2002-1585 (BE-1585) Mycobac-
terium tuberculosis genotype strain (18) was used. This strain was isolated from a patient 
in Vietnam in 2002 and was verified as a typical Beijing strain based on single nucleotide 
polymorphism analysis (19). Susceptibility assays performed according to CLSI guide-
lines (20) showed minimal inhibitory concentrations for rifampicin of 0.25 mg/L, for 
isoniazid of 0.125 mg/L, for ethambutol of 5 mg/L and for streptomycin of 2 mg/L.
mice
Specified pathogen-free female BALB/c mice were obtained from Charles River (Les 
Oncins, France) and acclimatized at least 7 days prior to starting experiments. Mice 
received food and water ad libitum. At the day of infection, animals were 13-15 weeks 
old and weighed 20-25 grams. Experimental protocols adhered to the rules specified 
in the Dutch Animal Experimentation Act and were in concordance with the EU animal 
directive 2010/63/EU. The Institutional Animal Care and Use Committee of the Erasmus 
MC approved the present protocols (117-12-08 and 117-12-13).
infection
A suspension of Mycobacterium tuberculosis stored at -80°C was thawed at room temper-
ature for 30 min and centrifuged for 10 min at 14.000xg. The pellet of mycobacteria was 
resuspended and diluted in fresh phosphate buffered saline (PBS). Mice were infected 
under general anesthesia using a mixture of medetomidine (Sedator®, 0.5 mg/kg; Eu-
rovet Animal Health, Bladel, the Netherlands), midazolam (Midazolam, 5 mg/kg; Actavis, 
Baarn, the Netherlands) and fentanyl (Fentanyl, 0.05 mg/kg; Hameln Pharmaceuticals, 
Hameln, Germany), by intratracheal installation of a 40µl suspension containing 1.4 x 105 
(0.3 – 2.0 x 105) CFU of BE-1585, using a repeating dispenser (Hamilton company; Bona-
duz, Switzerland), a 1 mL syringe and a 22-Gauge mouse gavage feeding needle (Fine 
Science Tools; Heidelberg, Germany), followed by proper inhalation. Mice were antago-
nized using a mixture of atipamezole (Antisedan®, 2.5 mg/kg; Orion Corporation, Espoo, 
Finland), flumazenil (Flumazenil, 0.5 mg/kg; Pharmachemie, Haarlem, the Netherlands) 
and naloxon (Naloxon, 1.2 mg/kg; Orpha-Devel Handels und Vertriebs, Purkersdorf, 
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Germany). Anesthetic and antagonistic agents were administered intraperitoneally, in a 
total volume of 175 μL and 250 μL, respectively.
antibiotic treatment
All treatment schedules started 14 days after infection. In the experiments assessing 
bactericidal activity of single anti-TB drugs, mice received 0.5x, 1x or 2x the human phar-
macokinetic equivalent dose (HED) (21) with rifampicin (R) (5, 10 or 20 mg/kg), isoniazid 
(H) (12.5, 25 or 50 mg/kg), streptomycin (S) (100, 200 or 400 mg/kg), ethambutol (E) (50, 
100 or 200 mg/kg) or pyrazinamide (Z) (75, 150 or 300 mg/kg), for 5 days a week, up to 
28 days. In the experiments assessing bactericidal activity and treatment outcome of the 
different anti-TB drug regimens, mice received treatment up to 6 months with different 
regimens of 1x the HED of each antibiotic 5 days a week. All drugs were administered via 
oral gavage except streptomycin, which was administered via subcutaneous injections. 
The different drug regimens are shown in Table 1.
assessment of mycobacterial load in the lungs
In order to assess the mycobacterial load in the lungs, mice were sacrificed by CO2 expo-
sure. To prevent carry-over of anti-TB drugs on subculture plates, treatment was stopped 
Table 1. schematic overview of the experiments
D0 a D7 D14 D28 M2b M3 M6 M6+3c
R 3 d 3 3 3
H 3 3 3 3
Z 3 3 3 3
S 3 3 3 3
E 3 3 3 3
RE (6 RE) 3 3 3 3 3 3 3 20
RZ (2 RZ / 4 R) e 3 3 3 3 3 3 3 15
RH (6 RH) 3 3 3 3 3 3 3 15
RHZ (2 RHZ / 4 RH) 3 3 3 3 3 3 3 21
RHZE (2 RHZE / 4 RH) 3 3 3 3 3 3 3 21
RHZS (2 RHZE / 4 RH) 3 3 3 3 3 3 3 21
HS (2 HS / 4 H) 3 3 3 3 3 3 3 9
HZ (2 HZ / 4 H) 3 3 3 3 3 3 3 20
HE (6 HE) 3 3 3 3 3 3 3 18
ZES (2 ZES / 4 E) 3 3 3 3 3 3 3 20
a D0= day 0 (start of treatment), b M2= 2 months after start of treatment, c M6+3= 3 months after stop of a 
6-months treatment course, d number of mice used for determination of mycobacterial loads in the lungs,e 
2 RZ / 4 R= two months of RZ treatment followed by 4 months of R treatment. Drugs were administered in 
their human pharmacokinetic equivalent dose, mice were infected at day -14.
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72 hours before sacrificing the mice. In addition, activated charcoal (0.4%) was added to 
the agar to inhibit the antibiotic residue from the tissue samples (22). The lungs were 
removed aseptically and homogenized according to protocol using the gentleMACS 
Octo Dissociator (Miltenyi Biotec BV, Leiden, the Netherlands) in 2 mL PBS. From each 
tissue homogenate 10-fold serial dilutions were made. Next, 200 μL per dilution was 
cultured on drug-free 7H10 Middlebrook agar and incubated for 28 days at 370C with 
5% CO2 followed by colony enumeration. The time points at which mycobacterial loads 
were evaluated are shown in the schematic overview of the experiments in Table 1.
data analysis and statistics
Analyses were performed and graphs were made using PRISM Graphpad 6 (Graphpad 
software, La Jolla, CA). All data are expressed as median ± range. Student’s t-test was 
used to calculate significance in figure 1. Two-way ANOVA followed by Bonferroni 
correction was used to calculate significance in table 3. P-values less than 0.05 were 
considered statistically significant.
Ethical approval
Experimental protocols adhered to the rules specified in the Dutch Animal Experi-
mentation Act and are in concordance with the EU animal directive 2010/63/EU. The 
Institutional Animal Care and Use Committee of the Erasmus MC approved the present 
protocols (117-12-08 and 117-12-13).
REsulTs
mortality and bactericidal activity after single drug exposure
Mice infected with the Beijing strain were treated with isoniazid, rifampicin, ethambutol, 
pyrazinamide, or streptomycin in 3 different doses. Figure 1 shows mortality and bacte-
ricidal activity after 7, 14 and 28 days of single drug exposure. Earlier observations in our 
model have shown that untreated Beijing-infected mice uniformly become moribund 
after 3-4 weeks of infection(16). Treatment with rifampicin, isoniazid or streptomycin 
was able to prevent mortality, whereas mice treated with pyrazinamide or ethambutol 
showed similar mortality as untreated mice.
Rifampicin effectively reduced mycobacterial loads in the lungs and showed a signifi-
cant dose-dependent bactericidal effect after 28 days (Fig. 1a). Isoniazid also showed 
bactericidal activity, but significant dose-dependent effects were only observed at day 7 
(Fig. 1b). Streptomycin reduced mycobacterial loads, but did not show dose-dependent 
effects (Fig. 1c). Ethambutol showed bactericidal activity after 7 days that was compa-
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rable to rifampicin or isoniazid, but failed to prevent mortality (Fig. 1d). Pyrazinamide 
did not display bactericidal activity in any of the dosages tested and did not prevent 
mortality (Fig. 1E).
Figure 1. bactericidal activity after single drug exposure
Mycobacterial loads in the lungs after single drug exposure over a 28-days treatment course, using 0.5x 
(dots), 1x (squares) and 2x (triangles) the human pharmaco-equivalent dose (HED) of the selected drugs. 
Data are shown as median with ranges with n=3 mice per time point. a) Rifampicin showed significant dose 
responses after 28 days of treatment between 0.5x, 1x HED and 2x HED (*) b) Isoniazid showed significant 
dose responses after 7 days of treatment between 0.5x and 2x HED (**) and between 1x and 2x HED (*). 
c) Streptomycin showed limited bactericidal activity, but prevented mortality d) Ethambutol showed no 
dose responses and could not prevent mortality. E) Pyrazinamide showed a significant dose-response be-
tween 0.5x and 2x HED after 7 days (**), but none of the administered dosages could prevent mortality. F) 
Comparison of 1x HED treatment with rifampicin, isoniazid and streptomycin shows significantly stronger 
bactericidal activity of rifampicin compared to the other two drugs after 28 days (****), * p< 0.05, ** p< 0.01, 
**** p<0.0001.
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Comparison of the bactericidal activity of rifampicin, isoniazid and streptomycin over 
the 28-days exposure window showed no significant differences between the differ-
ent drugs after 7 and 14 days of treatment (Fig. 1F). However, after 28 days rifampicin 
showed markedly stronger bactericidal activity than the other two drugs.
Treatment outcome and bactericidal activity after treatment with different 
anti-Tb drug regimens
Treatment outcome after a six-months treatment course for ten different anti-TB drug 
regimens is shown in Table 2. Interestingly, none of the regimens achieved 100% treat-
ment success.
Another finding was that treatment success depended critically on rifampicin. The six 
rifampicin-containing-regimens showed treatment success rates between 80-95%, com-
pared to 0% treatment success of all four non-rifampicin containing regimens (Table 
2). Among the different rifampicin-containing regimens themselves, no significant 
differences in treatment success could be detected. This indicates limited contribution 
of anti-TB drugs other than rifampicin on treatment outcome. Notably, the rifampicin-
pyrazinamide regimen even appeared to perform better than the rifampicin-isoniazid-
pyrazinamide regimen, which suggests potential antagonism between anti-TB drugs.
Next, we determined whether the degree of bactericidal activity after any given treat-
ment duration could predict the impact of rifampicin on treatment outcome as observed 
in Table 2. To this aim, we ranked the bactericidal activity of the different rifampicin-
Table 2. Treatment outcome against a beijing strain
drug regimen Treatment successa
RZ (2 RZ / 4R)b 95% (20/21)c
RHZs (2 RHZS / 4 RH) 95% (20/21)
RHZE (2 RHZE / 4 RH) 90% (19/21)
RH (6 RH) 87% (13/15)
RE (6 RE) 85% (17/20)
RHZ (2 RHZ / 4 RH) 80% (17/21)
Hs (2 HS / 4 H) 0% (0/9)
HZ (2 HZ / 4 H) 0% (0/20)
HE (6 HE) 0% (0/18)
ZEs (2 ZES / 4 E) 0% (0/20)
a percentage of mice with culture-negative lungs 3 months after stop of a 6-months treatment course, b (2 
RZ / 4 R) = 2 months RZ treatment followed by 4 months treatment with R only, c (20/21) = 20 mice with 
culture-negative lungs out of 21 mice assessed. All rifampicin-containing regimens are marked grey. R = 
rifampicin, H = isoniazid, Z = pyrazinamide, S = streptomycin and E = ethambutol.
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containing regimens and non-rifampicin-containing regimens after 7, 14 and 28 days 
and after 2, 3 and 6 months. The results are shown in Table 3.
After 7 and 14 days, no significant differences in mycobacterial load could be found be-
tween rifampicin-containing regimens and non-rifampicin-containing regimens. After 
28 days, the rifampicin-containing regimens started to show a trend towards stronger 
bactericidal activity compared to non-rifampicin-containing regimens, which is in line 
with the single drug exposure kinetics as shown in Fig 1F. At this time point, two out of 
six rifampicin-containing regimens showed significantly lower mycobacterial loads in 
the lungs compared to all non-rifampicin-containing regimens tested.
After two months of treatment, four out of six rifampicin-containing regimens showed 
significant lower mycobacterial loads compared to all non-rifampicin-containing 
regimens. However, a clear distinction in bactericidal activity between all rifampicin-
containing regimens compared to all non-rifampicin-regimens could only be made after 
three months of treatment (Table 3).
Table 3. bacterial loads over a 6-months treatment course
d0
intensive phase (all drugs administered) continues phase (no Z/s/E)b
d7 a d14 d28 m2 m3 m6
RHZE 7,3 RH 6,7 RHZ 6,1 RHZS 4,3* RHZSc 0,9**** RE 1,4**** RE 0
RZ 7,7 HS 6,8 HS 6,1 RE 4,3* RHZE 2,3**** RH 1,4**** RH 0
HS 7,7 RHZE 6,9 RHZS 6,1 RZ 4,5 RZ 3,0** RHZS 1,6**** RHZS 0
RH 7,7 RHZ 6,9 ZES 6,2 RH 4,7 RE 3,1* RZ 1,8**** RHZ 0
HZ 7,7 RHZS 7,0 RH 6,2 RHZ 4,9 RHZ 3,8 RHZE 2,1**** RHZE 0
HE 7,9 HE 7,2 RHZE 6,3 RHZE 5,3 RH 3,9 RHZ 2,3**** HSd 0,4
RHZ 8,0 HZ 7,2 RZ 6,4 ZES 5,3 ZES 4,3 HS 3,9 RZd 1,1
RE 8,0 ZES 7,3 HZ 6,6 HS 5,5 HS 4,3 ZES 4,0 HE 3,0
RHZS 8,0 RE 7,3 HE 6,7 HE 5,8 HZ 4,9 HZ 4,0 HZ 3,4
ZES 8,0 RZ 7,6 RE 6,7 HZ 6,2 HE 5,2 HE 4,9 ZES 4,9
The different anti-TB drug regimens were ranked based on the mean log value of colony forming units 
(CFU) of mycobacteria in the lungs of n=3 mice per time point. Rifampicin-containing regimens are marked 
grey. Mice were infected at day -14 and treatment was started at day 0. a D7=7 days after start of treatment, 
M2= 2 months after start of treatment, etc. b after 2 months Z, S and E were stopped, with the exception 
of the ZES, RE and HE regimen. c 2/3 mice of the RHZS group were culture negative at M2,d 2/3 mice of 
the HS and RZ group were culture negative at M6. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
after Bonferroni correction for multiple comparisons. Significance for rifampicin-containing regimens was 
calculated against all non-rifampicin-containing regimens at that point. R = rifampicin, H = isoniazid, Z = 
pyrazinamide, S = streptomycin and E = ethambutol
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At the end of the six-months treatment course no mycobacteria could be cultured from 
the lungs of nearly all mice treated with rifampicin-containing regimens. One exception 
was the RZ group, in which one out of three mice still had culture-positive lungs. Of the 
non-rifampicin-containing regimens, all mice treated with isoniazid (H) in the continu-
ous phase (HE, HZ and HS) showed reductions in mycobacterial load, but mycobacteria 
could still be cultured from the lungs. One exception was the HS group, in which two out 
of three mice had culture-negative lungs. All mice of the ZES group, which were treated 
with E in the continuous phase of treatment, showed an increase in mycobacterial loads 
compared to three months of treatment.
discussiOn
Two important findings in this study were that infection with a Mycobacterium tuber-
culosis Beijing genotype strain in mice is associated with lower treatment success rates 
compared to other strains in literature (13, 17, 23, 24) and that bactericidal activity is an 
unreliable predictor for treatment outcome in TB when assessed in the first 2 months of 
treatment.
Infections with Beijing strains are associated with treatment failure in TB patients (3, 
5-8). The data obtained in our mouse TB model reflect these clinical findings. None 
of the regimens tested, including the standard of care regimen 2RZH/4RH, achieved 
100% treatment success. In contrast, at least four different studies using Mycobacterium 
tuberculosis H37Rv strains, including one previous study in our own model, showed 
100% treatment success of the 2RHZ/4RH regimen in BALB/c mice (13, 17, 23, 24). In TB 
patients, treatment success rates with 2RHZE/4RH in controlled trial settings are 92% 
or less (25). This indicates that the repeatedly found 100% treatment success rates in 
preclinical mouse TB models using H37Rv might overestimate clinical treatment success 
rates. The 90% treatment success rate for 2RHZE/4RH observed in our model using a 
Beijing strain might approach clinical observations better.
The difference in treatment outcome between Beijing and H37Rv strains could poten-
tially be explained by the observation that only Beijing strains constitutively express 
proteins belonging to the DosR dormancy regulon (26, 27). These proteins regulate the 
mycobacterial metabolic state in response to stressors induced by the host-response. 
This might result in a more rapid or more profound conversion by Beijing genotype 
strains to a metabolic state in which the mycobacteria are less susceptible to anti-TB 
drugs. Other possibilities include the ability of Beijing strains to circumvent and ma-
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nipulate host-responses more effectively than H37Rv (28, 29), thus resulting in better 
localization in (intracellular) niches, shielded from anti-TB drugs (30).
In TB, clinical phase IIa trials were found to be a poor predictor for treatment outcome 
(9, 31). These studies measure early bactericidal activity (EBA) in patient sputum samples 
between 2-7 days or between 2-14 days in case of the extended EBA (11). Our mouse 
TB model clearly supports this clinical finding, as it is impossible to distinguish the 
rifampicin-containing regimens from the non-rifampicin-containing regimens after 
7 or 14 days of treatment, despite their markedly different treatment outcome after 6 
months of treatment.
Our single-drug exposure experiments showed that rifampicin only starts to show sig-
nificantly stronger bactericidal activity compared to other anti-TB drugs after a minimum 
of 28 days of treatment. Two clinical studies that continued EBA measurements up to 28 
days indeed found a markedly stronger association between bactericidal activity and 
treatment outcome for anti-TB drug regimens containing pyrazinamide and rifampicin 
(32, 33). These studies indicate that extending EBA to 28 days might be a better predic-
tor for treatment outcome. In our regimen-experiments we found that after 28 days the 
rifampicin-containing regimens showed a trend towards lower mycobacterial loads in 
the lungs compared to the non-rifampicin-containing regimens. However, a significant 
distinction in bactericidal activity between all rifampicin-containing regimens and all 
non-rifampicin-containing regimens could still not be made. Moreover, after 28 days 
the standard of care RHZE-regimen showed similar mycobacterial loads in the lungs as 
the non-rifampicin-containing ZES-regimen, while having markedly different treatment 
outcomes. Thus, based on our data we conclude that extending EBA for up to 28 days 
is more informative compared to 7 or 14 days, but remains an unreliable parameter for 
predicting treatment outcome.
Clinical phase IIb trials measure bactericidal activity over a 2-months period with 
sputum culture status as surrogate endpoint for treatment outcome (31). These studies 
were initially thought indicative for phase III trial outcomes in TB (31), but the disap-
pointing results of the recent phase III REMox trials show otherwise (9, 25). Our study 
shows that after 2 months of treatment, the rifampicin-containing regimens RH and 
RHZ still do not show significant differences in lung mycobacterial loads compared to 
the non-rifampicin-containing regimens. The inability at this time point to significantly 
distinguish between regimens with a markedly different treatment outcome after 6 
months supports the limited predictive value of measuring bactericidal activity during 
longer treatment durations in TB.
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Our mouse TB model did show a clear distinction in lung mycobacterial loads between 
rifampicin-containing regimens and non-rifampicin-containing regimens after 3 months 
of treatment. However, the value of such a late time point in clinical studies is highly 
questionable, especially when phase III trials strive to shorten treatment duration to 4 
months (25).
In conclusion, multiple approaches are currently evaluated for their potential to further 
increase the translational value of preclinical TB models. Examples such as implementa-
tion of mouse strains that better mimic human disease and integration of advanced 
biostatistics to generate more informative models are likely to improve future anti-TB 
drug research. Our data complement these developments by advocating the use of My-
cobacterium tuberculosis Beijing genotype strains to increase the translational value of 
preclinical models assessing treatment outcomes. Also, our data in this mouse TB model 
support the notion that bactericidal activity in the first 2 months of treatment as mea-
sured in clinical phase IIa/b trials has limited predictive value for treatment outcome, 
which emphasizes the need for better biomarker to guide future phase III trials.
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absTRacT
Preclinical treatment outcome evaluation of tuberculosis (TB) occurs primarily in mice. 
Current designs compare relapse rates of different regimens at selected time points, 
but lack information about the correlation between treatment length and treatment 
outcome, which is required to efficiently estimate a regimens’ treatment-shortening 
potential. Therefore we developed a new approach. BALB/c mice were infected with a 
Mycobacterium tuberculosis Beijing genotype strain and were treated with rifapentine-
pyrazinamide-isoniazid-ethambutol (RpZHE), rifampicin-pyrazinamide-moxifloxacin-
ethambutol (RZME) or rifampicin-pyrazinamide-moxifloxacin-isoniazid (RZMH). Treat-
ment outcome was assessed in n=3 mice after 9 different treatment lengths between 
2-6 months. Next, we created a mathematical model that best fitted the observational 
data and used this for inter-regimen comparison. The observed data were best described 
by a sigmoidal Emax model in favor over linear or conventional Emax models. Estimating 
regimen-specific parameters showed significantly higher curative potentials for RZME 
and RpZHE compared to RZMH. In conclusion, we provide a new design for treatment 
outcome evaluation in a mouse TB model, which (i) provides accurate tools for assess-
ment of the relationship between treatment length and predicted cure, (ii) allows for ef-
ficient comparison between regimens and (iii) adheres to the reduction and refinement 
principles of laboratory animal use.
Published in Nature Scientific Reports
2018, 5714. doi:10.1038/s41598-018-24067-x
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inTROducTiOn
Tuberculosis (TB) claimed 1.7 million lives in 2016, which is more than any other infec-
tious disease caused by a single pathogen (1). The global treatment success rate for 
drug-susceptible TB is 83%, which falls short of the > 90% target rate set by the WHO 
(1). Moreover, treatment success rates against multi-drug resistant (MDR; 52%) and 
extensively drug resistant (XDR; 28%) TB are markedly lower (1). These rates emphasize 
the need for more effective anti-TB drug regimens that can improve treatment success. 
In addition, new anti-TB regimens should allow for shortening of the current 6-months 
treatment length to increase compliance and minimize further drug resistance develop-
ment.
Recently, a large clinical Phase III trial failed to reduce anti-TB treatment length from 
six to four months by substituting conventional anti-TB drugs with moxifloxacin (2). 
This trial was conducted based on promising results from clinical Phase IIa/b trials and 
preclinical experiments in mouse TB models (3-5). Overall, this has led to the conclusion 
that early surrogates for treatment efficacy assessments as measured in clinical phase 
IIa/b trials are unreliable predictors for cure in TB (6, 7). This has further inspired efforts 
to improve preclinical mouse TB models aimed at evaluating treatment outcomes (8).
Preclinical evaluation of TB treatment outcome occurs primarily in mouse models (9). 
The conventional design involves a two-step approach. During the first step, early treat-
ment efficacy is measured by determining mycobacterial load reductions in the lungs 
of small groups of mice (n=3-5) at preset time points until culture conversion is reached 
(10-15). In the second step, relapse of infection is evaluated for regimens that resulted 
in culture negativity. This occurs by determining lung culture status three months after 
treatment has ended in larger groups of mice (n=12-30), after 1-3 selected treatment 
lengths) (10-15).
This conventional design seems to have several drawbacks. Most importantly, it allows 
for relapse rate comparison between regimens at selected time points, but does not 
provide an individual regimen’s correlation between treatment length and treatment 
outcome. This correlation is required to efficiently estimate a regimen’s treatment-
shortening potential. The conventional design also has limited screening potential for 
regimens with unknown efficacy, as prior knowledge on when a regimen will reach 
culture-conversion is required before relapse can be evaluated. Lastly, recent clinical 
and preclinical observations suggest that early treatment efficacy assessment as mea-
sured in step one of the conventional design has limited predictive value for treatment 
outcome after a full course of anti-TB treatment (6, 7, 16).
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In the current study we propose an alternative design for treatment outcome assess-
ment in our mouse TB model. We increase the number of treatment schedules assessing 
outcome three months after the end of treatment regardless of culture status at the end 
of treatment, but decrease the number of mice per treatment length (n=3 instead of 
n=12-30). This way of data collection allows for mathematical modeling of the observa-
tional data optimized for establishing a robust and informative link between treatment 
length and cure.
The mathematical modeling is based on conventional logistic regression, but is de-
signed to be more informative. This approach differs from survival-, or time-to-event 
analysis, because the bacterial burden is determined after a fixed period of time after 
stop of treatment. Therefore the time of culture-conversion relative to stop of treatment 
is unknown.
In silico simulations of the mathematical model can be used to visualize and accurately 
quantify the association between treatment length and predicted treatment outcome 
for each regimen. Advantages include the possibility to compare the curative potential 
of different anti-TB regimens with each other over time instead of at selected time points 
only and simultaneously assess the treatment-shortening potential of each individual 
regimen.
maTERial and mETHOds
mice, infection and mycobacterial strain
Specified pathogen-free female BALB/c mice, aged 13-15 weeks, were infected by 
intratracheal installation of 1.0-1.8 x 105 drug-susceptible Mycobacterium tuberculosis 
Beijing VN 2002-1585 (BE-1585) under general anesthesia as described previously (16, 
17). The mice were housed and experiments were conducted in the Erasmus MC animal 
biosafety level III facility.
Ethical approval
All protocols were approved by the Erasmus MC animal ethics committee under DEC 
number 117-12-13 and EMC number 2887, and were in accordance with the rules laid 
down in the Dutch Animal Experimentation Act and the EU Animal Directive 201/63/EU.
Treatment
Treatment consisted of either of three regimens: (i) rifapentine, pyrazinamide, isoniazid 
and ethambutol (RpZHE), (ii) rifampicin, pyrazinamide, moxifloxacin and ethambutol 
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(RZME) or (iii) rifampicin, pyrazinamide, moxifloxacin and isoniazid (RZMH). The first two 
months of each regimen consisted of treatment with all four drugs (intensive phase) 
followed by four months of treatment with rifapentine and isoniazid for the RpZHE regi-
men, rifampicin and moxifloxacin for RZME and rifampicin, moxifloxacin and isoniazid 
for RZMH. All drugs were administered 5 days a week via oral gavage in their human 
pharmacokinetic equivalent dose: rifampicin: 10 mg/kg, rifapentine: 10 mg/kg, moxi-
floxacin: 200 mg/kg, isoniazid: 25 mg/kg, ethambutol: 100 mg/kg, pyrazinamide: 150 
mg/kg (18, 19).
Treatment outcome evaluation
Treatment was initiated 2 weeks after infection and was stopped between 2 and 6 
months with intervals of 2 weeks (i.e. nine different treatment lengths per drug regi-
men). The protocol was designed to include three (n=3) mice per treatment length. A 
sample size of n=3 was found to be sufficient to detect a 50% difference in potency 
between different treatments and was expected to give reasonably high precision in 
model parameters, according to a statistical power calculation (described in supple-
mentary data file s1).
One ‘backup’ mouse was added per regimen to reduce the impact of unexpected animal 
loss. All mice were sacrificed 3 months post-treatment to determine mycobacterial loads 
in the lungs as described previously (16).
statistical analysis
The statistical analysis involved the development of a logistic regression model based 
on the observational data. These data were treated as a binary outcome variable of 
either cure (defined as a negative solid culture 3 months post-treatment) or failure 
(defined as a positive solid culture 3 months post-treatment). The independent variable 
was treatment length. The data were analyzed using the non-linear regression software 
NONMEM (version 7.3) with simultaneous estimation of all model parameters (20). Only 
if parameters were estimated close to a parameter boundary (as described below) they 
were fixed to the value of the respective boundary. NONMEM maximizes the likelihood 
of a model to fit the observational data. In NONMEM the model fit (defined as the likeli-
hood of the model to describe the observational data) was assessed using the objective 
function value (OFV), which is equal to -2 times the log value of the likelihood. In order 
to generate a model that best described (fitted) the data, the OFV between models was 
compared using the likelihood ratio test (LRT). To this aim, for each model comparison 
a reduced model and a full model were evaluated where the full model always included 
more model parameters than the reduced model. The null hypothesis was that the full 
model did not provide better fit than the reduced model. Testing was performed at the 
Chapter 6
150
5% significance level which corresponds to a drop in the OFV of at least 3.84 points 
with one degree of freedom. Data handling and graphical analysis were conducted in R 
(version 3.3.0) (21).
The model development was divided into two parts; in the first part, an appropriate 
relation between probability of cure and treatment length was identified (regardless 
of drug regimen). In the second part we explored if this relation between probability of 
cure and treatment length was significantly different between the drug regimens.
The starting point for the first part of model development was a base model which 
assumed that the probability of cure was identical regardless of treatment lengths ac-
cording to:
Equation 1: pfailure = 1 − pcure = pbase
In this model, pfailure and pcure are the predicted probabilities of failure and cure respec-
tively and pbase is the base probability of failure. The pbase parameter was constrained to 
be between 0 and 1. First, this base model was compared to a model assuming linear 
increase in cure rate with treatment length according to:
Equation 2: pfailure = 1 − pcure = pbase × (1 × Slope×T)
In this model ‘Slope’ is the linear increase in probability of cure with treatment length (T). 
The ‘Slope’ parameter was constrained to be between 0 and 1 divided by the maximum 
treatment duration of 6 months. Secondly, an Emax model was tested according to:
Equation 3: pfailure = 1 − pcure = pbase × (1 − )
Emax×T
T50+T
In this model ‘Emax’ is the maximal achievable probability of cure and ‘T50’ is the treatment 
length at which half the Emax is seen. The Emax parameter was constrained to be between 
0 and 1. Lastly, a sigmoidal Emax model was tested according to:
Equation 4: pfailure = 1 − pcure = pbase × (1 − )
Emax×T γ
T50+T γ
In this model ‘γ’ is a shape parameter controlling the steepness of the curve produced 
by the Emax equation.
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In the second part of model development, we explored if the identified relation between 
cure and treatment length from the first part of model development was significantly 
different for the different drug regimens by comparing the model parameters of the 
different drug regimens (Slope, Emax, T50 or γ, depending on the model). This was done in 
a step-wise approach, here exemplified for a sigmoidal Emax model, which includes the 
three model parameters Emax, T50 and γ. Firstly, one model was fitted to explore if Emax for 
each regimen was significantly different from the other two regimens. This procedure 
was repeated for the T50 and γ parameters, thus resulting in nine different models. Sec-
ondly, the models that did not significantly improve the fit (OFV drop of less than 3.84 
points) were not evaluated further. Of the remaining models that did result in an OFV 
drop of at least 3.84 points, the model with the lowest OFV was accepted. Thirdly, the ac-
cepted model with the greatest drop in OFV was combined with the remaining models 
that also improved the fit significantly (i.e. whose OFV drop was lesser than the accepted 
model but at least 3.84 points). If this combination improved the fit significantly, it was 
accepted as the new model. This whole three-step procedure was repeated until no 
significant improvement was seen anymore, which was defined as the final model.
In addition to assessment of OFV, model selection was guided by parameter uncertainty 
and visual predictive checks (VPC) generated using PsN (http://psn.sourceforge.net/ 
[cited 19-12-2016]) and Xpose (http://xpose.sourceforge.net/ [cited 19-12-2016]) using 
1000 simulated datasets. The VPC is a visual diagnostic which shows how well data 
simulated from a model agree with the observed data.
simulations
The observational data using n=3 animals can only theoretically generate cure rates of 
0%, 33%, 67% or 100%. Therefore, we used the mathematical model to simulate treat-
ment outcome from 1000 mice per time point to increase the resolution in the predicted 
cure rates (i.e. to allow cure rate to continuously range between 0-100%). Simulations 
were performed using Monte Carlo sampling from a random uniform distribution rang-
ing from 1 to 0. This was also used to determine the model-predicted treatment length 
required for each regimen to achieve 85%, 90% or 95% cure, respectively.
data availability
All data generated or analyzed during this study are included in this published article 
(and its Supplementary data files).
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REsulTs
Observed treatment outcome
A schematic overview of our method of data collection compared to the conventional 
design is found in Figure 1. The observed proportions of cured animals for the different 
treatment lengths for the RpZHE, RZME and RZMH regimens are shown in Table 1. RpZHE 
started to show cure rates above 0% after 2.5 months of treatment and showed 100% 
cure after 4 months. RZME displayed similar kinetics and also showed complete cure 
rates from 4 months of treatment onwards. In contrast, RZMH only started to show cure 
rates above 0% after 4 months of treatment and did not reach complete cure even after 
6 months of treatment.
1. Treatment outcome 
B: Proposed design 
A: Example of conventional design 
1. Early treatment efficacy (bactericidal activity) 
1 0 2 3 5 8 9 7 6 4 
2. Relapse 
n=3-5 
n= 
12-20 
n=3 
treatment 
post-treatment 
Time in months  
1 0 2 3 5 8 9 7 6 4 
Mtb-load determination 
2. Model development 
based on observational data 
3. In silico simulations 
𝑝𝑝𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 = 1 − 𝑝𝑝𝑐𝑐𝑓𝑓𝑓𝑓𝑓𝑓 = 𝑝𝑝𝑏𝑏𝑓𝑓𝑏𝑏𝑓𝑓 × (1 −
𝐸𝐸𝑚𝑚𝑓𝑓𝑚𝑚 × 𝑇𝑇
𝛾𝛾
𝑇𝑇50
𝛾𝛾 + 𝑇𝑇𝛾𝛾
) 
Time in months  
Figure 1. schematic examples of the conventional design and the proposed design for treatment 
outcome evaluation in mouse Tb models
a) Shows an example of the conventional design in which bactericidal activity is determined by measuring 
reductions in Mtb-loads in the lungs until culture negativity is reached, followed by cross-sectional evalua-
tion / comparison of relapse rates 3 months post-treatment (x in upper right figure).
b) Shows our proposed design in which treatment outcome is determined regardless of lung culture-status 
at stop of treatment. This allows for more informative mathematical modeling of the data and subsequent 
simulation of large numbers of mice to generate a high resolution correlation between treatment duration 
and treatment success.
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model development
Part	I:	Relation	between	treatment	length	and	probability	of	cure
The observational data from Table 1 were first converted into a dataset used for model-
ing (supplementary data file s2). Compared to the base model which does not assume 
any relationship between cure and treatment length, a linear relationship between 
treatment length and cure gave a significant improvement in model fit compared to 
the base model (p<0.001, OFV drop of 32.2 points). An Emax relationship between treat-
ment length and cure did not improve model fit compared to a linear relationship (OFV 
increased with 15.9 points) and was rejected. However, a sigmoidal Emax relationship 
improved model fit significantly compared to a linear relationship between treatment 
length and probability of cure (p=0.001, OFV drop of 13.3 points). Thus, the sigmoidal 
Emax model was identified as appropriate and was brought forward to the second part of 
model development.
Notably, the baseline probability (pbase) in this sigmoidal Emax model was estimated very 
close to 1, which resulted in an unstable model (not possible to obtain any parameter 
uncertainty). Fixing pbase to 1 could correct for this without affecting the OFV.
Part	II:	inter-regimen	differences
The generated sigmoidal Emax  relationship in part 1 of model development assumed 
a similar relationship between treatment length and probability of cure for all three 
regimens tested. In order to detect if the selected relationship deviated significantly 
between the different regimens, we determined if implementing drug regimen-specific 
Table 1. Observational data on cure
Treatment length RpZHE RZmE RZmH
2 months 0/3 0/3a 0/3
2.5 months 1/3 0/3 0/3
3 months 2/3 3/3 0/3
3.5 months 2/3 2/3 0/3
4 months 3/3 2/2b 1/3
4.5 months 2/2c 3/3 2/3
5 months 3/3 3/3 3/3
5.5 months 3/3 2/2b 3/3
6 months 3/3 3/3 3/4d
a 0/3 = 0 of 3 mice was cured (culture-negative lungs 3 months post-treatment) after indicated treatment 
duration; b Animal died of a non-tuberculosis cause prior to time point; c The plates for colony counting 
were contaminated and no counting could be performed; d The backup mouse included for the RZMH 
regimen was still alive at the 6 month time point. R=rifampicin, Rp= rifapentine, Z= pyrazinamide, M= moxi-
floxacin, H=isoniazid, E= Ethambutol
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model parameters (including γ, Emax and T50) improved model fit and could detect signifi-
cant differences between the different regimens.
Initially, the following models improved the model fit to the observational data signifi-
cantly: Model 1: separate T50 for RZMH (p<0.001, OFV drop of 18.6 points), Model 2: sepa-
rate Emax for RZMH (p=0.00298, OFV drop of 8.82 points), Model 3: separate γ for RZMH 
(p=0.0408, OFV drop of 4.18 points) and Model 4: separate T50 for RpZHE (p=0.0377, OFV 
drop of 4.32 points). Model 1 (separate T50 for the RZMH regimen) had the lowest OFV 
and was therefore accepted. When combined with model 2-4, no significant improve-
ments were observed. Therefore only model 1, which included simultaneous estimation 
of separate T50 parameters for RZMH only and for RZME and RpZHE, respectively was 
selected.
Notably, The Emax parameter for the sigmoidal Emax model with a separate T50 for the 
RZMH regimen was estimated very close to 1 which also resulted in an unstable model. 
Fixing Emax to 1 could correct for this and improved the model fit slightly (p=0.827, OFV 
drop of 0.048 points).
Taken together, the final model included a sigmoidal Emax relationship where the prob-
ability of cure increased with treatment length. The Emax parameter had the value of 1 
which implies that all included regimens can achieve 100% cure if the treatment length 
is sufficiently long. The baseline probability (pbase) also had a value of 1 which implies 
that at very short or no treatment duration at all (i.e. T=0) treatment failure will occur in 
all mice. Apart from pbase and Emax, all parameters were simultaneously estimated.
Importantly, our finding that estimating a separate T50 for the RZMH regimen significantly 
improved our model fit indicates that RZMH has reduced curative potential compared to 
the other regimens. The final model parameters are shown in Table 2. The final model 
code is supplied in supplementary data file s3.
model validation
To verify the model, a visual predictive check (VPC) was performed where the observa-
tional data and simulated data (presented as 95% confidence interval based on 1000 
simulated datasets) were compared in the same plot (Figure 2). As can be seen in the 
VPC, the observed proportions of cure fell within the 95% confidence of the simulated 
data. The confidence intervals may appear large at some time points which is due to the 
relatively low number of animals per time point and thus, given the data, the model can 
describe the observed data well.
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Part	I:	Cure	rate	predictions	based	on	model	simulation
Simulations of high numbers of mice (n=1000 per arm) using the developed model 
enabled us to provide a high-resolution estimate of the predicted cure rates of each 
regimen for different treatment lengths as shown in Figure 3. For RpZHE and RZME this 
estimates that mice must be treated at least 3.5 months to reach 85% cure and 4 months 
to reach 90% or 95% cure. In contrast, mice must be treated with RZMH for at least 5.5 
months to reach 85% or 90% cure and a full 6 months to reach 95% cure.
Part	II:	Model	comparison	to	conventional	relapse	assessment	other	mouse	TB	models
Next, we aimed to evaluate if the predicted cure rates generated in our model were com-
parable to observational data obtained from other mouse TB models using pulmonary 
infection. These data are shown in Table 3 (5, 12, 13, 22, 23). A direct advantage of our 
model-based approach is the possibility to compare our predicted cure rates for any 
treatment length evaluated in other mouse TB models (Fig. 3 and Table 3).
Our model predicted a cure rate of 60% for RZME after three months of treatment. This 
was lower than the observed cure rates from three other mouse TB models, which were 
80-100% (Table 3: models 2, 4, 5), but higher than the observed cure rate of 40% in 
model 6 (12). After four months of treatment no data on RZME was available in other 
mouse TB models and we could only compare our data to the RZM regimen. A 97% 
predicted cure rate for RZME in our model showed similar cure rates as observed for 
RZM in models 1 and 4 and a 13% higher cure rate than RZM in model 3 (Table 3). After 
five months of treatment, results were similar compared to one other mouse TB model, 
which also showed 100% cure.
Table 2. Final parameter estimates
Parameter description Parameter estimate standard error (%cV)a
pbase Baseline probability of no cure 1 FIX -
Emax Maximum achievable probability of 
cure
1 FIX -
T50RpZHE/RZME (months)b The treatment time at which half the 
Emax is reached for RpZHE and RZME
2.87 5.4
T50RZMH (months)b The treatment time at which half the 
Emax is reached for RZMH
4.35 6.0
γ Shape factor 9.82 23.0
Rp= rifapentine, Z= pyrazinamide, M= moxifloxacin, H=isoniazid, E= Ethambutol; CV coefficient of variance; 
a The standard errors were calculated using the covariance step in NONMEM; b T50 was significantly differ-
ent between treatment arms (no statistically significant differences were found in other parameters)
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For RZMH, our predicted cure rate of 2% after three months of treatment was lower com-
pared to the observed cure rates of 27%, 93% and 80% in models 2, 4 and 5, respectively, 
but higher than the 0% cure observed in model 6 (Table 3). After four months, RZMH 
in our model could only be compared to RZM in other mouse TB models. Our predicted 
cure rate of 29% for RZMH at this point was markedly lower than the cure rates observed 
for RZM of 100-95%, 84% and 95% in models 1, 3 and 4 respectively. In this regard it is of 
note to mention that after three months of treatment RZMH also showed inferior results 
compared to RZM in mouse TB models 1 and 4 and inferior results compared to RZME in 
mouse TB models 2,4 and 6 (Table 3).
Taken together, our finding that RZMH has significantly lower curative potential com-
pared to RZME is reflected in trends observed in other mouse TB models. Moreover, 
Figure 2. Visual predictive check (VPc) of the 
final model for each regimen
a) rifapentine, pyrazinamide, isoniazid and eth-
ambutol (RpZHE), b) rifampicin, pyrazinamide, 
moxifloxacin and ethambutol (RZME) and c) ri-
fampicin, pyrazinamide, moxifloxacin and isonia-
zid (RZMH). The open circles connected by the 
solid black lines are the observed probabilities 
of cure following different treatment lengths and 
the shaded areas are the 95% non-parametric 
confidence interval of the predicted cure rates 
following different treatment lengths.
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Figure 3. model-predicted cure at different treatment lengths for each regimen
The black horizontal lines indicate 95% (dashed line), 90% (dotted line) and 85% (dashed-dotted line) cure 
rates. R=rifampicin, Rp= rifapentine, Z= pyrazinamide, M= moxifloxacin, H=isoniazid, E= Ethambutol
Table 3. comparison of our model-based predictions of cure rates with observational data
Regimen
% cured at:
Ref.3 months 4 months 5 months
Our model
BALB/c, Beijing, HDIT
2 RpZHE/ 1,2,3 RpHa 62% 97% 100%
2 RZME/ 1,2,3 RMa 60% 97% 100%
2 RZMH/ 1,2,3 RMHa 2% 29% 81%
model 1
BALB/c, H37Rv, HDA
2 RpZM/ 1,2 RpM 100% 22
3,4,5 RZM 75% 100% 100% 5
2 RZM/ 1,2,3 RM 83% 100% 100% 5
2 RZM/ 2,3 RM 95% 100% 23
model 2
BALB/c, H37Rv, LDA
2 RZME/ 1 RM 80% 12
2 RZMH/ 1 RMH 27% 12
model 3
BALB/c, Erdman, HDA
2 RZM/ 2 RM 84% 13
model 4
BALB/c, Erdman, LDA
3 RZME 100% 12
3 RZMH 93% 12
2 RZM/ 1 RM, 2 RM 100% 95% 13
model 5
C3HeB/FeJb, H37Rv, LDA
2 RZME/ 1 RM 80% 12
2 RZMH/ 1 RMH 80% 12
model 6
C3HeB/FeJb, Erdman, LDA
3 RZME 40% 12
3 RZMH 0% 12
a Predicted cure for 3,4 and 5 months of treatment is shown as estimated in Figure 3, b C3HeB/FeJ mice can 
develop cavitating lesions that more closely resemble human disease, Abbreviations for route of infection: 
HDIT = high dose intratracheally, HDA = high dose aerosol, LDA = low dose aerosol, R=rifampicin, Rp= rifa-
pentine, Z= pyrazinamide, M= moxifloxacin, H=isoniazid, E= Ethambutol
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the discrepancy between our predicted cure rates for RZMH compared to RZM in other 
mouse TB models, suggests a negative effect of H on the efficacy of RZM in mouse TB 
models.
discussiOn
In this study we demonstrated that a model-based analysis of observational in vivo 
data on TB treatment outcomes can be used to generate a high resolution association 
between treatment length and probability of cure. The developed model could detect 
statistically significant differences in the curative potentials of RpZHE and RZME com-
pared to RZMH, which could not have been identified based on the observational data 
alone. Validation of our model against other mouse TB models supported a negative 
effect of isoniazid on the efficacy of RZM in mouse studies.
In our model RZMH showed significantly reduced curative potential compared to RZME. 
Interestingly, a similar trend was observed in other mouse TB models where RZMH 
consistently showed a trend towards inferior results compared to RZME and/or RZM 
(12). One explanation for this phenomenon might be a species-dependent, antagonistic 
effect of isoniazid on the therapeutic efficacy of rifampicin. Rifampicin is more essen-
tial for cure than isoniazid in mice (16). It has been demonstrated that concomitant 
administration of isoniazid negatively affects the pharmacokinetics of rifampicin by 
lowering the highest observed plasma concentration (Cmax) and area under the plasma 
concentration-time curve (AUC) (24). However, pharmacokinetics is an unlikely cause in 
our model as isoniazid co-administration previously did not affect rifampicin Cmax and 
AUC compared to rifampicin monotherapy (25). Also in patients no clinically significant 
pharmacokinetic interactions between isoniazid and rifampicin have been reported 
(26). Nevertheless, addition of isoniazid (H) to the combination of rifampicin and pyra-
zinamide (RZ) significantly reduced bactericidal activity and cure in other mouse TB 
models (24, 27, 28). In addition, an earlier study in our mouse TB model showed that RZ-
treated mice had higher cure rates than mice treated with RH or RHZ after a six-months 
treatment course (95% vs. 87% and 80%, respectively) (16). This previous comparison 
between RZ, RH and RHZ using the conventional design as shown in Figure 1 did not 
yield significant differences, but the observed inferiority of RZMH compared to RZME in 
the current study supports earlier observations of an antagonistic effect of isoniazid on 
the therapeutic efficacy of rifampicin in mice.
Advantages of the combination of animal research and mathematical modeling are the 
ability to detect significant differences in the curative potential of different regimens, 
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and the ability to compare our data with other studies that evaluated treatment out-
come after any given treatment length as demonstrated in Table 3. In addition, animal 
research experiments should always strive towards the 3R-principles of replacement, 
reduction and refinement (29). Our method adheres to the reduction and refinement 
principles. Firstly, the implementation of mathematical modeling and simulations can 
be considered a refinement as it enabled us to detect significant differences between 
regimens and allowed efficient comparison with other mouse TB models, which could 
not be derived from our observational data alone. Secondly, our approach enables as-
sessment of treatment outcome without requiring early treatment efficacy data. This 
reduces the total number of mice required (Fig. 1).
Early treatment efficacy as measured through bactericidal activity might be of limited 
predictive value for treatment outcome in TB (16). However, it remains an important 
screening tool in the setting of early drug discovery. The similar principle of observa-
tional data and mathematical modeling can be applied to bactericidal activity experi-
ments as well using ‘culture negativity’ as outcome parameter in order to improve data 
interpretation.
One initial concern with the proposed design was that with only n=3 mice per time 
point, the treatment outcome in a single mouse on a crucial time point might have a dis-
proportional impact, e.g. if in the RZMH group 4/4 mice would be cured after 6 months 
or if only 2/3 mice would be cured in the RZME group after 6 months (Table 1). However, 
sensitivity analysis of such scenarios did not alter the conclusions based on the model 
(results not shown). This can be explained by the notion that the fit of a model involves 
all mice evaluated at all time points and thus reduces the impact of potential outliers at 
a single time point.
A common method to analyze binary data is standard logistic regression but in this work 
we applied a new alternative to standard logistic regression. The main advantage with 
our new method is that it is more widely applicable than standard logistic regression. 
Observational data may not always behave similar to a logistic curve and in such situa-
tion our new method will outperform logistic regression. Additionally our new method 
can detect differences in the maximum probability of cure which standard logistic 
regression cannot provide. Furthermore, if different mouse models are compared, the 
treatment failure rate at no treatment may be different (i.e. different pbase between 
mouse models) which is another example of a scenario that can be handled using our 
approach but not using conventional logistic regression.
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A potential improvement of our model in its current form might be evaluation of the (re)
growth curve of M. tuberculosis during treatment failure. In the current design, the data 
were analyzed as a binary outcome because cure or failure was based on the absence 
or presence of mycobacteria in the lungs at a single time point three months after stop 
of treatment. If mycobacterial loads were measured at multiple time points after stop 
of treatment, e.g. after one, two and three months, as opposed to only three months, 
a time-to-event approach could have been used to analyze the data. A time-to-event 
analysis is considered more informative than analyzing the data as a binary outcome 
because it can provide information on the time course of cure or relapsing treatment 
failure. This could allow for better estimation of treatment success rates, but would also 
require substantially more mice.
In conclusion, we provide a new design for treatment outcome evaluation in our mouse 
TB model, which (i) provides accurate tools for assessment of the relationship between 
treatment length and predicted cure, (ii) allows for efficient comparison between regi-
mens, (iii) can be readily compared to other studies and (iv) adheres to the reduction 
and refinement principles of laboratory animal use.
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summaRiZinG discussiOn
Tuberculosis (TB) has been around for millennia and remains a serious health threat to 
date, despite the availability of curative treatment. Reasons for this persistent burden of 
disease include (i) mycobacterial factors such as newly emerging strains with increased 
virulence and the increasing rates and degrees of drug resistance; (ii) host factors such 
as large reservoir of latently infected individuals with the potential to progress to active 
disease and, lastly, (iii) treatment factors, including long treatment durations necessary 
to eradicate persistent populations of mycobacteria. Major questions that are currently 
in focus in TB research are:
• How and where do populations of mycobacteria persist that make anti-TB treatment 
so lengthy?
• How can we measure these persisting (perhaps dormant) subpopulation(s) of myco-
bacteria?
• How do host responses contribute to their persistence or reactivation?
• How do we develop and screen new anti-TB drugs to target these subpopulations?
The aim of this thesis was to improve TB treatment by (i) gaining insight into TB patho-
physiology in search for factors that can be modulated to our advantage during treat-
ment, and (ii) optimizing and increasing the translational value of the preclinical mouse 
TB model as screening tool for new TB drugs and regimens.
mycobacterial factors
Advances in genotyping technologies and clinical observations over the last two 
decades have shown mycobacterial strain variance to be an important factor in TB 
pathogenesis. The most illustrative example of this concerns the emergence of Beijing 
genotype strains, which have been a driving force behind the spread of multidrug-
resistant TB in Eurasia and have been associated with elevated treatment failure rates 
and disease relapse compared to other genotypes in other parts of the world (1-8). It is 
not difficult to imagine how drug resistance contributes to treatment failure, but other 
unique pathogenic mechanisms specific to Beijing strains such as their differential gene 
expression and immune modulating capacities are also thought to contribute to their 
clinical success. Therefore, strain diversity and its influence on treatment and pathogen-
esis is the mycobacterial factor that is addressed most prominently in this thesis.
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In contrast to most other Mycobacterium tuberculosis lineages, Beijing strains constitu-
tively express genes belonging to the DosR dormancy regulon (9-11), which comprises 
approximately 50 genes and is controlled by the DosR transcription factor (12). This 
regulon is an important virulence factor for M. tuberculosis as it is believed to play a piv-
otal role in mycobacterial progression to a persistent state under influence of (hypoxic) 
stress (13). Since mycobacteria in this persistent state are less affected by TB drugs, dif-
ferential expression of DosR regulon genes by Beijing strains could explain differences 
in treatment outcome (14, 15).
Preclinical mouse TB models evaluating treatment outcome often use mycobacterial 
strains such as H37Rv or Erdmann, which are no longer found in patients (16-20). Our 
specific aim in chapter 5 was to evaluate the impact of using a Beijing genotype strain 
on treatment outcome and increase translational value of our mouse TB model. Our 
characterization of the treatment response in Beijing-1585-infected mice showed that 
none of the ten regimens tested, including the standard of care regimen 2RZH/4RH 
(two months of rifampicin-pyrazinamide-isoniazid followed by 4 months of rifampicin-
isoniazid), achieved 100% treatment success. In contrast, at least four different studies 
using M. tuberculosis H37Rv strains, including one previous study in our own model, 
showed 100% treatment success of the 2RHZ/4RH regimen in BALB/c mice (16, 19, 21, 
22). This indicates that treatment success rates in mouse TB models using H37Rv prob-
ably overestimate clinical efficacy, as Beijing strains show increased survival within the 
host. Thus, the use of recent clinical isolates like Beijing-1585 instead of the laboratory 
H37Rv strain has the potential to increase the translational value of mouse TB models.
Another characteristic of the Beijing strain concerns the increased virulence, even called 
hyper-virulence. Virulent Beijing strains cause higher mycobacterial loads, more lung 
damage and earlier mortality in preclinical models compared to strains from other 
lineages and non-virulent Beijing strains (14, 23, 24). Previous studies in our mouse TB 
model confirmed these virulence factors for Beijing-1585, but also for EAI-1627, another 
clinical isolate prevalent in Southeast Asia and belonging to the East-African/Indian 
lineage (14, 25). This marked difference in virulence in our mouse TB model between 
currently circulating clinical strains compared to H37Rv inspired us to evaluate host re-
sponses for each strain more thoroughly. In the study described in chapter 3 we found 
that host responses against H37Rv were in line with the current basic paradigm of TB im-
munity characterized by an IL-12/Th1/IFN-γ response in the lungs as explained in Figure 
1 and box 1 in chapter 2. In marked contrast, host responses against Beijing-1585 and 
EAI-1627 were associated with an influx of B-cells rather than T-cells into the lungs at 
the peak of infection. Myeloid cell populations were present in the lungs at similar pro-
portions upon Beijing-1585-and EAI-1627- compared to H37Rv infection, but appeared 
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functionally impaired in infection with the Beijing- and EAI- strains with low iNOS and 
IL-12 expression. In addition, in the bone marrow of Beijing-1585- and EAI-1627-infected 
mice reduced expression was found of IFN-γ, TNF-α and IFN-β, cytokines essential for 
myeloid cell priming. This effect at distant site already became apparent on the third 
day post infection, before other systemic effects were detected. This combination of 
impaired myeloid cells in the lungs of mice infected with Beijing-1585 and EAI-1627 
and reduced expression of essential priming cytokines in their bone marrow suggests a 
previously unrecognized role for myeloid cell priming in the bone marrow with regard 
to strain-related virulence.
In chapter 2, figure 3 a detailed hypothesis is shown for such a mechanism. IL-12 
expression in the lungs, which is present during infection with H37Rv, but absent for 
the clinical strains, could cause IFN-γ-mediated myeloid cell development in the bone 
marrow towards a regulatory phenotype that prevents excessive innate inflammatory 
damage upon their migration to the lungs, while concomitantly stimulating protective 
adaptive responses. Another finding in chapter 3 concerned the role of type 1 interfer-
ons in acute TB. Previous studies speculated on a detrimental role for type 1 interferons 
in the pathogenesis of Beijing strains compared to H37Rv (26, 27). They found that the 
Beijing HN878 strain induced higher IFN-α mRNA expression levels in the lungs, which 
was associated with lower induction of IL-12 and TNF-α levels and reduced T-cell activa-
tion compared to H37Rv (27, 28). We also found lower induction of IL-12 by Beijing-1585, 
but refuted an association with elevated type 1 interferon levels. This was based on 
direct measurement of IFN-α/β mRNA expression similar to those previous studies, but 
was further substantiated by measurement of type 1 interferon-inducible genes.
Taken together, our combined findings from chapter 5 on the influence of strain 
variance on treatment outcome and chapter 3 on the influence of strain variance on 
host responses during acute infection suggest that integration of clinical mycobacte-
rial strains into preclinical mouse TB models should be pursued as it will increase their 
translational value and expand our basic knowledge on TB immunity. It is especially 
important to realize that much of our fundamental knowledge on TB immunity during 
acute infection is based on experimental data from mouse studies involving H37Rv, 
which we show not to be the best representative for host responses against modern day 
strains. This indicates that our basic paradigm of TB pathogenesis might be outdated.
Host factors
Our findings in chapter 3 on mycobacterial strain variance indicate differential regula-
tion of IL-12, which is part of the classical IL-12/T-helper 1/IFN-γ immune response in 
TB. However, we also found differences in B-cells, IL-4 and type 1 interferon responses 
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upon infection with different strains that do not fit the conventional paradigm so easily, 
but might be of influence in TB pathogenesis. Reasons to believe that such additional 
mechanisms beyond Th1 immunity are at play in TB immunity include unsatisfactory 
results of vaccine strategies aimed at boosting Th1 immunity (29), the inflammatory 
damage associated with increasing IFN-γ production by T-cells in the lungs of M. tu-
berculosis-infected mice (30) and the host-detrimental effect of blocking Th1-inhibiting 
pathways in mice (31, 32). Therefore, the aim in chapter 2 was to review and integrate 
the role of increasingly recognized immunological elements in TB pathogenesis such as 
B-cells, IL-17 and type 1 interferons into our current understanding of TB immunity. The 
major hypothesis that we formed is that type 1 interferon responses, the IL-17 pathway 
and their interaction converge onto a stimulatory effect on B-cells through the induc-
tion of B-cell activating factor (BAFF), stimulation and functioning of tertiary lymphoid 
structures (TLS) and stimulation of the Th17.1 response (chapter 2, Fig. 5). How this 
affects disease progression is multifactorial and dependent on the phase of disease as 
will be explained below.
Type 1 interferons are generally regarded as negative regulators of TB immunity because: 
(i) they induce a regulatory phenotype in myeloid cells, which favors mycobacterial 
persistence over eradication (33), (ii) they have been described to be upregulated by 
virulent strains (28, 34) and (iii) an interferon signature in blood cell RNA corresponds 
with active disease (35, 36). Based on our literature review, we conclude that the effects 
of type 1 interferon are diverse and depend on prior priming of myeloid cells by either 
IFN-γ and M-CSF or GM-CSF (chapter 2, Fig. 3).The most important consideration is that 
IFN-γ priming at precursor stage appears to lead to the induction by type 1 interferons of 
a regulatory phenotype in myeloid cells (37). This regulatory myeloid phenotype might 
favor mycobacterial persistence (33), but could also ameliorate destructive inflamma-
tion as the results described in chapter 3 suggest. A second consideration is that type 1 
interferons can only induce a regulatory phenotype in myeloid cells differentiated under 
M-CSF, as GM-CSF renders myeloid cells less responsive to type 1 interferon signaling 
(38). This might explain why effects of type 1 interferons are observed during acute 
infection and wane while infection progresses and GM-CSF levels rise. Lastly, the effects 
of type 1 interferon might differ between IFN-α and IFN-β and potentially serves as a 
mechanism to prevent excessive immune-mediated tissue damage (chapter 2, box 4 
and chapter 3).
The role of B-cells in TB immunity has been neglected over the past decades due to the 
established central role of protective T-cell mediated responses, but regained interest 
in the past years (39). Most notably, a functional role for antibody-mediated immunity 
in TB was demonstrated and circulating B-cells were shown to be dysfunctional and 
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reduced in absolute numbers in patients with active TB (39-41). Despite the potentially 
beneficial effects of B-cells and antibody-mediated immunity in chronic TB, we show in 
chapter 3 that acute infection with virulent Beijing-1585 and EAI-1627 in our mouse TB 
model is associated with increased B-cell influx and higher IL-4 protein levels in the lungs 
compared to infection with the less virulent H37Rv as outlined above. This suggests that, 
while protective during chronic infection, B-cells might also contribute to disease sever-
ity during acute infection, again emphasizing the complexity of TB immunity.
The importance of elucidating TB pathophysiology is emphasized by the central role 
that our own immune system plays in TB treatment. It is an effective and efficient first-
line barrier against TB as only 5-15% of all individuals with intact immunity infected with 
M. tuberculosis will progress to active disease (42). However, once that barrier fails and 
infection progresses to active disease, without treatment 50-70% of TB patients will die 
within two years (43). Paradoxically, upon disease progression, the same immunological 
barriers that can prevent active disease may hinder successful treatment. The granulo-
matous immune responses and intracellular residence of mycobacteria in macrophages 
and other myeloid cells shield mycobacteria from TB drugs and favor their persistence 
(44). Thus, the disease cannot be viewed separate from the host. This pivotal role of our 
own immune system in TB pathogenesis indicates the importance of integrating host 
factors into the exploration of new treatment modalities.
In chapter 4 we investigated if modulation of host responses adjunct to antibiotic treat-
ment could lead to improved treatment outcome in our mouse TB model. Host-directed 
therapies for TB include (i) strategies aimed at increasing macrophage effector function, 
such as metformin or high-dose immunoglobulins and (ii) strategies aimed at reducing 
inflammatory damage such as NSAIDs and statins (45). We followed the first strategy 
based on the hypothesis that host-directed therapy consisting of all-trans retinoic acid, 
α-galactosylceramide and 1,25 dihydroxyvitamin D could skew myeloid cell develop-
ment away from a M. tuberculosis-permissive and immune suppressive myeloid-derived 
suppressor cell (MDSC) phenotype towards a bactericidal phenotype. Mice were infected 
with M. tuberculosis H37Rv and were treated with isoniazid, rifampicin and pyrazinamide 
(HRZ), or HRZ in combination with host-directed therapy. We showed that HRZ in combi-
nation with host-directed therapy resulted in a significantly lower frequency of disease 
relapse after a shortened 12-weeks treatment course compared to HRZ alone (chapter 
4, Fig. 3). The most important conclusion that can be drawn from this study is a proof of 
principle that adjuvant immunotherapy aimed at increasing macrophage effector func-
tion can aid in the specific elimination of persistent mycobacteria that are responsible 
for relapse of disease.
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Treatment factors
Clinical implementation of novel treatment modalities identified in preclinical research, 
such as host-directed therapy or new drugs with anti-TB potential is a lengthy and ex-
pensive process. In the context of TB, the 2014 REMox trial taught an important lesson: 
early surrogate endpoints for treatment efficacy based on early bactericidal activity 
or sputum culture conversion as measured in clinical phase IIa/b trials are unreliable 
predictors for cure in TB (46, 47). In other words: the capacity of (new) anti-TB drugs to 
eliminate actively replicating mycobacteria during the initial phase of treatment does 
not guarantee efficacy against persistent mycobacteria in the second phase of treat-
ment. Clinical phase III trials are costly, require large numbers of patients and may take 
up to 10 years from study design to publication (48). Therefore, such trials should be 
based on preclinical evidence with maximum translational value. For the REMox trial the 
interpretation of preclinical data from mouse TB models might have been too optimistic 
(48). Therefore, current preclinical models require further optimization to improve their 
predictive value for treatment outcome in human trials.
To address this problem, a part of the work in this thesis was conducted on behalf of 
the PreDiCT-TB consortium, which consists of 19 public and private scientific partners in 
the European Union. The aim of PreDiCT-TB is to generate an integrated and validated 
preclinical pathway for new treatment options. This is achieved by validating multiple in 
vitro and in vivo preclinical TB models by testing currently used and new TB drugs and 
drug regimens and subsequent comparison of the results with clinical trial data. Our 
specific contribution was the Beijing-1585-infected BALB/c mouse TB model. A general 
criticism on the BALB/c mouse TB model is that the granulomas that are formed do not 
have a caseous center, which is thought to play a central role in human disease (49). The 
caseous center harbors mycobacteria, influences drug penetration and also results in 
different degrees of hypoxia and acidity (50-52). The clinical relevance of these lesions 
is best illustrated by the current resurgence of surgical resection in the context of drug 
resistance or poor treatment response (53, 54). The presence of caseous granulomas has 
been the major reason for preclinical testing in guinea pigs instead of mice and the de-
velopment of the C3HeB/FeJ mouse model, in which such lesions do develop (55). This 
model is currently validated within the framework of ‘Critical Paths to TB Drug Regimens 
(CPTR)’ the American counterpart of the European PreDiCT consortium. Interestingly, by 
comparing BALB/c and C3HeB/FeJ mice, it was show that sterilizing activity was shown 
not to be affected by the presence or absence of caseous granulomas (56). Also, for drug 
penetrance of pyrazinamide it should be mentioned that, despite the formation of dif-
ferent types of granulomas, this was similar for BALB/c and C3HeB/FeJ mice (57). Within 
the same study it was also found that the pH within C3HeB/FeJ mouse granulomas was 
outside the range in which efficacy was observed in vitro, indicating that acidification 
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within the granuloma does not alter drug efficacy . Lastly, persistent populations of my-
cobacteria are present in BALB/c mice despite the abcence of caseous granulomas and 
treatment failure rates approximate human clinical trial data. This is shown in chapter 
5, where HRZE in our model had a treatment success rate of 90% compared to 92% as 
found in the REMox trial (58). Taken together, this indicates that the BALB/c model is still 
a valuable preclinical TB model.
Another important finding in chapter 5 was that bactericidal activity of the antibiotic 
regimen early during treatment did not predict treatment outcome to a satisfying de-
gree, similar to clinical phase IIa/b trials (46, 47). Also, the current methods applied for 
treatment outcome evaluation itself in TB are of a relatively basic nature and involve 
simple Chi-square testing between large groups of mice after predetermined treatment 
lengths (59-63). This allows for relapse rate comparison between regimens at selected 
time points, but does not provide an individual regimen’s correlation between treat-
ment length and treatment outcome. This correlation is required to efficiently estimate 
a regimen’s treatment-shortening potential. Therefore, our next aim in chapter 6 was 
to improve the current methods of data collection for treatment outcome experiments. 
In this study we evaluated treatment outcome in n=3 mice after 9 different treatment 
durations and combined this with model-based analyses to create an accurate tool for 
assessment of the relationship between treatment length and predicted cure. Imple-
mentation of this model-based approach allowed us demonstrate that treatment with 
rifapentine-pyrazinamide-isoniazid-ethambutol (RpZHE) and rifampicin-pyrazinamide-
moxifloxacin-ethambutol (RZME) resulted in significantly better treatment outcome 
compared to rifampicin-pyrazinamide-moxifloxacin-isoniazid (RZMH). This could not 
have been identified based on the observational data alone. These data are in line with 
other mouse TB studies (chapter 6, table 3) and suggest a negative effect of isoniazid 
on the efficacy of RZM in mouse studies. Unfortunately, on a translational level our 
generated data for RZME and RZMH were not comparable to the human clinical trial 
data after 4 months (97% cure in mice versus 80% in humans for RZME and 29% in mice 
versus 85% in humans for RZMH) (58). This discrepancy between human and mouse data 
indicates that the translational value of mouse TB models should be further improved. 
Indeed, a recent study showed that correcting for additional factors including advanced 
pharmacodynamics and pharmacokinetic modeling, species-specific protein binding 
and species-specific pathology further improved the translational value of the BALB/c 
mouse model (64). Correction for these factors in combination with our integration of 
mycobacterial strain variance is likely to increase the translational value of mouse TB 
models further in order to guide the selection of new regimens eligible for future clinical 
phase III trial testing.
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FuTuRE diREcTiOns
The summarizing discussion emphasizes the complexity of the triangle between myco-
bacteria, host and treatment in TB, which only appears to increase as our understanding 
of each factor advances. The work described in this thesis is only a small contribution 
to the ongoing TB research efforts which result in approximately one hundred new TB-
related articles on a weekly basis. In this section I would like to present an integrated 
view on elements I believe to be essential for advancing our understanding of TB patho-
physiology and improving TB treatment.
1. shaping the host response
1.1.	 Prevention
The best initial step in prevention is maximizing the efficacy of host responses in unin-
fected individuals. Th1-stimulating BCG vaccination offers variable rates of protection in 
adults. Based on our analysis of the role of Th17 immunity in TB, an interesting alterna-
tive would be to develop a TB vaccine that stimulates Th17 immunity instead. A recent 
study showed suppressed Th17 responses in young adults progressing to active disease 
compared to latently infected controls (65). This result was confirmed in an independent 
cohort that received BCG revaccination, which was also associated with suppressed 
Th17 responses. There are (at least) three additional reasons why an IL-17-skewed initial 
host response might be beneficial in TB. The first reason is a specific protective effect of 
IL-17 against infection with a Beijing genotype strain during acute infection in a mouse 
TB model (66) (see chapter 2, Table 4). Increased efficacy against currently circulating 
strains would pose a major benefit, especially since current BCG vaccination appears 
to act as a selective force contributing to the spread of virulent Beijing strains (15). The 
second reason is that IL-17 inhibits the development of hypoxic necrotic granulomas 
and reduces disease severity, which has been demonstrated recently in a mouse TB 
model (67). A third reason why targeting IL-17 might be a promising approach concerns 
stimulation of the IL-23/IL-17/CXCL13/Tertiary Lymphoid Structure (TLS)-axis as shown 
in chapter 2, Fig. 4. Studies in mouse TB models indicate that IL-17 responses might 
not be essential during acute infection, but that the mentioned axis shapes an efficient 
micro-environment during acute infection that confers more efficient long-term protec-
tion. This is due to efficient recall immunity through the locally formed TLS (68). While 
speculative, this might also to some degree regulate the increasingly recognized role of 
B-cell responses in TB. Thus, with regard to preventive treatment, further development 
of Th17-inducing vaccines is of interest. Important considerations in developing such 
a vaccine based on our findings in chapter 2 section 3 are mucosal delivery, as this 
favors tissue-resident Th17 responses over systemic Th1 responses and TLS formation 
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(69, 70), specific attention to the plasticity of Th17 cells, which can alter their cytokine 
production upon recall immunity (70) and the role of neutrophils, which have shown to 
be essential in the induction of vaccine-elicited T-helper responses (71).
1.2.	 Treatment
Immunotherapy has the potential to improve treatment outcomes (chapter 4). Effective 
adjunct therapy, however, requires detailed knowledge of TB pathogenesis and specifi-
cally of the failing parts of immunity in case of active disease. Clinical studies continue 
to show involvement of type 1 interferon-related pathways in blood RNA signatures 
used for monitoring disease stage or progression in TB (35, 36). Since immunotherapy is 
primarily targeted at myeloid effector cells such as macrophages, a logical first step for 
future directions would be to establish the functional consequences of type 1 interferon 
exposure on myeloid cells more clearly. In chapter 2 the currently available literature 
on this topic has been reviewed. It would be interesting to test the hypothesis that IFN-γ 
priming of myeloid cells in the bone marrow indeed is required for type 1 interferons to 
induce a regulatory phenotype in the lungs in the context of M. tuberculosis, as has been 
demonstrated during viral infection and depicted in chapter 2, Fig 3 (37). This would 
indicate that a systemic effect lies at the base of the locally impaired immune response 
in the lungs observed in TB (72). In further support of the potential relevance of this 
systemic pathway, we found in chapter 3 that Beijing-1585 and EAI-1627 markedly af-
fect cytokine expression in the bone marrow, indicating that this pathway might be an 
essential factor in strain-dependent virulence.
Mycobacterial strain variance in general is still a relatively undervalued factor that can 
be used to improve our understanding of TB pathogenesis. Comparative experimental 
studies such as chapter 3 with a specific focus on host responses are still scarce and 
need to be verified and complemented with additional analyses such as gene signa-
ture studies and characterization/functional testing of the identified cell populations 
in the lungs. A specific research question here is why B-cells and IL-4 appear to play 
a detrimental role in our mouse TB model of acute infection, while beneficial effects 
of antibodies and B-cells have been described in patients. A second interesting devel-
opment is a recently described sequential association between type 1 interferon and 
the Th17 response. It was demonstrated that systemic interferon responses preceded 
and occurred concomitantly with Th17 inhibition which was observed prior to the de-
velopment of active TB in young adults (65). I believe that particularly the sequential 
association is relevant. In the context of TB drug evaluation, we find in chapter 5 that 
bactericidal activity during acute disease is not representative for treatment outcomes. 
Similar principles should be implemented for immunological studies, which should not 
only focus on characterization and modulation of host-pathogen interactions during 
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acute infection, but also during the chronic phase of infection. This could also be done in 
mouse TB models through similar methods as used in chapter 3, albeit with lower infec-
tion load of M. tuberculosis or less virulent strains, since mice infected with Beijing-1585 
and EAI-1627 become moribund after three weeks in our high-dose inoculum model.
A final point of interaction between host and pathogen relevant to our understanding of 
TB pathogenesis would a mycobacterial subpopulation study. We still do not know pre-
cisely where specific populations of mycobacteria in their respective metabolic states 
reside in different stages of infection. This knowledge would already be of high value 
in the BALB/c mouse model, where mycobacteria can persist for long durations of time 
without the presence of necrotizing granulomas. A specific alternative niche worthwhile 
exploring in this regard is the bone marrow (73). A pilot study within the framework 
of this thesis was performed to pursue this research question with fluorescent dyes to 
stain the mycobacterial wall and metabolic activity followed by flow cytometric analysis. 
Further optimization of this technique will likely provide answers to this fundamental 
question. Alternatively, culturing isolated samples in the presence of resuscitation-
promoting factor proteins might increase the sensitivity of our assays and reveal the 
populations of mycobacteria that are currently not cultured, but do cause relapse of 
infection.
2. creating the perfect Tb treatment
How would the perfect TB drug regimen look like? TB treatment exists of a short phase 
in which rapidly dividing mycobacteria are targeted, followed by a longer phase aimed 
at the low number of persistent mycobacteria that have adopted a metabolic state that 
is more resistant to killing as shown in Figure 1.
In the study described in chapter 5 we show that most current TB drugs possess 
bactericidal activity, but that only rifampicin-containing regimens target persistent 
subpopulations efficiently enough to achieve cure within 6 months. This persistent state 
is a mycobacterial stress response caused by antibiotic pressure on the one hand and 
immunological pressure (e.g. granuloma-associated hypoxia) on the other. Each of these 
stress-related factors can be manipulated and future TB treatment should make use of 
all these factors instead of antibiotic pressure alone. Starting with host factors, we show 
in chapter 3 that increasing immunological pressure has the potential to improve treat-
ment outcome. This is based on the hypothesis that latent mycobacteria reside within 
permissive myeloid cells and that boosting these cells increases their bacterial killing 
capacities. Alternatively, reducing immunological pressure on mycobacteria through 
immune suppression, e.g. through adjunct therapy with TNF-α blockers has also shown 
to improve treatment outcomes (45). This is based on the hypothesis that host responses 
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such as granuloma formation interfere with optimal drug efficacy. To determine which 
of these principles is more effective as adjunct to antibiotic treatment, comparative 
studies in mouse TB models would be a valuable first step. Also, specific attention should 
be given to the phase in which adjunct treatment should be initiated in the treatment 
process. When striving towards patient-specific treatment regimes, other factors, such 
as the degree mycobacterial resistance to antibiotic treatment and the immunological 
status of the individual patient might also influence the decision whether to increase or 
reduce host-originated stress.
With regard to the mycobacterial stress response, it might be worthwhile to explore in 
TB the ‘Shock and Kill’ principle applied in HIV research (75-77). This would mean treat-
ment with latency-disrupting compound in order to force mycobacteria from latency 
into a metabolically active state. This might increase susceptibility to currently used 
anti-TB drugs. Such a strategy has become hypothetically possible with the discovery 
of M. tuberculosis Resuscitation Promoting Factors (RPFs) (78), which have been shown 
to be major virulence factors (79). Current research on RPFs for M. tuberculosis primarily 
shows practical potential in culturing dormant / persistent mycobacterial populations 
Figure 1. biphasic kinetics of Tb treatment
Adapted from Sloan et al (74), sputum colony counting data from three patient cohorts.
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that do not propagate in conventional cultures (80). Therapeutic use of RPFs adjunct to 
antibiotic treatment has been hypothesized to be effective in TB, as its mechanism of 
action differs from antibiotic treatment and host-directed therapy (81). However, this 
remains to be tested in vivo.
The last, and clinically most relevant factor is antibiotic treatment, which can be opti-
mized through (1) the introduction of new drugs, (2) altering the dose of currently used 
drugs and (3) changing the treatment schedule.
The TB drug pipeline in particular shows exciting new developments. Bedaquiline is 
the most clinically advanced example of a drug that appears to have increased efficacy 
against persistent mycobacteria, but also other new compounds including pretomanid, 
teixobactin and CPZEN-45, a capreomycin derivate have shown potential specifically 
against non-actively replicating mycobacteria (82). An overview of the current global TB 
drug pipeline is shown in Fig. 2. Especially for the TB drugs pretomanid and bedaquiline 
multiple phase III clinical trials are currently ongoing to study their most optimal use in 
a TB drug regimens (74).
Figure 2. an overview of the Tb drug pipeline, available from http://www.newtbdrugs.org/pipeline/
clinical
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Summarizing discussion and future perspectives
Improving the dosing of current TB drugs has received attention in the last years, with 
a specific focus on the ryfamycins (83, 84). As shown in chapter 5, this is an essential 
component of the current TB drug regimen to achieve cure in our mouse TB model. 
Recently, a large clinical trial indeed showed that increasing the dose of rifampicin from 
10 mg/kg to 35 mg/kg was safe and reduced the time to culture conversion (85). A final 
interesting finding in both chapter 5 and chapter 6 is the role of isoniazid. This is one 
of the most effective drugs against actively replicating mycobacteria in humans during 
the first days of treatment. However, we found in chapter 5 that its efficacy against per-
sisting mycobacteria is limited in mice. Also in chapter 6 we found that the isoniazid-
containing regimen was less effective in achieving cure compared to the other regimens 
in mice. A potential antagonistic effect of isoniazid on the efficacy of other drugs has 
also been described in other mouse TB models (64). As mentioned in chapter 6, this 
might be a species-dependent flaw for mice that requires correction on a translational 
level. However, it could also be that the high efficacy of isoniazid against actively repli-
cating bacteria causes a relative increase of mycobacteria progressing to a metabolically 
less active state, which reduces the efficacy of other drugs. If this hypothesis is true, it 
might be more effective to use isoniazid only during the first weeks of treatment and 
replace it later during the course with drugs that are more effective against persistent 
mycobacteria. This is a hypothesis worthwhile exploring for which the newly designed 
treatment outcome evaluation as presented in chapter 6 is particularly useful. If this 
outcome then persists in mouse TB models it could be implemented in clinical studies 
that test new TB drugs as mentioned above.
Taken together, the perfect TB drug regimen in theory would consist of an initial anti-
bacterial multidrug treatment to kill all actively replicating mycobacteria. This should 
then be followed by a TB drug regimen with specific efficacy against metabolically less 
active mycobacteria combined with immunotherapy to alter host-induced stress on the 
mycobacteria. This combination could hypothetically be improved further by adding 
compounds that prevent mycobacterial transition to a persistent state. Such drugs 
remain to be developed and tested in vivo, preferably in preclinical TB models with high 
translational value.
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samEnVaTTinG Van dE bEsPREkinG
Tuberculose (TBC) brengt al millennia lang een forse ziektelast met zich mee voor de 
mensheid en blijft dit tot op heden doen, ondanks het feit dat curatieve behandeling 
inmiddels beschikbaar is. Dit relatieve ‘succes’ van TBC kan worden verklaard door 
een combinatie van mycobacteriële-, gastheer- en behandelingsfactoren. Belangrijke 
mycobacteriële factoren die bijdragen aan deze persisterende ziektelast zijn nieuw 
opkomende stammen met verhoogde virulentie en de toenemende mate en ernst van 
antibioticaresistentie onder deze stammen. Een menselijke (gastheer) factor die een 
belangrijke rol speelt is de grote hoeveelheid individuen die de bacterie Mycobacterium 
tuberculosis bij zich dragen zonder hier ziek van te zijn, maar wel actieve TBC kan ontwik-
kelen. Een laatste belangrijke factor is de huidige (te) lange behandelduur van TBC van 
gemiddeld zes maanden, die noodzakelijk is om persisterende bacteriën te elimineren. 
Belangrijke vragen waarop TBC onderzoek zich momenteel richt, zijn:
• Hoe en waar persisteren de mycobacteriën die de behandeling van TBC zo langdurig 
maken?
• Hoe draagt ons eigen immuunsysteem bij aan hun voortbestaan en reactivatie?
• Hoe kunnen we persisterende subpopulaties van mycobacteriën meten?
• Hoe ontwikkelen en screenen we nieuwe middelen specifiek gericht op deze persis-
terende populaties?
Het werk in dit proefschrift heeft als doel om de behandeling van TBC te verbeteren 
door; (i) meer inzicht te krijgen in de pathofysiologie van TBC om nauwkeuriger te bepa-
len welke factoren van ons eigen immuunsysteem mogelijk gemoduleerd kunnen wor-
den om behandeling te bespoedigen, en (ii) De translationele waarde van preklinische 
muismodellen voor TBC als screeningsinstrument voor potentiële nieuwe middelen 
of combinaties van middelen te optimaliseren. Hieronder volgt een samenvatting van 
het verrichte werk onderverdeeld in relevatie ten aanzien van mycobacteriële factoren, 
gastheer factoren en behandelingsfactoren.
mycObacTERiëlE FacTOREn
Vorderingen in genotypering in combinatie met klinische observaties over de afgelopen 
twintig jaar hebben laten zien dat de verschillen tussen M. tuberculosis stammen die TBC 
veroorzaken groter zijn dan aanvankelijk werd gedacht. Deze vormen een belangrijke 
factor in de pathogenese van TBC. Het beste voorbeeld betreft de stammen van het Beij-
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ing genotype. Beijing stammen hebben een prominente rol gespeeld bij de verspreiding 
van multiresistente TBC in Eurazië en zijn geassocieerd met falen van de behandeling en 
opvlamming van actieve TBC in patiënten in andere delen van de wereld. Het is niet 
moeilijk voor te stellen hoe antibioticaresistentie kan bijdragen aan het falen van de 
behandeling. Beijing stammen beschikken echter ook over een aantal andere unieke 
pathogene eigenschappen die beter in kaart gebracht moeten worden om hun klinisch 
succes te begrijpen. Om deze reden is de mycobacteriële factor die nader bestudeerd 
zal worden in dit proefschrift de variatie tussen M. tuberculosis stammen en hun invloed 
op de behandeling en pathogenese van TBC in muismodellen.
In tegenstelling tot de meeste andere M. tuberculosis stammen brengen stammen van 
het Beijing genotype ook onder normale omstandigheden een groep eiwitten tot ex-
pressie die behoren tot het DosR regulon. Dit bestaat uit circa 50 genen die onder con-
trole staan van de DosR transcriptie factor. Dit regulon is een belangrijke virulentiefactor 
voor M. tuberculosis, omdat een essentiële rol speelt in de mycobacteriële overgang naar 
een persisterende staat onder invloed van hypoxie. Aangezien mycobacteriën in deze 
persisterende staat beter bestand zijn tegen antibiotica kan de expressie van het DosR 
regulon onder niet-hypoxische condities een mogelijke verklaring zijn voor het verschil 
in behandeluitkomst tussen Beijing stammen en andere stammen.
Preklinische muismodellen voor TBC die behandeluitkomst meten gebruiken vaak M. 
tuberculosis stammen als H37Rv en Erdmann. Deze stammen waren klinisch relevant ten 
tijde van hun isolatie meer dan honderd jaar geleden, maar worden tegenwoordig niet 
meer geïsoleerd uit patiënten. Om deze reden was ons specifieke doel in Hoofdstuk 5 
om uit te zoeken wat het effect was op de behandeluitkomst van het gebruik van een 
Beijing stam in ons muismodel om op deze manier de translationele waarde van ons 
proefdiermodel te verhogen.
Onze evaluatie van behandeluitkomsten in muizen geïnfecteerd met de Beijing-1585 
stam liet zien dat geen van de tien geteste combinaties van antibiotica, inclusief de 
huidige standaardbehandeling van TBC bestaande uit 2RZH/4RH (twee maanden rifam-
picine-pyrazinamide-isoniazide gevolgd door vier maanden rifampicine-isoniazide), 
100% genezing kon bewerkstelligen. Dit is interessant, omdat ten minste vier eerdere 
vergelijkbare studies waarin de H37Rv stam werd gebruikt 100% genezing liet zien van 
2RHZ/2RH in BALB/c muizen, waaronder één studie met H37Rv in ons eigen muismodel 
voor TBC. Dit geeft aan dat het succespercentage van behandeling in muismodellen 
waarin H37Rv wordt gebruikt mogelijk overschat wordt. Op basis hiervan lijkt het er 
dus op dat het gebruik van stammen die recent uit patiënten zijn geïsoleerd, zoals Beij-
191
Nederlandse samenvatting
ing-1585, in plaats van een laboratoriumstam zoals H37Rv de translationele waarde van 
preklinisch muismodellen voor TBC kan verbeteren.
Een andere belangrijke eigenschap van Beijing stammen betreft hun virulentie. Infectie 
met virulente Beijing stammen resulteert in hogere aantallen mycobacteriën, meer 
schade aan de longen en verhoogde mortaliteit in vergelijking met andere stammen en 
niet-virulente Beijing stammen. Eerdere studies in ons muismodel voor TBC bevestigden 
deze virulentie voor Beijing-1585, maar ook voor EAI-1627, een ander klinisch isolaat dat 
veel voorkomt in Zuidoost-Azië en toebehoort aan het ‘East-African/Indian’genotype. 
Dit eerdere evidente verschil in virulentie tussen recent geïsoleerde klinische stam-
men in vergelijking met H37Rv inspireerde ons om de immunologische reactie op elk 
van deze stammen nader te onderzoeken. De resultaten beschreven in Hoofdstuk 3 
laten zien dat de immuunreactie uitgelokt door H37Rv overeen komt met het huidige 
paradigma van TBC pathogenese, gekarakteriseerd door een IL-12 / T-Helper 1 / Inter-
feron (IFN)-γ reactie in de longen zoals uitgelegd in Figuur 1 en box 1 in Hoofdstuk 
2. De immuunreactie tegen Beijing-1585 en EAI-1627 bleken echter geassocieerd met 
een toename van B-cellen in plaats van T-cellen in de longen op het hoogtepunt van 
infectie. Myeloïde cellen waren in vergelijkbare frequenties aanwezig bij Beijing-1585 en 
EAI-1627 in vergelijking met H37Rv, maar leken minder functioneel met lage expressie 
van iNOS en IL-12. Daarnaast vonden we in het beenmerg van muizen geïnfecteerd met 
Beijing-1585 en EAI-1627 verminderde expressie van IFN-γ, TNF-α en IFN-β, cytokines 
die essentieel zijn voor de ontwikkeling van myeloïde cellen. Dit was al meetbaar vanaf 
de derde dag na infectie, voordat andere systemische effecten gedetecteerd konden 
worden. Deze combinatie van myeloïde cellen in de longen die waarschijnlijk vermin-
derd functioneel zijn, in combinatie met de verminderde expressie in het beenmerg van 
cytokines essentieel voor de ontwikkeling van cellen met een bactericide fenotype is 
suggestief voor een eerder niet beschreven belangrijke rol van deze processen in stam-
gerelateerde virulentie in TBC.
In Hoofdstuk 2, Figuur 3 wordt een gedetailleerde hypothese beschreven over de 
invloed van cytokines op de ontwikkeling van myeloïde cellen. Interleukine (IL)-12, wat 
aanwezig is in de longen tijdens infectie met H37Rv, maar niet bij Beijing-1585 of EAI-
1627 infectie, zou systemisch kunnen zorgen voor een IFN-γ-gemedieerde ontwikkeling 
van myeloïde cellen met een fenotype dat excessieve inflammatoire schade door het 
aangeboren immuunsysteem in de longen voorkomt, maar het adaptieve immuun-
systeem stimuleert. Een andere bevinding beschreven in Hoofdstuk 3 betreft de rol 
van type 1 interferon in de pathogenese van TBC tijdens acute infectie. Eerdere studies 
in een ander muismodel voor TBC speculeerden dat toegenomen type 1 interferon 
signalering een bijdrage leverde aan de verhoogde virulentie van Beijing stammen in 
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vergelijking met H37Rv. In die studies werd er gevonden dat de Beijing HN878 stam een 
hoger IFN-α mRNA expressie-niveau induceerde in de long, wat geassocieerd was met 
lagere inductie van IL-12 en TNF-α en verminderde T-cel activatie in vergelijking met 
H37Rv. Wij vonden ook lagere inductie van IL-12 voor Beijing-1585, maar konden dit niet 
associëren met verhoogde type 1 interferon activiteit. Onze conclusie was gebaseerd op 
directe meting van IFN-α en IFN-β expressie, vergelijkbaar met de eerdere studie, maar 
verder versterkt door metingen van drie type 1 interferon-geïnduceerde genen.
Samengevat pleiten onze bevindingen uit Hoofdstuk 5 over de invloed van M. tuberculo-
sis stamverschillen op de uitkomst van behandeling en onze bevindingen uit Hoofdstuk 
3 over de invloed van stamverschillen op de immuunreactie tijdens acute infectie ervoor 
dat klinische mycobacteriële stammen in preklinische muismodellen gebruikt moeten 
worden. Dit kan de translationele waarde van deze modellen verbeteren en onze basale 
kennis over de immuunrespons tegen TBC uitbreiden. Een belangrijk gegeven bij dit 
laatste punt betreft dat veel van onze fundamentele kennis over de immuunreactie in 
TBC gebaseerd is op experimentele data van muisstudies die H37Rv gebruikten, terwijl 
wij laten zien dat de gemeten uitkomsten voor H37Rv niet representatief zijn voor de 
immuunreactie tegen stammen die op dit moment TBC veroorzaken in patiënten.
GasTHEER FacTOREn
Onze bevindingen zoals beschreven in Hoofdstuk 3 lieten een verschil zien in de 
regulatie van IL-12 tussen H37Rv en de klinische stammen. Daarnaast vonden we ook 
verschillen in B-cellen, IL-4 en de type 1 interferon respons die niet goed passen binnen 
het huidige IL-12 / T-helper (Th) 1 / IFN-y paradigma, maar wel van belang kunnen zijn 
in TBC pathogenese. Redenen om te geloven dat immunologische reacties naast Th1 
immuniteit van belang zijn komen voort uit (i) onbevredigende resultaten van vaccina-
tie studies gericht op het stimuleren van Th1-immuniteit, (ii) verhoogde inflammatoire 
schade geassocieerd met interventies leidend tot toegenomen IFN-y productie door 
T-cellen in de longen van M. tuberculosis-geïnfecteerde muizen en (iii) de toename van 
ziektelast geassocieerd met het blokkeren van systemen die de effectiviteit van Th-1 
immuniteit remmen in muizen. Om deze redenen was het doel in Hoofdstuk 2 om de 
inzichten in de rollen van B-cellen, IL-17 en type 1 interferon beter te integreren in ons 
huidige begrip van TBC pathogenese. De belangrijkste hypothese die we hierbij hebben 
gevormd is dat de type 1 interferon respons, IL-17 en hun interactie convergeren en 
leiden tot een stimulerend effect op B-cellen door: (i) de inductie van B-cell activating 
factor (BAFF), (ii) stimulatie van vorming en functie van tertiaire lymfoïde structuren 
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(TLS) en (iii) stimulatie van Th17.1 cellen die door hun hoog inflammatoire karakter sterk 
pathogeen kunnen zijn. (Hoofdstuk 2, Fig. 5).
Type 1 interferonen worden over het algemeen beschouwd als negatieve regulators in 
TBC pathogenese, omdat: (i) ze een regulatoir fenotype induceren in myeloïde cellen, 
waardoor intracellulaire mycobacteriën in deze cellen eerder persisteren dan geëlimi-
neerd worden, (ii) er beschreven is dat virulente stammen type 1 interferonen sterker 
induceren en (iii) dat een interferon genexpressie handtekening in RNA geïsoleerd uit 
perifere bloedcellen correleert met actieve TBC. Gebaseerd op ons literatuurreview zoals 
beschreven in Hoofdstuk 2 kan er geconcludeerd worden dat de effecten van type 
1 interferon divers zijn en sterk afhankelijk van de ontwikkeling van myeloïde cellen 
onder invloed van IFN-γ, M-CSF en/of GM-CSF voorafgaand aan het contact met type 1 
interferon (Hoofdstuk 2, Fig. 3). De belangrijkste overweging is dat ontwikkeling onder 
invloed van IFN-γ essentieel is voor het induceren van een regulatoir fenotype van my-
eloïde cellen door type 1 interferon. Dit wordt ondersteund door twee studies waarvan 
de resultaten laten zien dat type 1 interferonen juist een beschermend effect hebben in 
de acute fase van M. tuberculosis infectie in de afwezigheid van IFN-γ in muismodellen 
voor TBC. Een tweede overweging is dat type 1 interferonen alleen een regulatoir feno-
type kunnen induceren in myeloïde cellen die gedifferentieerd zijn onder invloed van 
M-CSF, omdat GM-CSF myeloïde cellen minder gevoelig maakt voor type 1 interferon. 
Dit kan een mogelijke verklaring zijn voor het feit dat de effecten van type 1 interfero-
nen vooral gezien worden tijdens acute infectie, maar afnemen als de infectie doorzet 
en de systemische hoeveelheid GM-CSF toeneemt. Ten slotte kunnen IFN-α en IFN-β een 
verschillend effect bewerkstelligen waarbij IFN-α voornamelijk pro-inflammatoir lijkt te 
werken en IFN-β juist regulatoir (Hoofdstuk 2, box 4 & Hoofdstuk 3).
De rol van B-cellen in TB pathogenese is de laatste decennia naar de achtergrond 
verdrongen door de aangetoonde centrale rol van T-cellen, maar heeft de afgelopen 
jaren hernieuwde aandacht ontvangen. In patiënten is aangetoond dat antilichaam-
gemedieerde immuniteit een actieve rol speelt in TBC en dat patiënten met actieve 
TBC over lagere aantallen, dysfunctionele B-cellen beschikken. Deze bevindingen sug-
gereren dat B-cellen een beschermend effect hebben tijdens chronische TBC infectie in 
patiënten. In ons muismodel van TBC in Hoofdstuk 3 zien we echter dat acute infectie 
met Beijing-1585 en EAI-1627 geassocieerd is met hogere aantallen B-cellen en IL-4 eiwit 
levels in de longen in vergelijking met de minder virulente H37Rv. Deze ogenschijnlijke 
discrepantie tussen humane en muisbevindingen suggereert dat B-cellen beschermend 
zijn tijdens chronische TBC, maar eventueel bij kunnen dragen aan de ernst van de 
ziekte tijdens acute infectie.
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Het belang van een verbeterd begrip van TBC pathogenese is benadrukt door de 
centrale rol die ons eigen afweersysteem speelt in de behandeling van TBC. Het is een 
effectieve en efficiënte eerste barrière, gezien het feit dat ‘slechts’ 5-15% van alle niet 
immuun-gecompromitteerde patiënten geïnfecteerd met M. tuberculose daadwerkelijk 
actieve TBC ontwikkelt. Echter, op het moment dat deze barrière geen stand houdt en 
een actieve TBC zich ontwikkelt zal 50-70% van de patiënten binnen twee jaar overlijden 
als zij geen behandeling krijgen. Paradoxaal kan dezelfde granulomateuze afweerreactie 
en de intracellulaire verblijfplaats van mycobacteriën in macrofagen en andere myelo-
ide cellen juist bescherming bieden tegen antibiotica en mycobacteriën ondersteunen 
hun ontwikkeling tot een persisterend fenotype. Om deze reden kan de ziekte in het 
geval van TBC niet los gezien worden van de gastheer. Deze essentiële rol van ons eigen 
afweersysteem in de pathogenese van TB geeft het belang aan van het integreren van 
gastheerfactoren in de ontwikkeling van nieuwe behandelopties.
In de studie beschreven in Hoofdstuk 4 onderzoeken we of het moduleren van ons 
eigen afweersysteem, naast het toedienen van antibiotica, kan leiden tot betere be-
handeluitkomsten in ons muismodel voor TBC. Immuuntherapie in TBC kan bestaan uit 
strategieën gericht op het verbeteren van de capaciteit van myeloïde cellen om intracel-
lulaire mycobacteriën te doden. Onze strategie was gebaseerd op de hypothese dat 
immunotherapie opgebouwd uit all-trans retinoic acid, α-galactosylceramide en 1,25 
dihydroxyvitamine D de ontwikkeling van myeloïde cellen stuurt naar een bactericide 
fenotype in plaats van een regulatoir fenotype. Muizen werden geïnfecteerd met M. 
tuberculosis H37Rv en behandeld met isoniazide, rifampicine en pyrazinamide (RHZ) 
of een combinatie van RHZ met immunotherapie. De resultaten laten zien dat RHZ in 
combinatie met immunotherapie leidt tot significant minder opvlamming van ziekte na 
12 weken behandeling in vergelijking met alleen RHZ (Hoofdstuk 4, Fig. 3). De belang-
rijkste conclusie die hieruit getrokken kan worden is dat adjuvante immunotherapie 
gericht op het verhogen van de effectorfunctie van myeloïde cellen kan helpen in de 
specifieke eliminatie van persisterende mycobacteriën die opvlamming van ziekte op 
een later moment kunnen veroorzaken.
bEHandElinGsFacTOREn
Klinische implementatie van nieuwe behandelopties, zoals immunotherapie of nieuwe 
antibiotica die goede resultaten hebben laten zien in preklinische studies is een langdu-
rig en kostbaar proces. In de context van TBC heeft de negatieve uitkomst van de REMox 
studie uit 2014 ons een belangrijke les geleerd: vroege surrogaat eindpunten gebaseerd 
op bactericide activiteit of de aanwezigheid van mycobacteriën in het sputum zoals 
195
Nederlandse samenvatting
gemeten in klinische fase IIa/b studies zijn onbetrouwbare voorspellers voor de uitein-
delijke behandeluitkomst. In andere woorden: de capaciteit van (nieuwe) middelen om 
actief delende mycobacteriën te doden zoals aanwezig in de eerste fase van infectie 
en behandeling garandeert geen effectiviteit tegen persisterende mycobacteriën zoals 
aanwezig in de tweede fase van behandeling. Klinische fase III studies zijn duur, afhan-
kelijk van grote groepen patiënten en kunnen wel 10 jaar duren van het ontwerpen van 
de studie tot het publiceren van de resultaten. Om deze reden moeten deze klinische 
studies gebaseerd zijn op preklinisch onderzoek met maximale translationele waarde. 
Voor de REMox studie waren de resultaten van de preklinische studies in muismodellen 
mogelijk te optimistisch geïnterpreteerd. De noodzaak blijft om deze reden aanwezig 
om de huidige preklinische modellen verder te optimaliseren om hun voorspellende 
waarde voor behandeluitkomst in klinische studies te verbeteren.
Met dit specifieke doel voor ogen hebben wij een deel van het onderzoek uit dit proef-
schrift verricht als onderdeel van het PreDiCT-TB consortium. Dit bestaat uit 19 publieke 
en private wetenschappelijke partners binnen de Europese Unie. Het doel van PreDiCT-
TB is het genereren van een geïntegreerd en gevalideerd preklinisch traject voor nieuwe 
behandelopties voor TBC. Dit wordt bereikt door huidige en nieuwe antibiotica in 
meerdere in vitro en in vivo preklinische modellen te valideren tegen uitkomsten van kli-
nische studies. Onze bijdrage bestond uit de evaluatie van diverse behandelmethoden 
in het Beijing-1585-geïnfecteerde BALB/c muismodel voor TBC. Een algemeen punt van 
kritiek op het BALB/c muismodel is het feit dat de granulomen die gevormd worden in 
de longen geen necrotische kern bevatten. Deze necrotische, of verkazende, kern lijkt in 
humane TBC een belangrijke rol te spelen, omdat het mycobacteriën kan beschermen 
tegen antibiotica, omdat het de weefselpenetratie beïnvloedt en kan fluctueren in mate 
van hypoxie en pH. De klinische relevantie van deze laesies kan het beste worden geïl-
lustreerd door de huidige toename van chirurgische resectie hiervan in patiënten met 
refractoire ziekte. De afwezigheid van necrotische granulomen is de belangrijkste reden 
geweest voor het testen van behandeling in cavia’s in plaats van muizen en de ontwik-
keling van het C3HeB/FeJ muismodel voor TBC, waarin zulke laesies zich wel vormen. 
Echter laten andere studies zien dat de behandeluitkomst in modellen met of zonder 
necrotische granulomen identiek was. Ook de Ph-afhankelijke antibiotica pyrazinamide 
moet vermeld worden dat de mate van weefselpenetratie identiek was voor BALB/c en 
C3HeB/FeJ muizen. Ten slotte wijzen onder andere onze eigen studies uit dat, ondanks 
de aanwezige limitaties van het BALB/c muismodel voor TBC, er nog steeds sprake is van 
persisterende subpopulaties van mycobacteriën en dat de behandeluitkomsten verge-
lijkbaar zijn met humane studies. Dit blijkt ook uit de resultaten beschreven in Hoofd-
stuk 5 waarin de combinatie RZHE een succespercentage had van 90% vergeleken met 
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de gevonden 92% in de REMox studie. Concluderend kan er dus gesteld worden dat 
het BALB/c muismodel, ondanks zijn limitaties, een bruikbaar preklinisch TBC model is.
Een andere belangrijke bevinding beschreven in Hoofdstuk 5 was dat bactericide 
activiteit tijdens de eerste fase van behandeling niet voorspellend was voor behandel-
uitkomst, net zoals eerder is besproken voor klinische TBC studies. Daarnaast zijn de hui-
dige methoden die gebruikt worden om verschillende regimes met elkaar te vergelijken 
gebaseerd op relatief simpele Chi-square testen tussen grote groepen muizen na een 
vooraf bepaalde behandelduur. Op deze manier kan er gekeken worden naar verschillen 
in behandeluitkomst na één specifieke behandelduur, maar kan er geen correlatie ge-
maakt worden tussen behandelduur en behandeluitkomst. Deze correlatie is juist nodig 
om nauwkeurig in te schatten met welke mate een nieuw getest regime de behandel-
duur eventueel kan verkorten. Om deze reden was het doel van de studie beschreven 
in Hoofdstuk 6 om de huidige methoden van evaluatie van behandeluitkomst te 
verbeteren. In deze studie hebben we de behandeluitkomst bepaald in n=3 muizen na 9 
verschillende behandelduren en combineerden dit met modelgebaseerde analyses om 
een methode te ontwikkelen waarin de relatie tussen behandelduur en voorspelde kans 
op genezing accuraat voorspeld kon worden. Implementatie van deze methode stelde 
ons in staat om aan te tonen dat de behandeling met rifapentine-pyrazinamide-isoniazi-
de-ethambutol (RpZHE) en rifampicine-pyrazinamide-moxifloxacin-ethambutol (RZME) 
effectiever is in vergelijking met rifampicine-pyrazinamide-moxifloxacine-isoniazide 
(RZMH). Dit verschil kon niet aangetoond worden op basis van alleen de observationele 
data. Deze uitkomsten waren vergelijkbaar met trends geobserveerd in andere muismo-
dellen voor TBC en wekken de suggestie dat isoniazide een negatief effect heeft op de 
effectiviteit van RZM in muismodellen. Helaas bleek de translationele waarde van onze 
nieuwe methode voor RZME en RZMH beperkt in vergelijking met de humane data na 
vier maanden behandeling (97% genezing in muizen versus 80% in mensen voor RZME 
en 29% in muizen versus 85% in mensen voor RZMH). Deze discrepantie tussen data 
afkomstig van humane studies en muisstudies geeft aan dat de translationele waarde 
van ons muismodel voor TBC nog verder moet worden verbeterd. Een recente studie 
laat zien dat correctie voor additionele factoren, waaronder geavanceerde farmacoki-
netische factoren en farmacodynamische modelering, soort-specifieke eiwitbinding en 
pathologie de translationele waarde van het BALB/c muismodel voor TBC verder verbe-
tert. Correctie voor deze factoren in combinatie met onze beschreven methodologie en 
integratie van mycobacteriële stamverschillen in het BALB/c muismodel voor TBC zal de 
translationele waarde van dit model ongetwijfeld verbeteren zodat er nauwkeuriger en 
efficiënter gezocht kan worden naar nieuwe regimes die geïncludeerd kunnen worden 
in toekomstige klinische onderzoeken.
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26-10-2016 Information video exposition antibiotics resistance Natuurhistorisch Museum
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De eerste stappen van dit proefschrift heb ik gezet in 2011, als onstuimige, wereldrei-
zende geneeskundestudent die tropenarts wilde worden, maar ook wel wat onderzoek 
wilde doen. Deze laatste stap van mijn proefschrift in de vorm van het dankwoord schrijf 
ik als getrouwde man en vader van twee kinderen. In de tussenliggende zeven fantas-
tische jaren zijn er een hoop mensen op mijn pad voorbij gekomen die allen op hun 
eigen unieke manier een positieve bijdrage hebben geleverd aan de totstandkoming 
van dit proefschrift. Allen betrokkenen persoonlijk bedanken is lastig, maar graag zou ik 
de volgende personen hier willen noemen.
Allereerst zou ik het dankwoord graag willen richten aan de twee onmisbare pijlers 
tijdens mijn onderzoeksperiode: mijn twee co-promotoren Pieter leenen en Jurriaan 
de steenwinkel. Beste Pieter, ontzettend bedankt voor het geduld en de flexibiliteit 
waarmee je mij hebt aangestuurd deze jaren. Jouw vertrouwen in mijn ideeën en de 
hulp in de praktische invulling ervan zijn onmisbaar geweest. Zelfs als ik voor de 5e keer 
in de week enthousiast met een nieuw plan of paper je kamer binnen kwam stormen 
zonder afspraak wist je nog tijd te vinden voor een kritische discussie. Beste Jurriaan, 
zonder jouw voorwerk op het TB lab, de verworven fondsen en kennis over de muis-
TBC-modellen (vooral geen muismodel ;) had dit proefschrift nooit kunnen bestaan. 
Specifiek bedankt voor de vrijheid en het vertrouwen wat je me hebt gegeven in het 
uitvoeren en inrichten van mijn promotieonderzoek.
Mijn promotor, annelies Verbon, beste Annelies, hartelijk dank voor je begeleiding, 
de sterke inhoudelijke feedback op de manuscripten en jouw enthousiasme over het 
onderzoeksproject en de creatieve invulling ervan.
De leden van de kleine commissie, beste Jon laman, marleen bakker en Tom Ot-
tenhoff. Hartelijk dank voor het feit dat jullie de tijd hebben gevonden in jullie drukke 
levens om dit proefschrift kritisch door te lezen en te beoordelen. Beste Tom, daarnaast 
natuurlijk ook ontzettend bedankt voor de samenwerking en het brainstormen tijdens 
het schrijven van het review, ons magnus opus, en de steeds extreem snelle feedback.
De leden van de grote commissie, hartelijk dank voor de tijd die jullie hebben geïnves-
teerd om mijn werk kritisch te beoordelen, te bediscussiëren en op waarde te schatten.
Vanaf hier ga ik chronologisch de verschillende mensen langs met wie ik gewerkt heb. Te 
beginnen met de persoon die mij heeft laten zien dat de wetenschap een prachtig iets 
is. maarten Frens, bedankt voor de inspiratie en dat ik onderdeel mocht uitmaken van 
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de allereerste honours class, al was het maar deels omdat ‘als we alleen de allerslimste 
kandidaten hadden gekozen het maar een saaie groep zou worden’.
De volgende halte was de research master ‘Infection & Immunity’. Beste Jan nouwen en 
Frank van Vliet, bedankt voor jullie geweldige opleiding. De researchmaster was voor 
mij dé manier om met alle onderzoeksafdeling in contact te komen en samen te werken. 
Bedankt voor de schat aan kennis, jullie steun, enthousiasme en flexibiliteit. Daarnaast 
moet je het ook hebben van je klasgenoten waarbij ik specifiek wil noemen marco 
Goeijenbier. Marco, ouwe tijger, wat een heerlijke tijd hebben we gehad, eindeloos 
trainen tot de meest extreme trainingschema’s, mudmasters en alle fantastische dingen 
eromheen. Om een of andere reden ben ik alleen maar minder door in vorm geraakt en 
jij steeds meer.. Je arbeidsethos en discipline zijn bewonderenswaardig ik ben blij dat ik 
je tegen ben gekomen. lennert vd dries, nog zo’n mooie baas, trouwen en promoveren 
in één maand, wie verzon het, maar jij deed het gewoon met Tjitske, veel geluk samen. 
Tijdens mijn eerste onderzoeksstage onder supervisie van Pieter Leenen bij de im-
munologie was daar adri van Oudenaren, of zoals iedereen hem kent a3. Beste A3, 
bedankt alle instructies en onmisbare hulp in het lab en het inwerken op de FACS, maar 
vooral bedankt voor je geduld. Verder zou ik graag van de immunologie alle collega’s 
van de werkgroep willen bedanken. Mijn ‘thuisstation’ was natuurlijk de microbiologie, 
vandaar dat ik minder vaak bij jullie in de buurt was, maar bedankt voor de collegialiteit 
en attentheid. Specifiek nog Ruth Huizinga, beste Ruth, ontzettend bedankt voor de 
leuke samenwerking en de hulp bij alle PCR experimenten. marjan Versnel, de type 1 
interferon autoriteit, bedankt voor de fijne gesprekken. Ik ben blij dat je pols zo mooi 
hersteld is.
Vanuit de immunologie weet ik nog goed dat ik aan kwam kloppen bij de TB werkgroep 
van Irma en Jurriaan met de vraag of we de TB muizen misschien immunotherapie 
mochten geven. Beste irma bakker-woudenberg, ontzettend bedankt voor je altijd 
aanwezige interesse en enthousiasme, niet alleen over werk-gerelateerde zaken, maar 
ook daarbuiten. marian ten kate, lieve Marian, bedankt voor alle ondersteuning in het 
lab en het EDC en natuurlijk ook alle gezelligheid eromheen, onmisbaar voor een lab-
vreemde geneeskunde student, je bent fantastisch! Gerjo de knegt, voor de eindeloze 
uurtjes in het TB lab en in de door jou geliefde kantoortuin. Ontzettend bedankt voor 
alle hulp, co-auteurschap en humor. Veel geluk, zowel met de nieuwe carriere als thuis! 
sanne v/d berg, voor jou hetzelfde, bedankt voor alle hulp en gezelligheid en veel 
plezier met Daag en de kleintjes! corné de Vogel, ouwe warlock, het was gezellig. aart 
v/d meijden, voor mij blijf je altijd de persoon op wie ik het charcoal-plate-validation-
experiment heb kunnen afschuiven, veel succes in je onderzoekscarriére. Hannelore 
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bax, bedankt voor het kritisch meedenken en schrijven van de PreDiCT manuscripten 
en excuses voor de soms wat verhitte discussies hierover. Elise Pieterman, de hollow 
fiber heldin, succes met het afronden van je PhD, gaat helemaal goed komen. Heleen 
v/d spek, ondanks het beperkte contact weet ik dat je vaak valt met de fiets na het 
uitgaan. maarten sarink, eigelijk geen TB werkgroep meer, maar vooruit, opvallend 
veel aanwezig in de weekenden zo vroeg in het onderzoek, succes met je PhD. Jullie 
waren een geweldige groep om mee samen te werken!
Vanuit de TB werkgroep grijp ik graag de kans om door te pakken naar de collega’s van 
de Medische Microbiologie met wie ik heb samengewerkt. Collega’s van de befaamde 
kantoortuin Na 9.02. Allen bedankt voor alle humor, steun, collegialiteit en gezelligheid 
die ik bij jullie heb gevonden. Het was fantastisch samenwerken. Bij deze een tevens een 
collectief sorry, ik heb in de weekenden ongetwijfeld van jullie allemaal wel een keer iets 
opgegeten wat jullie vergeten waren op te bergen. Specifiek nog astrid Heikema, heel 
veel succes met de verdere postdoc carriére, ik ben benieuwd hoe het afloopt met die 
B-cellen. michiel bexkens, de man van 18 Februari, succes met de afronding van het 
onderzoek. wendy kaman, altijd mooie verhalen, bedankt voor de samenwerking. Het-
zelfde geldt natuurlijk voor alle collega’s van het lab van de B-toren, jullie ook bedankt 
voor de gezelligheid tijdens de koffiepauzes en de samenwerking!
Een groot gedeelte van het onderzoek is gedaan in het EDC, graag zou ik ook alle EDC 
medewerkers willen bedanken voor hun hulp, specifiek mathieu sommers in de hulp 
met het rondkrijgen van de autorisatie, zodat ik überhaupt zelf mijn experimenten 
mocht uitvoeren. Vanaf de Reumatologie ook dank aan Erik lubberts voor de discussies 
en het gezamelijk werken aan het review. 
Ten slotte voor een ieder op werkgebied die ik vergeten ben te noemen, alsnog bedankt!
Naast werkgebied zijn er uiteraard ook nog vrienden en familie die ik specifiek wil be-
danken en benoemen. Allereerst mijn ouders, lieve papa en mama, volgens jullie was 
ik al van kinds af aan een wetenschapper en was het doen van promotie onderzoek de 
meest logische keuze. Bedankt voor jullie onvoorwaardelijke steun. Papa, samen naar 
Parijs om de FEDEX samples terug te halen was een van de beste verhalen van mijn 
promotie onderzoek. sarah mourik, mijn grote zus en gynaecoloog, bedankt voor de 
gezellige lunches in het EMC, ik ben trots op jou en blij dat je mijn paranimf bent! dirk 
mourik, de entrepeneur van de familie, heel veel succes met Decorista, het is fantastisch 
wat jullie aan het doen zijn. daan mourik, mijn andere paranimf en de nieuwe content-
held van T-Mobile, heel veel succes met je nieuwe job. denise wijngaarden, lieve 
schoonmoeder, bedankt voor je prachtige dochter en je steun en hulp met de kinderen 
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als we door alle drukte weer eens klem zaten met de planning. maarten kloek, bedankt 
voor de afwisselingen en uitdagingen tijdens de soms drukkere perioden en de back-
packtrips in de rustigere perioden van het onderzoek. Altijd goed om iemand te hebben 
die perspectief biedt. novaro mourik, mijn kleine sprinter, bedankt dat je papa zoveel 
geluk geeft in zijn leven en met je komst hebt benadrukt wat de belangrijke dingen zijn 
in het leven. ché mourik, mijn kleine krijger, bedankt dat je samen met je broer zo lief 
bent geweest voor mama als papa in het weekend weer eens op het Erasmus MC aan het 
werken was. Ik ben nu al ongelooflijk trots op jullie allebei. Als allerlaatste, lieve Genelva 
mourik-lo-kioeng-shioe, zonder jouw onvoorwaardelijke steun, flexibiliteit en kracht 
de afgelopen jaren had ik mijn promotie onderzoek nooit af kunnen maken. Ontzettend 
bedankt voor je geduld en je begrip, je bent een fantastische vrouw. Ik bewonder je en 
ik hou van jou.
